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Abstract
Many viruses have evolved complex mechanisms to avoid or block either the 
induction of, or the action of interferons. Interferons (IFNs) are the main innate 
cytokines that are able to induce a cellular antiviral state, thereby limiting viral 
replication and disease pathology. Plasmacytoid dendritic cells (pDCs) are 
specialised interferon producing cells and play a crucial role in the control of viral 
infections. Here we examine the interaction of plasmacytoid dendritic cells with two 
viruses -both of which are capable of blocking interferon in host cells. Using density 
gradient separation and cell sorting, we have highly enriched a population of bovine 
cells capable of producing high levels of biologically active IFN. These cells 
represented less than 0.1% of the total lymphocyte population in blood, 
pseudoafferent lymph, and lymph nodes. Phenotypic analysis identified these cells as 
bovine pDCs (CD3-CD14- CD21-CDllc- NK- ySTCR- CD4+ MHC 11+ CD45RB+ 
CD172a+ CD32+). High levels of type-I IFN were generated by these cells in vitro 
in response to Toll-like receptor 9 (TLR-9) agonist CpG and foot-and mouth disease 
virus (FMDV) immune complexes. In contrast, immune complexes with UV- 
inactivated FMDV or FMDV empty capsids failed to elicit a type-I IFN response. 
Depletion of CD4 cells in vivo resulted in a significant reduction of serum type-I IFN 
serum early during FMDV infection compared to control animals. Bovine pDCs are 
also the main producers of IFN in response to Bovine Viral Diarrhoea Virus 
(BVDV) infection however the IFN produced was predominantly type-III IFN both 
in vivo and in vitro. In conclusion, pDCs interacting with immune-complexed virus 
are the major source of type-I IFN production during acute FMDV infection in cattle, 
very little type-III IFN is produced. Infection of pDCs with BVDV leads to the 
production of predominantly type-III IFN.
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1. Introduction
Interferons (IFNs) were first described in 1957 by Swiss microbiologist Jean 
Lindenmann and British bacteriologist Alick Isaacs (Lindenmann and Isaacs, 1957), 
and were named for their ability to interfere with viral proliferation within host cells. 
IFNs are members of the cytokine family of proteins and are produced and released 
by cells in response to infection with pathogens such as viruses, bacteria and 
parasites. IFNs are especially important in combating viral infections. Based on their 
structure, receptor usage, and biological activities, three types of IFN have been 
described to date. Type-1 IFNs bind to a specific cell surface receptor complex 
(IFNAR1 and IFNAR2 chains)-known as the IFN-a receptor (IFNAR: de Weerd et 
al., 2007). Type-II IFN (IFN-y) binds to the IFN gamma receptor (IFNGR; Thiel et 
al., 2000) and type-III IFNs (IFN-A.) bind and signal through a receptor complex 
consisting of IFNLR1 (also called CRF2-12) and IL10R2 (also called CRF2-4) 
(Vilcek, 2003).
Production of type-I, and the more recently described type-III IFNs in response to 
viral infection, form part of the early innate immune response and these cytokines 
allow communication between cells, to initiate the protective defenses of both the 
innate and adaptive immune responses that are crucial in controlling or eliminating 
infection (Fensteri and Sen, 2009).
The majority of cells are capable of producing type-I and type-III IFN in response to 
viral infection but there is a specific population of cells, plasmacytoid dendritic cells 
(pDCs), that specialize in interferon- alpha (IFN-a) production and are capable of 
rapidly producing extremely high levels of interferon following stimulation. These 
cells play a crucial role in the production of IFN following viral infection especially 
in response to viruses that actively inhibit IFN in other host cells (reviewed in Liu,
2005).
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1.1 Action of type-I IFN on the immune response
The production and secretion of type-I IFN by pDCs following recognition of viral 
infection, and subsequent binding of secreted type-1 IFN to cognate receptors, leads 
not only to an enhanced anti-viral state but also to immune modulation (Fig 1.1) 
through various mechanisms such as increasing major histocompatibility complex-I 
(MHC-I) expression on dendritic cells to promote antigen presentation, stimulating 
dendritic cell maturation, promoting T-cell survival, recruitment and up-regulation of 
natural killer cell (NK) activity and activation of monocytes (Barber, 2001; 
Fitzgerald-Bocarsly et al., 2007). In studies carried out by Santini et a l, (2000) and 
Paquette et al., (1998), type-I IFN was shown to induce monocytes to differentiate 
into dendritic cells. Fonteneau et a l, (2004) proposed a mechanism whereby pDCs 
regulate the function of myeloid dendritic cells (mDCs). For example, they 
demonstrated that the production of type-1 IFN and tumor necrosis factor-a (TNFa) 
by pDCs following human immuno deficiency virus-1 (HIV-1) infection, leads to the 
activation of mDCs and monocytes, upregulation of co-stimulatory molecules and 
increased interleukin-12 (IL-12) secretion. Activated mDCs can subsequently induce 
a TrI and cytotoxic T lymphocyte response in both mice and humans (reviewed in 
Liu. 2005). pDC derived type-1 interferons have been shown to stimulate natural 
killer cells (Tomescu. et a l, 2007), and together with IL-6, drive B cell 
differentiation into mature plasma cells (Jego et al., 2003). Type-I IFN has also been 
shown to have an impact on lymphocyte recirculation. Kalaaji et ah, (1988) 
demonstrated that recombinant bovine interferon alpha-1 inhibited the egress of 
lymphocytes from lymph nodes but had no effect on ingress (Sometimes referred to 
as lymph node shutdown). When this effect occurs locally, an increase in the number 
of lymphocytes within the responding lymph tissue may be benefical in terms of an
9
immune response. However if this effect is systemic, it may play a role in the 
transient immunosuppression described early during acute viral infection. This also 
go some way to explaining the transient lymphopaenia described early during acute 
viral infections. When taken together, these multiple roles for type-1 interferon, 
suggest a crucial role for pDCs in the initiation of a protective immune response 
against viruses.
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Figure 1.1-1: Immune modulation by type-1 IFN
In the circulation prior to activation pDCs and nDCs are in an im m ature state (iPDC 
and iMDC). Follow ing activation, pDC-derived IFN induces DC subset interaction 
and influences innate and adaptive imm une responses. Type-1 IFN produced in 
response to virus by pDC (and in som e cases m DC) leads to antiviral activity, 
recruitm ent and up-regulation o f  NK activity, activation o f  m onocytes as well as 
activation and maturation o f  mDC.
D epending on the nature o f  the stim ulus received, the mDC and pDC have the 
capacity to activate B cells for the production o f  antibody and activate T ,,!, T,,2, 
Treg, CDS T cell activity and T m em ory, with IFN-a playing a central role in these 
activities.
Figure from Fitzgerald-Bocarsly et al., (2007)
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1.2 Pathogen recognition
Pathogen recognition by cells of the innate immune system is the one of the earliest 
lines of defence that protects the host against invading bacteria and viruses. Host 
cells express various pattern recognition receptors (PRRs), both on the surface and 
on internal membranes (Kumagai et aL, 2008). These receptors recognise pathogen 
associated molecular patterns (PAMPs) such as lipids, lipoproteins, proteins and 
nucleic acids. Toll-like receptors (TLR) expressed on antigen-presenting cells such 
as macrophages and dendritic cells are primary examples of PRRs, (see Table 1.1) 
and play key roles in the induction of innate immune responses and the subsequent 
development of adaptive immune responses. Other PRRs expressed on the surface of 
dendritic cells include complement receptors, C-type lectin receptors such as the 
macrophage mannose receptor (MMR1), and DEC205, which are type I multi-CRD 
(carbohydrate recognition domain) lectins, DC-SIGN (Specific ICAM-3 grabbing 
non-integrin), which is a type II lectin with mannose specificity, FcR (Fc receptors) 
and scavenger receptors (Lee & Kim 2007). Recognition of pathogen associated 
molecules also takes place within the cell. The toll-like receptors TLR-3, TLR-7, 
TLR-8 and TLR-9, are expressed on internal membranes and are involved in 
recognition of pathogen-derived molecules, as are members of the CARD (caspase 
recruiting domain) family of helicases RIG-1 and MDA5, which recognise dsRNA. 
Members of the NOD-like receptors (nucleotide binding oligomerisation domain) 
family, NODI and NOD2, recognize intracellular bacterial PAMPs and host-derived 
molecules leading to the activation of the transcription factor NFkB and activation of 
antimicrobial defences (Wilmanski et al. 2008). Takaoka et al., (2007) have reported 
the presence of a cytosolic DNA sensor, DNA-dependent activator of interferon- 
regulatory factors (DAI) that selectively enhances the DNA-mediated induction of
12
genes involved in innate immunity including type-I IFN. There are also thought to be 
as yet unidentified cytosolic receptors that recognise dsDNA released from DNA 
viruses, bacteria and damaged host cells (Akira et a l 2006; Ishii and Akira, 2006).
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Receptor
TLR1
TLR2
TLR3
TLR4
TLR5
TLR6
TLR7
TLR8
TLR9
TLR10
Receptor expression
m on o cy te /M a cr o p h a g e ,  
s o m e  DC, B-cells
m o n ocyte /M ac rop h age ,  
myelo id  DC, mast cells
DC, B-cells
m o n ocyte /M ac rop h age ,  
myelo id  DC, m ast  cells, 
intestinal epithelial  cells
Receptor
Location
Cell surface
Cell surface
Cell com partm en t  
Cell surface
m on ocyte /M acrop h age ,  
s o m e  DC, intestinal 
epithelial cells
m on ocyte /M acrop h age ,  
mast cells, B-cells
m on ocyte /M ac rop h age ,  
plasmacytoid  DC, B-cells
m on ocyte /M acrop h age ,  
s o m e  DC, m ast  cells
m on ocyte /M acrop h age ,  
plasmacyto id  DC, B-cells 
m o n ocyte /M ac rop h age ,  B- 
cells
Cell surface
Cell surface
cell co m partm en t
cell co m partm en t  
cell surface
Ligand(s)
Triacyl lipopeptides  of  
gram-posit ive  bacteria 
Glycolipids, bacterial 
lipoproteins and 
peptidoglycan  
lip tote ichoicacid  
Heat Shock Protein 
(HSP) 70  
Zymosan
Double-stranded RNA, 
poly l:C
Lipopolysaccharide
Ligand location
Bacteria
Bacteria
Host cells
Fungi
Viruses
Gram-negative
bacteria
HSPs Bacteria and host  cells
Heparan sulphate  and  
hyaluronic acid
fragments, fibrinogen Host cells
and s o m e  viral
proteins
Flagellin Bacteria
Diacyl
l ipopeptides,l ipote ich M ycoplasm a  
o icac id
Imidazoquinoline,  
bropir im ineand
Cell co m partm en t  Loxoribine (guanosine  
analogue) , ssRNA 
(viral)
Single-stranded RNA 
Small synthetic  
com pou nds;  single ­
stranded RNA (viral) 
UnmethylatedCpG  
DNA
Small synthetic  
co m p o u n d s
Unknown
Bacteria
Unknown
m on ocyte /M ac rop h age ,  
TLR11(TLR12) liver cells, kidney, bladder cell surface  
epithel ium
Profil in
Uropathogenic
bacteria
Table 1.1: Toll-like receptors (TLR), their cellular expression patterns, ligands 
and ligand locations
Adapted from Doan et #/., (2007) and references there in.
*TLRl-9 share homology between human and mouse. TLR 10 can be found in the 
human genome but not TLR11,12 and 13. The mouse genome has TLR 11,12 and 
13, but not TLR 10.
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1.2.1 Induction of type I Interferon (IFN-a/p)
Mammals have between one and three IFN-p genes, multiple IFN-a genes and other 
genes such as IFN-omega ( go) , epsilon (-é ), tau (-%), delta (-5), and kappa ( - k). The 
majority of mammalian cells are capable of synthesizing type-1 IFN (IFN-a/p), but 
some cells such as plasmacytoid dendritic cells (pDCs) have a more pronounced 
ability to produce these cytokines. Interferon-a/p induction is controlled at the 
transcriptional level and interferon regulatory factors (IRFs), a family of transcription 
factors, play a pivotal role in this process. IRF-3 and IRF-7 have been shown to play 
a critical roles in the retinoic acid inducible gene-I (RIG-I), melanoma differentiation 
associated gene-5 (MDA5), and toll-like receptor (TLR)-mediated type-I IFN 
production pathways (Reviewed in Taniguchi et al., 2001).
There are three major pathways leading to the production of type-I interferon and 
the pathway utilized is not only dependent on the cell type and receptor used but also 
the nature of the inducer such as double stranded RNA (dsRNA), single stranded 
RNA (ssRNA) and CpG oligodeoxynucleotides etc. These major pathways are 
summarized in table (1.2).
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PATHWAYS
THelkaseT"""
RIG-1 p athw ay
TRIP pathw ay
IRF-7 pathw ay
iWHÊÊÊÊm
Sing le -  a n d C o n v e n t io n a l Kato e t  al.,
RIG-I C y to p la sm ic d o u b l e ­ DCs, 2 0 0 5 ;
(M D A 5)
s tr a n d e d  RNA F ibroblasts , Y o n e y a m a  e t
v ir u s es H e p a t o c y t e s al., 2 0 0 4  and  
2 0 0 5 ;  Kawai  
e t  al., 2 0 0 5 ;  Li 
e t  al., 2 0 0 5 ;  
Perry e t  al., 
2 0 0 5 ;
S u m p t e r  e t  
al. , 2 0 0 5
TLR3-TRIF
Internal v e s i c l e s U n m e t h y l a t e M a c r o p h a g e s
d dsRNA , H e p a t o c y t e s Li e t  al., 2 0 0 5 ;  
Perry e t  al., 
2 0 0 5 ;
TLR4-TRIF
P lasm a Viral S u m p t e r  e t
m e m b r a n e g ly co l ip id s al., 2 0 0 5 ;  
B i e n e m a n  e t  
al., 2 0 0 5 ;  
Kariko e t  al., 
2 0 0 5 ;
TLR9-My D 8 8 -  
IRF-7(IRF-5)
T L R 7 /8 -M y D 8 8 -
IRF-7(IRF-5)
E n d o s o m e
U n m e t h y l a t e  
d CpG DNA,  
c h r o m a t in  
i m m u n o  
c o m p l e x e s
U n m e t h y l a t e  
d RNA from  
p a t h o g e n s  
a n d  d a m a g e d  
h o s t  c e l ls
P la s m a c y to id
DCs
Kariko e t  al., 
2 0 0 5 ; H o n d a  
e t  al., 2 0 0 5 ;  
Rifkin e t  al., 
2 0 0 5
Table 1.2: Three M ajor pathways involved in IFN-a/p production
The RIG-1 IFN-a/p induction pathway is activated following cytoplasmic 
recognition o f dsRNA or ssRNA generated during RNA viral infection in 
conventional DCs, fibroblasts and many other cell types. Activation o f the TIR- 
domain-containing adapter-inducing interferon-p (TRIF)-TLR3/4 pathway follows 
recognition o f unmethylated dsRNA and viral glycolipids. The adaptor protein TRIF 
is recruited by TLR3 and TLR4 on either internal vesicles or at the plasma 
membrane and is involved in the induction o f type-I IFN. This pathway has been 
shown to be active in macrophages and hepatocytes. The IRF-7 pathway is triggered 
in pDCs in endosomes following recognition o f unmethylated CpG DNA, chromatin 
immunocomplexes, and unmethylated RNA from pathogens and damaged host cells.
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1.2.2 Toll like receptor signalling in interferon induction
Selective usage of adaptor molecules that are recruited to the cytoplasmic portion of 
individual TLRs following ligand stimulation regulate the signalling pathways (Fig. 
1.2). These adaptors, including myeloid differentiation primary response gene 88 
(MyD88), TRIF, toll-interleukin 1 receptor (TIR) domain-containing adaptor protein 
(TIRAP/Mal), TRIF-related adaptor molecule (TRAM) and selective androgen 
receptor modulator (SARM), are used differentially by the TLR molecules, providing 
some degree of redundancy (reviewed in Smith et al, 2005; Bonjardim et a l, 2009). 
TLR signalling is initiated following binding of the relevant pathogen associated 
molecular pattern (PAMP) to the receptor. It was initially believed that MyD88 was 
an essential component for the activation of innate immunity by all TLRs (Muzio et 
aL, 2000), however, it has since been shown that there is a MyD88-independent 
pathway for TLR3 and TLR4 signalling (reviewed in Akira and Takeda, 2004),
TLR3 being the only receptor relying completely on MyD88-independent signalling 
(reviewed in Pandey and Agrawal, 2006; Bonjardim et aL, 2009). MyD88 and the 
TIR domain-containing adaptor inducing IFN-p (TRIF) are known to be critical in 
the regulation of TLR signalling and are activated following specific TLR 
stimulation (reviewed in Pandey and Agrawal, 2006; Bonjardim et aL, 2009). TLR 
signalling via MyD88 leads to the activation of NF-kB and signalling via TRIF leads 
to the activation of IRF-3 and IRF-7.
Signalling through the MyD88-dependent pathway involves the association of 
MyD88 with the cytoplasmic TIR domain of the TLR. This recruits IL-1 receptor 
associated kinases (IRAK) -1 and -4 (Muzio et aL, 2000) which autophosphorylate 
and then bind TNF-associated factor-6 (TRAF-6; Gohda et al, 2004). In turn, this 
activates the mitogen activated protein kinase kinase kinase (MAP3K) pathway and
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linker molecules, transforming growth factor p-activated kinase (TAK-1), TAK- 
binding protein-1 (TAB-1) and TAB-2, which in turn activate downstream IkB  
kinase kinases resulting in the activation of c-Jun N-terminal kinase (JNK), activator 
protein-1 (AP-1) and the nuclear translocation of NF-kB (reviewed in Pandey and 
Agrawal, 2006; Kawai and Akira, 2006). This activation pathway leads to the 
production of tumour necrosis factor alpha (TNFa), interleukin-1 (IL-1), interleukin- 
6 (IL-6), interleukin-8 (IL-8) and interleukin-12 (IL-12; reviewed in Pandey and 
Agrawal, 2006; Bonjardim et aL, 2009). In pDC, MyD88 associates with IRF-7 
(Kawai et ah, 2004, Honda et aL, 2004) via the TRAF6/IKKa/IRF-7 signalling 
pathway (fig 1.2.2-1). IRF-7 is then phosphorylated by IRAKI and ubiquitinated by 
TRAF6 (Kawai et al, 2004), upon which it translocates to the nucleus and IFN-a/p 
production is initiated. pDCs have been demonstrated to express IRF-7 
constitutively and this may explain their ability to rapidly produce many different 
subtypes of type-I and type III IFN upon stimulation (Coccia et al, 2004, Ito et al,
2006). Endosomal detection of viral RNA via either TLR7/9 leads to the activation 
of the TRAF 6/IKKa/IRF-7 pathway resulting in high level production of type I/HI 
interferon (a,p,co and L)(reviewed in Bonjardim et al., 2009).
TLR3 or TLR4 mediated IFN-a/p production has been shown to be regulated by the 
TRIF-dependent pathway which involves the association of TRIF with the TLR via 
the adaptor molecule TRAM (Yamamoto et aL, 2003). NF-kB is then activated via a 
mechanism involving TRAF6 or the kinase receptor interacting protein (RIP-1) 
(Meylan et al, 2004). TRIF also associates with TRAF family member-associated 
NF-kB activator-binding kinase-l(TBK-l) and inducible IkB kinase (IKK-s; 
Fitzgerald et al, 2003) which phosphorylates IRF-3 and IRF-7 and leads to the 
production of type-I IFN (Pandey and Agrawal, 2006; Bonjardim et aL, 2009).
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TRAF3 has also been shown to be associated with MyD 8 8-dependent and 
independent signalling (reviewed in Pandey and Agrawal, 2006) and the use of this 
adaptor may result in the production of type-I IFN and IL-10. However, MyD 8 8 was 
shown to be non-essential in the production of pro-inflammatory cytokines (Hacker 
et al, 2006).
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Figure 1.2 Endosomal and cytosolic detection of viral nucleic acid
Endosomal recognition of viral nucleic acid via TLR7, 9/MyD88 results in the 
activation of the TRAF6/IKKa/IRF-7 signalling pathway, which culminates in type 
I/IIIIFN production. Cytoplasmic recognition of ss/dsRNA/dsDNA via RIG- 
I/MDA5 /DAI pathway (a) will be discussed elsewhere. TLR7, 9/MyD88 also leads 
to activation of the PI3K/mTOR/S6K pathway followed by IFN-a/p production (c). 
Downstream targets of TRAF6 also include: (i) TAK1 ZIKKa/p/NF-kB , a pathway 
that leads to the expression of inflammatory cytokines (b) and (ii) TAKl/MAPKs. 
Members of the latter cascade then migrate to the nucleus and activate the 
transcriptional regulator API, which in turn controls the expression of co-stimulatory 
molecules CD80 and 86 (d). Viral recognition via TLR3/TRJF is followed by the 
engagement of TRAF3/NAP1 or TANK-TBKl/IKKs molecules and the subsequent 
activation of IRF-3. IRF-3 translocates to the nucleus and activates transcriptional 
regulation of type I IFN genes. Full activation of IRF-3 also requires PI3K/AKT (e). 
Signal transduction downstream of TRAF3 also results in the activation of MAPKs 
and N F - kB  and leads to the expression of co-stimulatory molecules (d) and 
inflammatory cytokines (b). Viral recognition by endosomal TLRs is autophagy 
dependent. Mice deficient in the autophagy protein atg-5 failed to produce type-I 
IFNs.
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1.2.3 Helicase recognition of viral infection
Two molecules that have a major role in host cell recognition of viral dsRNA are 
retinoic acid-inducable protein-I (RIG-I; Yoneyama et al, 2004) and melanoma 
differentiation-associated gene-5 (MDA5; Kang et al, 2002). dsRNA is recognised 
by the immune system via two distinct receptor-mediated pathways; the Toll-like 
receptor 3 (TLR3) pathway is stimulated by dsRNA phagocytosed in endosomes 
whilst the helicases (RIG-I) and (MDA5) are stimulated by dsRNA generated during 
viral replication. A further RNA helicase, called LGP2 has also been identified, 
although it is proposed to be a negative regulator of RIG-I and MDA5 (Yoneyama et 
al, 2005). The following protein interactions are described in Akira et a l, (2006). 
RIG-I and MDA5 contain carbohydrate recognition domains (CARD)-like structures 
that are required for signalling. The CARD domains of these helicases interact with 
an adaptor protein IPS-1 (also known as MAYS, VISA or CARDIF). IPS-1 localises 
to the mitochondria and initialises intracellular signalling pathways that lead to 
activation of IRF-3, NFkB and AP-I TBKl/IKKi, IKKa/IKKp and MAP kinases, 
respectively. Both RIP1 and F ADD are implicated in RIG-I- and MDA5-dependent 
pathways. Both F ADD (Fas-asscociated protein with death domain) and RIP1 
(Receptor-interacting protein 1) activate NF-kB, and interferon-p stimulator protein 1 
(IPS-1) promotes F ADD- and RIP-1-mediated NF-kB activation. However, the 
precise mechanisms of how IPS-1 activates IRF-3, NF-kB and AP-1 remain unclear 
(Akira et a l, 2006).
1.2.3.1 Retinoic acid-inducible gene I (RIG-I)
RIG-I was first identified by Yoneyama et al, (2004) as a DExD/H box helicase that 
has two caspase-recruiting (CARD)-like domains, the helicase domain is required for 
interaction with dsRNA, and signaling is transduced via the CARD-like domains
(Yoneyama et al, 2004). The RIG-I pathway is crucial for induction of type-I IFNs 
following infection with RNA viruses in fibroblasts and mDCs, however, 
plasmacytoid DCs were shown to use the TLR system rather than RIG-I for viral 
detection (Kato et al, 2005). It has also been shown that RIG-I is essential for the 
production of type-1 IFN in response to RNA viruses including Japanese encephalitis 
virus, paramyxoviruses, influenza virus, whereas MDA5 is critical for the detection 
of picomaviruses (Kato et al, 2006).
1.2.3.2 Melanoma differentiation-associated gene-5 (MDA5)
MDA5 is structurally related to RIG-I in that it also has two CARD-like domains 
and one helicase domain (reviewed in Kawai and Akira, 2006). Using bone marrow- 
derived DC and macrophages from MDA5 knock-out mice, Gitlin et al, (2006) 
demonstrated an essential role for MDA5 in recognition of dsRNA, as evidenced by 
the lack of type-1 IFN production in response to pI:pC in knock-out mice. In the 
same publication, it was shown there was a role for MDA5 in vivo for induction of 
the anti-viral immune response to a positive strand RNA picornavirus; 
encephalomyocarditis virus (Gitlin et al, 2006).
1.3 Transcriptional activation of type-1 IFN genes in response to viral infection
Transcriptional activation of the IFN-a/p genes, which are induced via TLR3, TLR7 
or TLR9 in endosomes, or MDA5 or RIG1 in the cytoplasm, is mediated by complex 
pathways involving many transcription factors including the IRFs.
Induction of the IFN-p gene is better understood than that of IFN-a and optimal 
induction requires binding of several transcription factors including NFkB, IRF-3 
and the c-jun/ATF-2 (activating transcription factor-2) heterodimer to the four 
positive regulatory domains (PRDs) on the promoter to form the enhanceasome
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complex (Merika and Thanos, 2001; Figure 1.3). Within the enhanceosome, IRF-3 
and/or IRF-7, bind to IFN-stimulated response element (ISRE) sites (PRD I and III), 
nuclear factor (NFkB) binds to the /cB site (PRD II), and the c-jun/ATF2 (activated 
transcription factor-2) heterodimer binds to the c-AMP-responsive element (PRD 
IV). The high- mobility group chromatin-associated protein (HMGA) is also known 
to play a role in the formation of this complex, (Merika and Thanos, 2001). The 
components of the enhanceasome complex are involved in recruiting the cAMP 
response element binding protein (CREB)-binding protein (CBP)/p300, which 
promotes the assembly of the basal transcriptional machinery and RNA polymerase
II. The enhanceasome model suggests that individual transcription factors bind to the 
promoter with limited affinity and that cooperation between them is necessary for 
optimum induction. However, several publications have reported that binding of 
transcription factors to individual binding sites can induce a level of interferon 
production with IRF-3 and/or IRF-7 being considered essential but activation of 
NFkB or c-jun/ATF2, or their binding to the promoter, not required (Ellis and 
Goodboum 1994; Peters et al., 2002).
The transcriptional activation of IFN-a is not as clearly defined as that of IFN-p but 
it is known that the promoters of these genes do not have NFkB binding sites but do 
have binding sites for multiple members of the IRF family, IRF-3, IRF-5 and IRF-7 
(Schafer et aL, 1998; Barnes et al., 2001; Au et al., 2001). It is still unclear which 
members of the IRF family stimulate different IFN-a gene transcription and it may 
be that different IRFs are required for the activation of the promoters of the different 
IFN-a genes. There is, however, an increasing body of evidence suggesting that in 
many cases IRF-7 plays a crucial role in the stimulation of IFN-a genes. Studies 
carried out by Au et al, (1998) and Lin et al., (2000), provide evidence that IRF-7
24
preferentially stimulates IFN-a gene transcription. A further study by Morin et al, 
(2002) demonstrated that IRF-7, in association with IRF-3, was necessary for the 
induction of IFN-a gene transcription; The apparent requirement for IRF-7 in the 
induction of IFN-a gene transcription correlates with the high level of IFN-a/p 
produced by pDC, in which IRF-7 is known to be constitutively expressed. The 
constitutively higher level of IRF-7 in pDCs is believed to be associated with the 
rapid induction and high level of expression of type-1 IFN in response to ssRNA or 
CpG DNA recognised by TLR7 or TLR9 respectively following viral infection.
In cells other than pDCs, a positive feedback model has been proposed in which the 
initial induction of IFN-P occurs via IRF-3. The IFN then feeds back onto the cells 
and induces the synthesis of IRF-7 which not only enhances the transcription of IFN- 
P but also facilitates the transcription of IFN-a genes (Sato et a l, 1998; Prakash et 
a l, 2005).
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Figure 1.3 ssRNA -  TLR7 and TLR9 dependent signalling and the IFN-p 
promoter in pDCS
In pDCs, ssRNA or CpG DNA is recognised by TLR7 or TLR9 respectively, in 
endosomes. This can occur by endocytosis of extracellular nucleic acids or uncoating 
of endocytosed viral particles, or by degradation of engulfed apoptotic cells. TLR7 is 
also stimulated by viral PAMPs taken into the endosomes from the cytoplasm by 
autophagy. Activated TLRs recruit the adaptor MyD88 that recruits IRAK-1 and 
IRAK-4. This complex recruits further signalling components that feed into either 
the IRF-7 or NF-kB pathways. IRF-7 recruitment to the MyD88 adaptor complex 
requires polyubiquitination by TRAF6 in a RIP 1-dependent manner. IRF-7 is 
phosphorylated by IRAK-1 and a complex containing IRF-7, MYD88, TRAF6, 
IRAK-1 and possibly IRAK-4, is released and migrates to the nucleus (blue arrows). 
Here it assembles on the IFN-p promoter with NF-kB and other factors, leading to 
the stimulation of transcription. IRF-7 can also stimulate IFN-a promoters strongly.
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1.4 Type-1 IFN induced gene expression
Binding of type-1 IFN to cellular receptors leads to the activation of signaling 
cascades via the Jak/STAT pathway, which results in the activation of transcription 
of interferon responsive genes that are normally expressed at either a low level or are 
not expressed until stimulated. The type-I IFN receptors are composed of 
heterodimers of IFNR1 and IFNR2. Activation involves receptor dimérisation and 
tyrosine phosphorylation involving members of the Janus kinase (Jaks) family. 
Activated Jaks phosphorylate the receptor subunits themselves, and specific 
members of the signal transducers and activators of transcription (STATs) family of 
proteins. The Jaks recruit the STATs either directly or via Src homology (SH)-2 
domain-containing adaptor proteins. The phosphorylated STATs form homo- or 
heterodimers which translocate to the nucleus and associate with the DNA-binding 
protein IRF-9 to form a heterotrimeric complex called ISGF3. ISGF3 is a 
transcription factor which binds the interferon stimulated response element (ISRE) 
present in the promoter region of all IFN-a^5 responsive genes and enhances 
transcription (Randall and Goodboum 2008; Figure 1.4). This is the generally 
accepted mechanism of type-I IFN induced gene expression, however, a publication 
by Tang et aL, (2007) suggests that assembly of the ISGF3 complex may be 
coordinated at the receptor. The authors suggest that following IFN stimulation, 
CREB binding protein (CBP), a transcriptional co-factor, is recruited to the IFNR2 
receptor chain which catalyses its acétylation creating a docking site for IRF-9, 
which is also acetylated, as is STAT1 and STAT2. This acétylation of IRF-9 is 
necessary for DNA binding and they believe acétylation of the STAT factors may aid 
ISFG3 assembly.
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Figure 1.4: Overview of type-1 interferon induced gene expression
Signalling pathway activated by IFN-a/p. The biological activities o f IFN-a/p are 
initiated by binding to the type-I IFN receptor. This leads to the activation o f the 
receptor associated tyrosine kinases JAK1 and Tyk2, which phosphorylate STAT1 
and STAT2. Phosphorylated STAT1 and STAT2 interact strongly with each other by 
recognizing SH-2 domains, and the stable STAT1-STAT2 heterodimer is 
translocated into the nucleus, where it interacts with the DNA-binding protein IRF-9. 
The IRF-9— STAT1—STAT2 heterotrimer is called ISGF3 and it binds to a sequence 
m otif (the IFN stimulated response element or ISRE) in target promoters and brings 
about transcriptional activation.
Figure from Randall and Goodboum, (2008)
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1.5 The type-1 IFN induced anti-viral response
IFN inducible proteins include, proteiris involved in antigen presentation, 
transcription factors, signalling proteins, enzymes, chemokines, heat shock proteins 
and proteins involved in apoptosis. No single gene has been identified as pivotal in 
the antiviral response, but rather, subsets of these genes appear to be required to limit 
viral replication for any given virus. The best characterised genes that are up- 
regulated in the antiviral response encode enzymes such as dsRNA-dependent 
protein kinase R (PKR), 2’-5’ oligoadenylate synthetases (OAS) and interferon 
inducible Mx proteins. These genes and their protein products all form part of the 
anti-viral response though there are many other factors involved.
1.5.1 dsRNA-dependent protein kinase R (PKR)
PKR is a serine / threonine kinase that is involved in the control of both transcription 
and translation (Clemens and Elia, 1997). This enzyme is constitutively expressed in 
mammalian cells and is normally in the inactive state but can be activated by binding 
to dsRNA (Meurs et al., 1990). It is postulated that in its active form, this enzyme 
dimerises and the two molecules transphosphorylate each other. Activated PKR can 
phosphorylate selected cellular proteins including the translation initiation factor elF- 
2a, leading to the inhibition of protein synthesis and promotion of apoptosis (Meurs 
et aL, 1992). Phosphorylation of eIF2a also inhibits translation of viral mRNA and 
this is the basic mechanism through which PKR exerts its antiviral effects (Lee et aL, 
1996; Balachandran et aL, 2000). In addition to its translational regulatory function, 
PKR is involved in signal transduction and transcriptional signalling in response to 
IFNs, dsRNA, TNF-a, and other environmental stresses via the IkB /N F kB  pathway 
(Myskiw et aL, 2009). The IFN inducible, dsRNA-activated protein kinase PKR, 
(also known as PI kinase, p68 kinase or eukaryotic translation initiation factor 2-
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alpha kinase 2 [EIF2AK2]), is a member of the eIF2a family of protein kinases 
which are activated under conditions of cellular stress. Edwards et aL, (2007) clearly 
demonstrate the involvement of PKR in N F kB  mediated gene transcription of pro- 
inflammatory cytokines via IkB  kinase-p following dsRNA production during 
rhinovirus infection of an immortalized human bronchial epithelial cell line (BEAS- 
B2). Using 2- aminopurine, a new small molecule inhibitor and genetic inhibition of 
dsRNA binding to PKR, they achieved a striking inhibition of the production of 
chemokines CCL5, CXCL8 and cytokine IL-8.
1.5.2 2’-5’ oligoadenylate synthetases (OAS)
The products of the 2 ’ -56 oligoadenylate synthetases (OAS), the 2’-5’- 
oligoadenylates, activate a latent ribonuclease (RNase 1), which cleaves both cellular 
and viral RNA. On binding to RNA, the OAS are activated and polymerise adenosine 
triphosphate (ATP) into 2’-5’ linked oligoadenylates. There are three size classes of 
these enzymes, small (OAS1) around 40kD range, medium (OAS2) around 70kD 
range and large (OAS3), around lOOkD range (Rebouillat and Hovanessian, 1999). 
Each class is encoded by a separate gene and within each class there are multiple 
isozymes resulting from alternative splicing of mRNA. These isozymes may have 
different post-translational modifications and different sub-cellular locations. The 2’- 
5’ oligoadenylates activate RNase 1 by causing dimérisation of the inactive RNase 1 
monomers. This enzyme system inhibits the replication of specific families of 
viruses, especially picomaviruses (Chebath et aL, 1987; Rysiecki et aL, 1989).
1.5.3 Mx proteins
Mx proteins are members of the dynamin superfamily of guanosine triphosphatase 
(GTPase) and are involved in endocytosis and vesicle transport. They were originally
31
reported as IFN induced proteins with the ability to inhibit the replication of 
Influenza virus (Horisberger et aL, 1983). It is now known that Mx proteins are 
capable of inhibiting many RNA viruses including members of the Togaviridae, 
Rhabdoviridae, Orthomyxoviridae, and Paramyxoviridae families (Haller et aL, 
1998). Mx proteins are believed to interfere with viral replication using a dynamin- 
like force generating mechanism to wrap around viral nucleocapsids and inactivate 
their function (Haller et. aL, 2007). For some virus infections, Mx proteins may 
direct viral nucleocapsids to alternative sites in the cytoplasm where they are no 
longer functional in RNA synthesis but rather are immobilized and targeted for 
degradation (Kochs et aL, 2002; Haller et aL, 2007).
1.6 Type II IFN
Type II IFN in mammals consists of a single member known as IFN gamma (IFN-y). 
This cytokine is involved in the regulation of the inflammatory and immune 
responses and is produced by activated T-cells, natural killer cells (NK), NKT cells 
and some antigen presenting cells such as macrophage (Flaishon et aL, 2000; Frucht 
et aL, 2001; Harwich et aL, 2009). IFN-y has some anti-viral and also some anti­
tumor effects, but these in general are weaker than those seen with type-I IFNs. 
However, it is known that IFN-y can potentiate the effects of type-I IFNs. IFN-y 
released by Tyl cells, can increase inflammation by recruiting leukocytes to a site of 
infection. It can stimulate macrophages to kill phagocytosed bacteria and IFN-y 
released by Tyl cells is important in down-regulating the Th2 response. This 
cytokine has been shown to be involved in the regulation of immune responses and 
its over-production can lead to autoimmune disorders (reviewed in Schroeder et aL, 
2004).
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The importance of IFN-y in the immune response is in part its ability to directly 
inhibit viral replication by inducing anti viral enzymes such as PKR (Meurs et aL, 
1990), but the immunostimulatory and immunomodulatory effects of this cytokine 
are much more important. IFN-y is produced by cells of both the innate and adaptive 
immune response, predominantly by natural killer (NK) and natural killer T (NKT) 
cells, and by CD4 and CDS cytotoxic T lymphocyte (CTL)T cells once antigen- 
specific immunity develops (Schoenbom and Wilson, 2007).
Cellular responses to IFN-y are initiated following receptor interaction. The receptor 
for IFN-y is separate from the type-I IFN receptor and consists of Interferon gamma 
receptor l(IFNGRl) and Interferon gamma receptor 2 (IFNGR2). Binding to the 
receptor complex leads to activation of the Jak-STAT pathway (Fig 1.6-1). IFN-y can 
also bind to glycosaminoglycan heparan sulphate (HS) on the cell surface, however, 
this interaction has been shown to be inhibitory, reducing IFN-y biological activity 
(Sadir et aL, 1998).
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Figure 1.5 Type-II IFN signal transduction
Ligand binding causes a conformational change in the IFN-yR (IFNGR1, yellow; 
IFNGR2, green), such that the inactive Jak2 kinase undergoes autophosphorylation 
and activation, which in turn allows Jakl transphosphorylation by Jak2. The 
activated Jakl phosphorylates functionally critical tyrosines on residue 440 of each 
IFNGR1 chain to form two adjacent docking sites for the Src homology (SH)2 
domains of latent STAT1. The receptor-recruited STAT1 pair is phosphorylated near 
the C terminus which induces dissociation of a STAT1 homodimer from the 
receptor. STAT1 homodimers localize to the nucleus and bind to the promoter’s 
IFN-y activation site (GAS) elements to initiate or suppress transcription of IFN-y 
regulated genes, depending on the recruitment of co-activators or co-repressors 
(reviewed in Ramana et al., 2000). Many of IFN-y -regulated genes are in fact 
transcription factors (e.g., IRF-1), which are activated by IFN-y and are able to drive 
regulation of the next wave of transcription. STAT1 :STAT1 : IRF-9 heterodimers, 
ISGF3, and IRF-1 are able to bind to IFN-stimulated response element (ISRE) 
promoter regions in target genes to regulate transcription. IRF-1 is also able to 
promote transcription of STAT1 through an unusual ISRE site (IRF-E/GAS/IRF-E). 
Signalling molecules activated by IFN-y are depicted in red text. ICAM-1, 
(Intercellular adhesion molecule-1); MIG, (monokine induced by IFN-y); iNOS, 
(inducible nitric oxide synthase).
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IFN-y alters transcription of many genes leading to diverse cellular responses. 
Among the effects are: promoting NK cell activity, increasing antigen presentation 
and enzyme activity in macrophages and activation of inducible Nitric Oxide 
Synthase (iNOS; reviewed in Schroeder et aL, 2003). IFN-y has also been shown to 
promote ThI T cell differentiation by up-regulating the transcription factor T-bet. 
This results in activation of cell mediated immunity by stimulating cytotoxic CD8+ 
T-cells and macrophage activity, while suppressing TH2 differentiation and an 
antibody response. IFN-y also increases expression of MHCI molecules as well as 
MHCn on antigen presenting cells, specifically by inducing antigen processing 
genes, it also promotes adhesion and binding required for leukocyte migration and 
trafficking. IFN-y can also induce the expression of intrinsic defense factors 
(reviewed in Schroeder et ah, 2004).
1.6.1 Cross-talk between type I and type II IFN
Cross-talk between type I and type II IFN occurs at multiple levels. The signalling 
pathways and target genes of type I and type II IFN are known to partially overlap 
which provides the opportunity for cross-talk to synergise or antagonise specific 
functions within the cell. In a biological system this allows for signalling events 
elicited by a cocktail of cytokines to produce specific effects and instruct gene 
expression through the integration of multiple signalling pathways. During the initial 
signaling cascade, IFN-y primarily signals through STAT1 homodimers, however 
additional signalling molecules are also activated including interferon stimulated 
gene factor 3 (ISGF3), the archetypal type-I signalling molecule, which would allow 
cross-talk between the types-I and -II IFN pathways (Matsumoto et aL, 1999). Type-I 
IFN can also induce type-II IFN signaling molecules such as active STAT1 
homodimers which are able to bind to GAS sites to activate the transcription of target
genes (Min et al., 1998; Sen, 2000). Data published by Takaoka et aL, (2000), 
suggests that a sub-threshold level of type-I IFN in mouse embryonic fibroblasts 
leads to the interaction of the IFNGR2 and IFNAR1 chains in caveolar membrane 
domains of the cell membrane. In their model they suggest that low levels of type-I 
IFN are necessary to maintain the type-II IFN receptor in its phosphorylated form 
and thereby provide promote efficient assembly of IFN-y activated STAT1 
homodimers. A more recent paper by Gough et aL, (2010) has presented data to 
support a model in which autocrine priming of cells by low levels of constitutively 
expressed type-I IFN primes the expression of type-II IFN by regulating expression 
of STAT1. They attribute continuous expression of the transcriptional activator c-jun 
as being responsible for producing basal levels of a type-I IFN, which prime the cells 
with sufficient STAT1 to respond robustly to a subsequent type-II IFN signal. This 
they suggest is an alternate mechanism to the involvement of part of the type-I IFN 
receptor (IFNAR1) acting as a component of the type-II IFN receptor.
1.7 Type-III IFN
The discovery of a trio of novel interferon (IFN)-like cytokines that are referred to 
as either IFN-11, -À2, and -13 or interleukin-29 (IT-29), IL-28A, and IL-28B, 
respectively and grouped as type-III IFN, was independently reported by two groups 
in 2003 (Kotenko et aL, 2003 Sheppard et aL, 2003). In humans there are 3 IFN-1 
genes that encode 3 distinct but highly related proteins. In mouse only IFN12 and 
IFN13 appear to be functional with IFN11 being reported as a pseudogene (Lasfar et 
aL, 2006) and more recently it has been reported that there are two IFN-1 genes 
(IFNX2/3) active in swine (Sang et aL, 2010). Diaz-San Segundo et aL, (2011) have 
recently reported the identification and characterisation of bovine IFN13 and have 
demonstrated that it is biologically active. Their recombinant adenoviral vector
expressing bovine type-III IFN (Ad5-boIFN-X3) was capable of inducing systemic 
antiviral activity against foot and mouth disease virus (FMDV) following inoculation 
of cattle. Until recently there had been no description of selective induction of type- 
III IFN rather than type-I IFN. Recently however, there have been several 
descriptions of a selective induction of type-III IFN (IFN-À,) (Okabayashi et aL,
2011; Zhang et aL, 2011). Zhang et aL, (2011) have identified a novel cytosolic 
DNA sensor Ku70 that preferentially induces IFN-11 via IRF-1 and IRF-7. A further 
study carried out by Okabayashi et aL, (2011) clearly demonstrated the preferential 
induction of type-III IFN by nasal epithelial cells (NEC) in response to respiratory 
viruses, including measles virus, respiratory syncytial virus (RSV) and mumps virus. 
However, in most cases type-1 and type-III IFN appear to be co-produced in 
response to viral infection which strongly suggests that generally they are regulated 
by common mechanisms, with similarities in terms of the mechanism of induction, 
signal transduction and biological activities having been described (Uzé and 
Monneron 2007).
1.7.1 Transcriptional activation of type-III IFN genes in response to viral 
infection
Type-III IFNs or IFN-A/s differ genetically and structurally from type-I IFNs (Fig 
1.7.1-1). The IFN-A, genes are clustered together on human chromosome 19 
(19ql3.13 region) or murine chromosome 7 (7A3 region; Donnelly and Kotenko, 
2010). The IFN-A3 gene (IL28B) is transcribed in the opposite direction of the IFN- 
Ad (IL29) and IFN-A2 (IL28A) genes. To date, the only described bovine IFN-A., 
IFN-A3 (IL-28B), is located on bovine chromosome 18. The coding region for each 
of these genes is divided into 5 exons and has similarity to the genes encoding the 
IL-10-related cytokines (Kotenko 2003; Donnelly and Kotenko 2010), in contrast, 
the type-I IFN genes lack introns.
Despite the genetic differences in type-I and type-III IFN, their similar antiviral 
functions, have led to the assumption that their expression is regulated in a similar 
fashion (Fig 1.7.1-2). Osterlünd et aL, (2007) analyzed the regulation of IFN-A, 1 and 
IFN-X3 gene expression in human monocyte-derived dendritic cells (moDCs) in 
response to Sendai virus (SV) infection. Using cloned promoter elements of these 
genes, they identified the transcription factors and signaling pathways that control 
IFN-A. gene expression.The authors demonstrated that the IFN-A. 1 gene is regulated 
by both IRF-3 and IRF-7 in a similar manner to IFN-P gene regulation, whereas the 
major regulator of IFN-A2/3 genes is IRF-7. Osterlünd et al., (2007) also examined 
the role of NFkB components in the induction of type-I and type-III IFN, 
demonstrating that although IFN-a promoters are only weakly activated following 
transfection of p50 and p65 subunits of NFkB, IFN-A, promoters and the IFN-P 
promoter activation are readily induced by p50/p65 heterodimers to levels similar to 
or exceeding those induced by Sendai virus. This suggests that although IRF-7 is the 
major controller of IFN-A.2/3 induction, significant levels of type-III IFN can be 
induced following transfection of biologically active NFkB p50/p65 heterodimers 
indicating that type-III IFN may be more reliant on NFkB than type-I IFN and 
represent a mechanism whereby type-III IFN can be produced in response to viruses 
that specifically target the type-I IFN pathway.
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oFigure 1.6. Organization of the genes encoding the IFN-ls and their receptors.
Schematic representations o f the chromosomal regions o f the human and mouse 
genomes that encode the IFN-X (A) and IFN-X receptor (B and C) genes.
The genes are transcribed in the direction indicated by the arrows. Although the 
human and murine IFN-X and IFN-X receptor loci are co-linear, the human genome 
encodes 3 functional IFN-X genes and 1 pseudogene (denoted IFN-X4XF), whereas 
there are only 2 functional IFN-X coding genes in the murine genome: IL-28a (IFN- 
X2) and IL-28b (IFN-X3). mIFN-XlY and m IFN-XW  genes are pseudogenes. 
Unspliced transcripts for the IFN-X genes (red box -A), and red box (B) for the IFN- 
X receptor genes are schematically shown as strings o f filled or open boxes (exons) 
joined by intervening lines (introns). Spliced transcripts are also shown as 
shaded/open boxes with vertical lines indicating the relative positions o f former 
introns. The coding regions o f exons are shaded and the segments corresponding to 
the 5’ and 3 ’ untranslated regions are open (not shaded).
Figure from Donelly and Kotenko, 2010
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Figure 1.7 Model of the expression of Interferon
A variety o f sensors are used by cells to sense pathogens or damage. When engaged 
these sensors trigger several overlapping pathways leading to the activation o f 
transcription factors that induce expression o f type-I and type-III IFN genes. Two 
classes o f transcription factors nuclear factor kB (NFkB) and interferon regulatory 
factors (IRFs) are crucially important in the induction o f both type-I and type-III IFN 
expression. AP-1 transcription factor (dimeric transcription factor containing 
members o f the JUN, ATF, FOS and MAF protein families) is involved in the 
regulation o f the IFN-P gene. AP-1 binding sites are also predicted in the promoters 
o f IFN-À, genes but their functions have not yet been described.
Figure from Kotenko et aL, 2011
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1.7.2 Type-III IFN induced gene expression
Type-III IFNs are genetically and structurally distinct from type-I IFNs and act 
through a different receptor system (Fig 1.7.2-1). These cytokines act through a cell 
surface receptor composed of two chains, (IFNLR1) being IFN-X specific component 
of the IFN-X receptor and (IL-10R2), which also forms part of the receptor 
complexes for IL-10, IT-22 and IL-26. IL-10R2 is ubiquitously expressed, whereas 
IFNLR1 although apparently expressed in most organs, is not expressed in all cell 
types, lending cell type specificity to the biological actions of type-III IFN (Donelly 
and Kotenko, 2010). IFN-X and type-I IFNs (IFN-a and IFN-p) both activate the 
Jak/STAT pathway (Kotenko et a l, 2003; Zitmann et a l, 2006). Signaling via the 
IFN-XR results in phosphorylation of STAT1 and STAT2 (also STATS and STAT5) 
and induces assembly of the ISGF3 and STAT1 homodimer complexes (Kotenko et 
aL, 2003; Dumoutier et aL, 2004). Therefore, many of the genes induced by type-I 
IFN are also induced by IFN-X (Kotenko et a l, 2003; Sheppard et a l, 2003). A more 
recent study by Maher et a l, (2008) has shown that IFN-a and IFN-X differ not only 
in the duration of Jak/STAT signalling activity induced but also in their anti­
proliferative effects. HaCaT cells, a human keratinocyte cell line that can be growth 
inhibited by IFN-a treatment was driven to apoptosis when treated with IFN-X. The 
authors show that IFN-X treatment lead to prolonged activation of STAT1 and 
STAT2, with a delayed but stronger induction of interferon stimulated genes (ISGs) 
compared to IFN-a treatment. There have also been reports where IFN-Xs exhibit 
potent anti-viral activity in vivo but show no such response on in vitro virus 
replication on cells that are known to be responsive to IFN-X. Bartlett et a l, (2005) 
demonstrate that a recombinant vaccinia virus expressing IFN-X2 or IFN-X3 
replicates normally in tissue culture but is attenuated in mice following intranasal or
intra-dermal delivery of these cytokines. A further study by Ank et aL, (2006) clearly 
demonstrates that IFN-X cannot protect HepG2 cells (a human liver hepatocellular 
carcinoma cell line) from herpes simplex virus type-2 (HSV-2) infection, but IFN- X 
treatment of HSV-2 infected mice significantly reduced the hepatic viral titre. The 
authors also demonstrated that IFN-X treatment completely blocked viral replication 
in the vaginal mucosa and prevented development of disease.
The fact that only specific cells express the receptor for type-III IFN, including 
epithelial cells and dendritic cells, together with the results described by both Barlett 
et aL, (2005) and Ank et aL, (2006), suggest a more selective anti viral role for type- 
III IFN, restricted to specific cell populations. The results from the two studies 
described indicate a role for type-III IFN at mucosal surfaces and suggests type-III 
IFN may have an important role to play in immunomodulation in response to virus 
infection.
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Figure 1.8 Jak/STAT signalling pathway activated by type - 1 / II IFN and type 
III IFN (IFNI / IL29, IL28a, IL28b)
Signal transduction activated by the binding o f IFNs to their cognate receptors 
induces expression o f many IFN-stimulated genes (ISGs). The proteins encoded by 
these genes in turn mediate the antiviral activity o f the IFNs, particularly the type-I 
and -III IFNs.
Among the STATs phosphorylated by Tyk2 and Jakl tyrosine kinases, STAT2 and 
STAT1, together with IRF-9, form the ISGF3 transcription factor which migrates 
into the nucleus and activates the transcription o f a large number o f IFN-Stimulated- 
genes (ISGs) carrying an IFN-stimulated response elements (ISRE) in their 
promoters, such as IRF-7, M xl, and OAS1.
Figure from Donnelly and Kotenko 2010
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1.8 Viral evasion of the IFN system
Due to the potent anti-viral effects of interferon, almost all mammalian virus families 
have evolved strategies to evade or inhibit the IFN system. Viruses employ a variety 
of strategies to block different parts of the interferon pathway and it is common to 
find inhibition at multiple steps. The mechanisms of interference with the IFN 
pathway include blocking IFN synthesis, blocking IFN signalling, blocking IFN 
induced protein function, blocking host cell gene expression or protein synthesis, or 
having a replication strategy that is relatively insensitive to the action of interferon 
(Table 1.8-1). Specific targeting of components of the interferon pathway by viruses 
that cause persistent infection have been reported e.g. The Npro protein of classical 
swine fever virus which targets IRF-3 (Ruggli et aL, 2005; Seago et ah, 2007), 
whereas lytic viruses often simply employ a general block on host cell transcription 
and translation, e.g. proteinases of picomaviruses such as foot and mouth disease 
vims (FMDV; de Los Santos et aL, 2006).
A dynamic equilibrium exists between the hosts’ ability to produce IFN in response 
to viral infection and therefore limit viral replication, and the ability of the vims to 
block or inhibit the production of IFN, thereby ensuring its survival. Better 
understanding of the relationship between vimses and the IFN system will hopefully 
lead to the design of new strategies for prevention and therapy.
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M EC H A N IS M S VIRUS VIRAL PR O TEIN S /  INTERACTION
Block in IFN sy n th e sis
IFN -R eceptor D ecoys
Block in IFN signalling
Block in IFN -induced 
p ro te in  function
Hum an
pap illom avirus 16  
(HPV-16)
H um an
p ap illom avirus (HPV)
H um an h erp esv iru s 8  
(HHV-8)
Influenza Virus
Foot and m ou th  
d isea se  virus 
(FMDV)
P o x v iru ses
A denovirus
H epatitis B virus 
(HBV)
Hum an
p ap illom avirus (HPV) 
Sim ian virus 5 (SV5)
A denovirus
Epstein Barr virus 
(EBV)
H erpes s im p lex  virus 
t y p e l  (HSV-1)
Vaccinia virus
Influenza virus
o p e n  read ing fram e C 
produ ct (ORF-C) 
and th e  viral term inal 
protein
E6 p rotein  o f  HPV-16 binds 
IRF-3, E7 protein  binds IRF-1
E ncodes a viral IRF th a t 
in ter feres  w ith  cellu lar IRF 
fu n ction s
NS1
Virus e n c o d e d  p r o tea ses  
c lea v e  tran sla tion  initiation  
fa c to rs  elF4-G and elF4A
Vaccinia virus B18R binds 
IFN-a/P
E1A - inhibits or  in terferes  
w ith  m ultip le s te p s  in IFN 
signalling
S eq u estra tion  o f  STATs or 
altering th eir  
p h osp h ory lation
HPV E7 protein  in terferes  
w ith  IRF-9
structural p rotein  V - lead s to  
d egred atiion  o f  STATI
VAI RNA - partial d ou b le  
stran d ed  RNA structure
EBER RNA- partial d ou b le  
stran d ed  RNA structure
2 -5 (A )syn th etase /P K R
E3L protein  - blocks PKR 
activation
R onco e t  al., 1998
Park e t  al., 2 0 0 0
Zimring e t  al., 19 9 8
Satterly e t  al., 2 0 0 7
D evaney  e t  al., 1988; Kirchweger  
e t  al., 1994; C hinsangaram  e t  al., 
1999; B elsham  e t  al. 2000; Li e t  
al. 2 0 01a; d e  Los S an tos e t  al., 
2 0 0 6
Sym ons e t  al., 1 9 9 5
Leonard e t  al., 1996; C h atterjee-  
Kishore e t  al., 2 0 0 0
Christen e t  al., 2 0 0 7
Barnard & M cM illan, 1999; 
Barnard e t  al., 2 0 0 0
D idcock e t  al., 1 9 9 9  
G oodb ourn  e t  al., 2 0 0 0
G oodb ourn  e t  al., 2 0 0 0
San ch ez and M ohr, 2 0 0 7
Sharp e t  al., 19 9 8  
B eattie  e t  al., 19 9 1
K3L p rotein - fu n ctio n s as a 
d e c o y  o f  elF-2
N SI p rotein  b inds IFN-
ind uced  p rotein , ISG15, and Yuan and Krug, 20 0 1  
block its action
Table 1.3: Selected mechanisms of viral interference with the IFN pathway
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1.9 Plasmacytoid dendritic cells
Lennert and Remmele (1958) first described a population of cells found in the T cell 
zones of human lymphoid tissue that had similar morphology to plasma cells. They 
described these cells as “lymphoblasts”. Subsequent to this, these cells were also 
recognized by other researchers but received little attention until the 1980s and the 
advent of antibodies to lineage-associated markers. Studies carried out using these 
antibodies led to these cells being given a number of different names including 
plasmacytoid T cells (Müller-Hermelink et a l, 1983) and plasmacytoid monocytes 
(Facchetti et a l, 1989). The function of these cells and their importance in immunity 
and in pathological conditions only began to emerge in the late 1990s as researchers 
began to isolate and culture these cells for in depth study. These studies revealed that 
not only could these cells differentiate in vitro into dendritic cells, but also their 
capacity to produce high levels of interferon alpha (IFN-a). This led to these cells 
being described as natural interferon-producing cells (NIPC) or plasmacytoid 
dendritic cells (pDC). pDCs provide a crucial link between the innate and adaptive 
immune response to bacterial components and are crucial for the control of viral 
infections, especially to viruses that have the machinery to block interferon induction 
in target host cells. They have been isolated and characterised from a number of 
species including, human, mouse and pig, (Facchetti et al, 1989; Grouard et al., 
1997; Asselin-Paturel et al., 2001; Summerfîeld, A. et al., 2003)) but until recently, 
not from ruminants. Pascale et al., (2008) have recently identified and partially 
characterised these cells in sheep and pigs (figure 1.3.1).
Conventional or myeloid DCs and plasmacytoid DCs are able to secrete IL-12 and 
TNF-a, both of which are involved in driving innate immune responses (Kohrgruber
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et al, 1999). It is known that mDCs, like most cells in the body, produce type-1 IFN 
but at a much lower level than pDCs.
Plasmacytoid dendritic cells (pDCs) are morphologically distinct from myeloid 
dendritic cells (mDCs) and were characterised as having poor antigen presentation 
and T-cell stimulatory capacity. More recent publications have challenged this 
observation by demonstrating that both human and mouse pDCs are capable of 
efficiently capturing exogenous antigen, and activating T cells (Hoeffel et a l 2007; 
Sapoznikov et a l  2007). Human pDCs exposed to inactivated influenza A virus have 
been shown to activate both CD4+ and CD8+ T cells in vitro (Fonteneau et a l, 2003). 
In mice, pDCs stimulated through TLR9 promote CD4+ T cell responses ( Boonstra 
et a l, 2003), and pDCs have been shown to prime CD8+ T cell responses during 
cytomegalovirus infection (Dalod et a l, 2003). These studies demonstrate that pDCs, 
just as mDCs, retain full T cell stimulatory capacity.
Cross presentation involves uptake and processing of exogenous antigens and 
presentation by class IMHC molecules and is normally restricted to dendritic cells 
and macrophages. This pathway is crucial not only for the induction of tolerance but 
also in the development of CD8 T cell responses in microbial immunity and in 
response to tumor cells. In mice, until recently, CD8a+ conventional dendritic cells 
were considered to have the unique ability to cross present exogenous antigen. 
Mouries et a l, (2008) published data confirming the ability of mouse splenic pDCs 
to efficiently capture exogenous antigen in vivo and following TLR7 or TLR9 
stimulation, in vivo and in vitro, cross-present soluble or particulate antigen in a 
TAP-(transporter associated with antigen presentation) dependent manner to CD8+ T 
cells. However, at steady state conditions these cells do not, or have limited ability 
to, cross-present antigen. The generation of CD8+ T cell memory has been shown to
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require IFN-a produced by pDCs as a third signal in conjunction with the cDC 
peptide-MHC and co-stimulatory molecules (Curtsinger et a l, 2005; Yoneyama et 
al., 2005). However, the defining characteristic of these cells remains their ability to 
recognise viral nucleic acid through the endosomal toll-like receptros TLR7 and 
TLR9 and the ability to secrete large amounts of IFN-a (Dalod et al., 2002).
1.9.1 Plasmacytoid dendritic cell lineage
Since the identification of pDCs as a specific cell type, their lineage has been 
difficult to define. It is now generally accepted that myeloid DCs and plasmacytoid 
DCs are generated from a common haematopoietic precursor, (CD34+), however, the 
relationship between these two lineages remains controversial. In human blood, two 
sub- populations of dendritic cells have been identified, which can be differentiated 
by expression of CD 11c, a leukocyte-specific integrin referred to as inactivated-C3b 
(iC3b) receptor 4 (CR4; O’Doherty et a l, 1994). It was previously believed that 
these sub-populations were generated from separate developmental pathways, with 
CD1 lc+ dendritic cells expressing the receptor for GM-CSF and other myeloid 
markers including CD 13 and CD33. These CD I lc+ cells are found in the tissues and 
are involved in antigen capture, processing and presentation, and are usually reported 
as (mDC) myeloid-related dendritic cells or (cDC) conventional dendritic cells 
(Banchereau et al., 2000). The second population is described as CD 11c", pDCs. 
These cells lack myeloid cell markers, but express the receptor for IL-3 and have 
been shown to be potent inducers of interferon-a (IFN-a; Celia et al., 1999). These 
cells were characterised as being CD4+, CD 11c-, MHCII4" when isolated from human 
blood (Slegal et al, 1999) and could be identified by their lack of expression of 
lineage markers (non-B, non-T, non-NK, non-monocyte/macrophage). In contrast to 
human pDCs, mouse pDCs express CD1 le (Nakano et al., 2001; Lian et al., 2003;
Omatsu et al., 2005). Even within this population of murine C D llc+pDCs, a degree 
of heterogeneity has been described in relation to the expression of either CD4 or 
CD8a (Martin et a l, 2002; Lian et a l, 2003; McKenna et a l, 2005). Ovine pDCs 
have been reported as GDI le negative, (Pascale et a l, 2008). Porcine pDCs have 
been characterised as GDI lc low (Summerfîeld et a l, 2003) however a recent 
publication by Calzada-Nova et a l, (2010), determined this molecule to be absent 
from porcine pDCs. At this time the reason for the variability between species has 
not been addressed but there are several possibilities including differing isolation 
techniques, specificity of reagents, and the possibility that a certain degree of 
developmental plasticity and/or functional heterogeneity of the population ofpDCs 
within a species may exist. All of these possibilities need to be explored further if we 
are to expand our understanding of the nature and function of plasmacytoid dendritic 
cells.
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1LT1 - v e Cella e t  a l ,  (1533)
C D l a - v e Cella e t  a l ,  (1535)
L y6C w e
A sse lin -P a tu re l e t a l ,  (2001); H ochrein  e t  a l ,  
(2032); Lia n e t a l ,  (2333);O m atsu  e t a l , (2005)
B220 w e
A sse lin -P a tu re l e t a 1,(2031): H ochrein e t  a l ,  
(2002); O m atsu  e t  a l ,  (2335)
m P D C A -1 w e
A kiba, H. (1533), K jaergaard, J. (2331)., a l -  
S h am k h an i, A. (1556)
SiglecH w e : Loschko e t a l ,  201 1 ;E lasiu s  and  C olonna, 2D0S
B S T -2  / T e t h e r i n w e T o k a rev e t a l ,  2033: Eego e t a l ,  2012
Toll receptors
T L R 7 + v e w e w e w e
P asc a le  e t a l ,  (2003): McKenna e t a l ,  (2005); 
A sse lin -P a tu re l e t a l ,  (2001)
T L R 9 + v e w e w e w e  N D
P asc a le  e t  a l ,  (203S); McKenna e t a l ,  (2335): 
A sse lin -P a tu re l e t a l ,  (2001)
Table 1.3.1 Comparison of known pDC markers from different species
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1.10 Foot and mouth disease (FMD)
It has previously been shown that porcine pDCs produce type-I IFN only in response 
to immune complexed FMDV. In order to identify bovine pDCs, FMDV immune 
complexes were used as a tool in the initial part of this study.
Foot and mouth disease virus (FMDV) is the etiological agent responsible for foot- 
and- mouth disease (FMD), an economically important, highly contagious, acute 
vesicular disease that affects over 70 animal species including economically 
important farm animals such as cattle, pigs, sheep and goats and numerous species of 
cloven-hoofed wildlife (Alexandersen et a l, 2003). Transmission of the virus can 
occur in a number of ways including direct animal contact, aerosols, fomites, 
including movement of contaminated persons or inanimate objects such as motor 
vehicles. The most common mode of transmission is believed to be the aerial transfer 
of virus containing droplets and droplet nuclei between infected and susceptible 
animals that are in close proximity. Long-range airborne transmission of virus is a 
rare occurrence but is a documented route of infection. Long-range airborne 
transmission requires the chance combination of various factors including the 
number and location of the transmitting and recipient animals, the animal species and 
viral load needed to initiate disease within that species and favourable topographical 
and meteorological conditions (Alexandersen et a l, 2003). Species differences can in 
part determine the characteristics of FMDV transmission. One clear example of this 
is that swine are relatively resistant to infection by virus containing aerosols, and can 
more often be infected by the oral route, or through skin abrasions (Alexandersen et 
a l, 2003), but once infected can release approximately 60 times the amount of 
aerosol FMDV compared to infected cattle or sheep (Alexandersen et a l, 2003). In 
cattle FMDV frequently gains access to a host via the inhalation of airborne virus
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particles resulting in effective delivery of the virus to the dorsal surface of the soft 
palate, pharynx and tonsils, which are thought to be important sites for the primary 
replication of the virus (Alexandersen et a l, 2003; Murphy et a l, 1999; reviewed in 
Arzt et ah, 2011). Variable virus incubation periods have been described of between 
1-14 days (Garland & Donaldson, 1990; Charleston et al., 2011). Following primary 
replication the virus disseminates rapidly through the host.
In a study carried out by Brown et aL, (1992), FMDV nucleic acid was detected 6 
hours post challenge in epithelial tissue distant to the inoculation site (i.e. respiratory 
tract), in calves which had been experimentally exposed to aerosol virus. Viral 
replication in primary sites of infection is reported to peak 2-3 days after exposure to 
the virus (Alexandersen et aL, 2001; Oleksiewicz et aL, 2001) and virus has been 
detected in the pharynx 1-3 days prior to the onset of viraemia (Burrows, 1968; 
McVicar and Sutmoller, 1976; Burrows et aL, 1981; Alexandersen et aL, 2002). 
Following initial replication, several routes for the establishment of viraemia have 
been proposed. The first of these routes suggests virus enters through regional 
lymph nodes and into the bloodstream, allowing transportation to secondary sites of 
replication, the comified stratified squamous epithelia of the skin (including the feet 
and mammary gland) and mouth (including the tongue) (Burrows et aL, 1981; 
Alexandersen et aL, 2001; Oleksiewicz et aL, 2001). It is here that the majority of the 
viral amplification takes place and epithelial cell lysis gives rise to the lesions that 
characterise this disease (Fig 1.9). A more recent study by Arzt et aL, (2010) 
demonstrated considerably higher levels of virus in the lungs than the pharynx during 
the establishment of viraemia and suggests a pulmonary portal for viral entry to the 
vascular system. In younger animals the myocardium has been cited as a site of 
viral replication leading to heart lesions and death of the infected animal (Gulbahar et
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a l, 2007). There is no significant evidence supporting viral replication in the blood 
during the viraemic period (Zhang & Alexandersen, 2004), however a transient 
lymphopenia has been described in pigs (Bautista et a l, 2003) but not in cattle 
(W indsor et a l, 2011). There is also a significant difference between the species in 
the level o f type-I IFN generated in response to FMDV.
Figure 1.9 FMDV lesions in pigs (top left foot and knees; bottom left- 
lesion on the snout) ami cattle (top right -  lesion on the foot, bottom right -  
lesion in the mouth).
Images of infection in pigs reproduced from (\\\\ u.DKFRA.gox ). 
Images of infection in cattle reproduced tiom Iu \\\\. csiro.au).
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Species differences in clinical pathology have also been reported during the acute 
stages of disease with pigs displaying the most acute reactions to FMDV infection. 
Clinical manifestations include acute fever, loss of appetite and lameness due the 
development of painful lesions on the feet, knees, hocks and in and around the 
mouth. Vesicles / lesions at other sites such as the snout, teats, mammary glands and 
other sites of the skin have also noted (Alexandersen et aL, 2003; reviewed in 
Grubman and Baxt, 2004 and Alexandersen and Mowat, 2005). Although clinical 
pathology during the early stages of infection in cattle may be less severe than that 
recorded for pigs, secondary infections of lesions and complications resulting from 
FMDV infection are common, and can lead to hoof deformities, abortion, mastitis 
and permanent weight loss / loss of condition (Alexandersen et aL, 2003).
1.11 Foot and mouth disease virus classification and biology
FMDV is a member of the family Picornaviridae, which includes nine genera; 
Enterovirus, Hepatovirus, Rhinovirus, Cardiovirus, Parechovirus, Erbovirus, 
Kobuvirus, Teschovirus and Aphthovirus, the latter of which comprises FMDV as the 
type species, and now also includes equine rhinitis A and bovine rhinitis B (Fauqet et 
aL, 2005). Seven immunologically distinct serotypes of FMDV have been identified 
(O, A, C, SAT1, SAT2, SAT3, and Asial) and within each serotype a large number 
of strains have evolved due to the high rates of genomic mutation that are common in 
RNA viruses (Domingo et aL, 2005; and Knowles and Samuel, 2003).
FMDV is a non-enveloped, icosahedral virus that is 26nm in diameter. The genome 
is a single linear molecule of positive sense ssRNA of between 7.5-S.5 kb in size and 
is attached to a VPg protein which acts as a primer for viral RNA replication (Falk et 
aL, 1992). The genome is polyadenylated and encodes a single polyprotein which is 
processed by the viral protease in infected cells to yield polypeptide precursors and
mature viral proteins which self-assemble into pentameric structures. Twelve 
pentamers then form the complete viral capsid containing 60 copies o f each o f the 
four structural proteins VP 1-4 (Fig 1.10). VP 1 contains the immunodominant 
epitopes o f the virion and differs by 30-50% at the genome level between FMDV 
serotypes (Alexandersen et a l, 2003).
Figure 1.10 The structure of type C^BFS FMDV virion based on X-ray 
crystallographic data
The structures shown are based on the data o f Acharya et a/.,(1989) and Logan et aL, 
(1993). (a) A viral protomer highlighting the |3-barrel-and-loop organisation o f the viral 
proteins, (b) A pentamer positioned on the fivefold axis, (c) The organisation o f the 
entire virion, highlighting the G-H loop (yellow) and the RGD sequence (white), (d) A 
protomer highlighting the positions o f the G-H loop (purple) and RGD sequence 
(yellow). All structures are representative o f the mature virion (cleaved VP0). and the 
viral proteins are coloured blue (VP1), green (VP2), and red (VP3). VP4 is buried within 
the particle and is visible only in panel (a), where it is coloured yellow.
Figure from Grubman and Baxt (2004)
56
FMDV attaches to the cell surface of target cells via specific receptors. Several 
integrins such as avp3, avp6, avpl; a5pl and avp8 have been reported to bind 
FMDV and, at least for the ctvpô integrin, facilitate clathrin mediated endocytosis of 
the viral particle into the cell (Jackson et aL, 1997; 2000; 2002; 2004; Berryman et 
aL, 2005). Heparan sulphate has also been shown to be a receptor for FMDV 
(Jackson et aL, 1996), and this is the preferred receptor following viral passage in 
BHK 21 cells. Following receptor mediated endocytosis, endosome acidification 
leads to the breakdown of the capsid structure and the release of the viral genome 
and genomic RNA is infectious. Replication occurs in the cytoplasm of infected cells 
in association with virus-induced membranous vesicles (Belsham and Bostock,
1988). Although the origin of the membranes remains unknown, O’Donnell et aL, 
(2011) have shown that non-structural proteins 2B, 2C and 3A co-localize with LC3 
(an autophagasome marker) and treatment of infected cells with rapamycin (an 
autophagy inducer), led to an increase in viral yield. An initial round of protein 
translation takes place which produces the viral proteins necessary for RNA 
replication and genome packaging. At this point a switch from translation of viral 
proteins to replication of genome occurs and it has been proposed that the signals 
required for control of the different roles of the viral RNA must be included within 
the viral RNA sequence (Belsham, 2005).The virally encoded RNA dependent RNA 
polymerase, 3D polymerase and VPg primer are primarily responsible for viral 
replication, producing templates for subsequent rounds of translation and genomes 
for packaging. The switch from replication to translation is required as these 
biological processes proceed in opposite directions on the mRNA and cannot occur 
in tandem. In most picornavirus infections, the production of progency virus leads to 
cell lysis and the release of newly formed virions within 5 -10 hours of infection.
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Figure 1.11: Schematic diagram of the FMDV genome and the proteolytic 
processing of the viral polyprotein.
The open reading frame (ORF) is shown in the boxed area and the viral proteins are 
named according to the nomenclature o f Rueckert & W immer (1984).
Foot and Mouth Disease Virus (FMDV) has a linear ssRNA(+) genome o f 7.5-8.5 
kb, which is polyadenylated, composed o f a single ORF encoding a polyprotein. 
Viral genomic RNA has a viral protein, VPg (3B), at its 5’untranslated region. The 
long UTR at the 5 ’ end contains a type II internal ribosome entry site (1RES). The PI 
region encodes the structural polypeptides. The P2 and P3 regions encode the non- 
structural proteins associated with replication. The genome also encodes a N - 
terminal leader proteinase (L pro) in addition to two other proteinases, 2A and 3C pro. 
The shorter 3’ UTR is important in (-) strand synthesis. Translation o f the 
polyprotein can occur at two ATG codons (indicated by blue arrows) at the amino- 
terminal end o f Lpro leading to Lb and Lab proteins. Proteolytic processing o f the 
FMDV polyprotein is initiated by the viral proteinases Lpro, 2A, and 3Cpro, while 
the cleavage o f the structural protein precursor VPO occurs by an unknown 
mechanism.
Figure from Grubman el a!., (2008)
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1.11.1 Disease duration and persistence
Following acute disease, viral clearance from the periphery normally occurs within 
2-3 weeks (Salt, 1993; Zhang & Alexandersen, 2004), however, for a significant 
proportion of cattle, sheep and goats this was shown not to be the case and viral 
persistence was recorded at least 28 days post infection. It does appear that ruminants 
exposed to FMDV can become carriers for variable lengths of time, dependent on the 
animal species and virus strain involved. The maximum duration of the carrier state 
for sheep and goats has been recorded in months and cattle and African buffalo in 
years (reviewed in Alexandersen et aL, 2003b). Using virus isolation as an indicator 
of persistent infection pigs do not appear to become persistently infected and clear 
the virus within three to four weeks. However, a study by Mezencio et a l, (1999) 
provided evidence of persistent infection in pigs and yet another study by Eblé et al., 
(2007) demonstrated the presence of high levels of IgA in both probang and serum 
samples, which would be indicative of replicating virus. The sites of persistence are 
still being debated but there is evidence that the epithelium of the pharynx is 
involved (Woodbury et aL, 1995; Murphy et aL, 1999; Zhang and Kitching, 2000,
2001) and in yet another study, Juleff et a l, (2008) have detected persistent FMDV 
in the lymph nodes of cattle.
The development of the asymptomatic carrier state in ruminants such as the African 
buffalo and cattle pose a major problem in disease control. Although the levels of 
virus recovered from oropharyngeal fluid are relatively low, maintenance of 
infectious virus and intermittent excretion serve as a potential disease reservoir even 
though there is some limited evidence to suggest that carrier animals are able to 
infect healthy livestock (Alexandersen et a l, 2002; Zhang & Kitching, 2001).
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1.11.2 Control of FMDV
The FMD status of any particular country or region can be defined as epidemic 
(sporadic), endemic or free. Disease free status is maintained mainly by movement 
restrictions and specific import / export testing. Sporadic outbreaks in regions or 
countries where the virus is not normally seen can have severe economic 
consequences not only in the significant loss of livestock and the costs involved in 
controlling the outbreak itself but also the loss of income due to the subsequent ban 
on international trade. Disease eradication occurs through various mechanisms 
depending on the control policies in place. In disease free areas bordering regions 
where FMDV is endemic or where a sporadic outbreak has occurred, vaccination is 
often carried out in order to establish a buffer zone to prevent the spread of the virus. 
Legislation introduced in 2006, The Foot and Mouth Disease (control of vaccination) 
(England), move the use of emergency vaccination to the forefront of disease control 
(http://archive.defra.gov.uk/foodfarm/farmanimal/diseases/atoz/fmd/control/legislati 
on.htm). However, in Europe, control measures involve quarantine, destruction of 
infected animals, and export bans on meat or meat products to countries that have 
been declared FMDV free (Racaniello, 2001; Alexandersen et aL, 2003).
1.11.2.1 FMDV vaccines
The currently available commercial vaccines for ruminants consist of chemically 
inactivated FMDV suspended in an oil or aluminium hydroxide/saponin 
supplemented adjuvant (Doel, 1999), while the preferred vaccine for use in pigs 
consists of a double oil emulsion (Doel, 2003). Vaccine efficacy is only preserved 
through a cold chain and animals require boosting one month after the initial 
vaccination, and at 4-6 month intervals from then on (Doel, 2003; Saiz et a i, 
2002).Vaccines are serotype specific and do not provide cross-protection, neither do
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they produce sterile immunity and may allow viral replication at epithelial surfaces. 
Vaccinated ruminants have also been reported to develop carrier status to a similar 
degree as their non-vaccinated cohorts (Alexandersen et al., 2002).
1.11.2.2 FMDV eradication
Rapid and extreme measures are required to eradicate FMDV to prevent any 
outbreak becoming epidemic. Use of the slaughter policy, which includes the 
destruction of all animals on infected premises and any dangerous contact premises, 
is designed to limit viral excretion and transmission. Ring vaccination has been used 
to limit viral transmission during epidemic outbreaks, but these animals must also be 
destroyed if FMDV free status is to be achieved quickly (Alexandersen et aL, 2003). 
It is known that vaccinated animals as well as infected animals may go on to become 
persistently infected and pose a risk to livestock (Alexandersen et aL, 2002). A 
recent study by Charleston et aL, (2011) identified a 24 hour window of opportunity 
where FMDV infection can be diagnosed prior to the onset of clinical symptoms and 
the infected animal being able to transmit infection. This highlights the possibility of 
selective culling of infected animals during outbreak situations thereby limiting the 
loss of livestock while still limiting viral transmission.
In many regions of the world the disease is now considered to be endemic, including 
much of Africa, Asia and some countries in South America (Office International des 
Epizootics (OIE)). The lack of resources and infrastructure to be able to effectively 
control the disease means that in some countries the disease is tolerated. In regions 
where FMDV has become endemic, control is often achieved by mass prophylactic 
vaccination to reduce virus excretion and transmission. Movement restrictions, 
supplementary vaccination and slaughter of infected animals may be used in cases 
where outbreaks have occurred (World organisation for animal health - OIE). The
policy of control rather than eradication is therefore not without cost, with mass 
vaccination, reduced productivity, and limited access to international markets having 
significant economic impact.
1.12 The immune response to FMDV infection
The early immune response to FMDV infection is typified by the induction of a 
strong neutralising antibody response. In cattle, serum levels of IgM appear 3-7 days 
post infection, peaking between days 5-14, followed by a slow decline. Early studies 
in nude mice demonstrated that this IgM production occurred in the absence of T-cell 
help (Borca et al., 1986; Collen et a i, 1989) and has recently been confirmed by 
CD4 depletion studies in cattle (Juleff et aL, 2009). Antibody isotype switching is 
rapid with IgGl and IgG2 detected from day 4 post challenge, peaking between days 
14-20 (Salt et aL, 1996; Doel, 2005) and virus neutralising antibody has been 
detected up to 4.5 years post experimental challenge (Cunliffe, 1964). IgA antibody 
can be detected in serum and probang samples from 7 days post infection and peaks 
at 7-14 days in serum and approximately 14 days in probang samples (Salt et aL, 
1996). It has been recorded that IgA titres decline from 14 days, except in ruminants 
that go on to become carriers. Parida et aL, (2006) proposed the use of secretory IgA 
as a diagnostic tool to identify carrier animals or those with sub-clinical infection, 
with 11 out of 12 animals shown to be positive for virus 28 days post infection 
(carriers), also positive for secretory IgA. However, in pigs, a species in which 
persistence has not been demonstrated conclusively, the level of IgA produced 
following infection is variable. In a study carried out by Eblé et aL, (2007), infection 
of animals that had been singly vaccinated against O Taiwan 3/97, resulted in the 
production of higher levels of IgA than that recorded for animals that had received 
four times as much vaccine. Infection of unvaccinated controls led to the induction of
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high levels of IgA in both serum and probang samples that persisted at high levels for 
116 days. The high levels of IgA recorded for these animals suggest viral replication 
and therefore persistent infection. The present methods used to assess persistent 
infection are dependent on virus isolation techniques, if however the virus is immune 
complexed with IgA antibodies, this method may not give accurate results.
In general there is a close, but not perfect, correlation between high levels of 
neutralising serum antibody and protection. Antibody driven opsonisation of virus 
and its subsequent destruction by cells of the reticuloendothelial system has been 
proposed as yet another critical component of the immune response to FMDV 
infection (McCullough et aL, 1992). Several other roles for antibody in response to 
FMDV have been described. Direct lysis of virions by antibody has been recorded 
for both poliovirus and FMDV and aggregation of non-neutralising antibody on the 
virion may also contribute to protection by reducing virus infectivity (Reviewed in 
Reading and Dimmock, 2007). However, a good antibody response is not always 
indicative of protection, because the antibody response is strain-specific and may not 
confer adequate cross-protection. Some vaccinated cattle with high antibody titres 
can still become infected by homologous virus, and in carrier animals, live virus can 
persist in the face of high titres of neutralising antibody (DiMarchi et a i, 1986; 
McCullough et a l, 1992), suggesting that for successful protection from FMDV 
infection, other aspects of the immune system must be involved.
1.12.1 The cell mediated response to FMDV
The majority of the research into the immune response to FMDV has focussed on 
humoral responses and much less is known about the role of cell mediated responses 
in the generation of protective immunity. The antibody response has been shown to 
be strain specific however the T-cell response to FMDV infection in cattle has been
shown to be more cross-reactive between serotypes/strains and may therefore be of 
interest in vaccine design (Collen etal., 1998). The role of T-cell responses in 
immunity to FMDV is poorly understood, however, T-cell epitopes have been 
identified in structural and non-structural proteins following vaccination and 
infection studies (Collen et a l, 1991 and 1998; van Lierop et a l ,1992), but their 
inclusion in vaccine strategies has had limited success. Borrego et a l, (2006) 
demonstrated that DNA vaccination of mice with FMDV B and T cell epitopes did 
not induce an antibody response but was sufficient to protect from disease. In pigs, 
the identification of T-cell epitopes within the non-structural FMDV protein 3D was 
carried out using a recombinant vaccinia virus expressing the RNA dependent RNA 
polymerase (3D) and subsequent screening with an in vitro lymphoproliferative 
assay against peptides. However, only partial protection could be achieved in the 
absence of neutralizing antibody (Garcia-Bridnes et a l, 2004). In the murine model, 
Borca et a l, (1986) demonstrated that the protective immune response to FMDV was 
T-independent (TI), however the demonstration of FMDV-specific CD4+ T-cell- 
proliferative responses following infection or vaccination with virus or peptide 
indicated that in ruminants, there was a role for CD4+ T-cells in the induction of 
antibody (Collen et a l, 1990; Blanco et a l, 2001; Gemer et a l, 2007). In a recent 
depletion study, Juleff et a l, (2009) have shown that in cattle, the initial antibody 
response is T-independent (TI), whereas later antibodies are directed against the non- 
structural proteins and the G-H loop and are T-cell dependent.
T-cells are necessary for protection following vaccination and a memory CD4+ T- 
cell population has been detected in vaccinated cattle (Glass & Millar, 1994; 
Naessens et a l, 1998). Peptide vaccination studies carried out by Hohlich et a l,
(2003), demonstrated that the T-cell response in cattle was highly variable and that
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animals protected from disease exhibited significant T-cell proliferation to at least 
one of the peptides tested. Until recently, CD8+ T-cell responses to FMDV had only 
been demonstrated for infected animals (Childerstone et a l, 1999). Using CD8+ T- 
cell enriched fractions from the blood of infected cattle, the authors demonstrate 
lymphoproliferation in response to viral antigen but were unable to demonstrate 
whether or not the detected responses were major histocompatibility complex (MHC) 
class I restricted. It is also of note that the responses were low, variable and 
completely absent in some animals. More recently, Guzman et aL, (2008) have 
demonstrated MHC I-restricted CD8+ T-cell responses in cattle that had been 
infected or vaccinated with FMDV, using a sensitive ELISpot (Enzyme-linked 
immunosorbent spot) assay to detect FMDV-specific IFNy- secreting CD8+ T-cells 
albeit at low levels. A cross-reactive MHC I-restricted CD8+ T cell epitope in VP 1 of 
FMDV has also been identified as being recognised by FMDV vaccinated cattle 
(Guzman et aL, 2010). Using a recombinant adenovirus vector to deliver a mutated 
FMDV PI protein, Patch et aL, (2010) have shown that impaired processing of the 
PI protein enhanced cytolytic activity of CD8+ T-cells in vaccinated pigs by 
increasing MHC I/FMDV peptide concentration, however this elevated activity 
waned by 14 days post vaccination. The authors however did not challenge these 
CD8 T-cells with MHC I matched FMDV infected cells, choosing to challenge with 
the adenoviral vaccine infected cells. Several questions remain regarding the role of 
CD8+ T-cells in immunity to FMDV infection. Due to host cell protein synthesis shut 
off, FMDV is known to down regulate MHC I expression on infected cells, thereby 
limiting recognition by CD8+ cells and it has been suggested by Badovinac et a l, 
(2002) and Harty and Badovinac, (2002), that the immune system may “switch o ff’ 
CD8 T-cells early in infection, even if infection is not fully cleared.
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FMDV serotypes 0  and C infection in pigs have been reported to cause a severe but 
transient lymphopenia with CD8+ cells most heavily affected (Bautista et aL, 2003; 
Diaz-San Segundo et aL, 2006) and following resolution of lymphopenia, T-cells 
responded poorly to mitogen, demonstrating impaired function (Bautista et aL, 2003; 
Diaz-San Segundo et aL, 2006). In the case of C serotype infection, the authors 
demonstrate productive FMDV infection of both T and B lymphocytes without cell 
death, excluding the possibility that the lymphopenia was related to lymphocyte 
killing by the virus (Diaz-San Segundo et aL, 2006). In FMDV infection in cattle, 
there is no conclusive evidence of lymphopenia following infection with integrin 
binding virus (Windsor et aL, 2011). However, a study by Joshi et aL, (2009) 
demonstrated infection of lymphocytes and lymphopenia using heparan sulphate 
adapted viruses of O, A and Asial.
There remains the question of the role of CD8+ T-cells and the resolution of the 
carrier state. Persistent infection in ruminants whether vaccinated or not, suggests an 
escape of the normal immune-surveillance. CD8+ cells play a critical role in the 
elimination of virally infected cells, however, Juleff et aL, (2008) have demonstrated 
live virus retained in immune complexes on follicular dendritic cells in lymph nodes 
for prolonged periods, which CD8+ T-cells would not be able to resolve.
Natural killer (NK) cells are also considered critical in the initial host response to 
intracellular pathogens including viruses. Recognition of infected cells in part relies 
on the lack of MHCI expression on the surface of infected cells, also signals derived 
from dendritic cells following pathogen sensing are known to initiate NK cell 
responses (Gerosa et aL, 2002; Reschner et aL, 2008). However, during FMDV 
infection of pigs, Toka et aL, (2009) have shown that ex vivo NK cells have reduced 
cytotoxic activity against not only FMDV infected target cells but also tumour cells.
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They also show a temporary reduction in the proportion of NK cells capable of 
producing IFN-y and perforin granules. There is no conclusive evidence of FMDV 
infection of NK cells but the reduction of NK cytotoxic activity was coincidental 
with increased viral titres, suggesting that FMDV influences or blocks the ability of 
NK cells to recognise infected cells through an as yet undetermined mechanism. 
Relative to the number of studies concerning the adaptive immune response to 
FMDV, the innate defence against the virus has received little attention.
It is thought that due to the lytic nature of the virus, the infection of epithelia results 
in local tissue damage and inflammation leading to the release of inflammatory 
mediators and the recruitment of mononuclear cells to the sites of infection (Goldsby, 
2000). Very little is known of the interaction of these mononuclear cells and FMDV. 
Rigden et aL, (2002) were able to demonstrate phagocytosis of FMDV by 
macrophages and propose that these cells may maintain viable virus in neutral pH 
compartments before releasing it back to the extracellular environment, thereby 
increasing the spread of infection. However it is also thought that macrophages play 
a critical role in the resolution of infection by destroying opsonised virus 
(McCullough et aL, 1992).
The interaction of FMDV with dendritic cells (DCs) has generated conflicting results 
in the literature. Until recently the majority of the studies had been performed with 
either murine (Ostrowski et al., 2005) or porcine dendritic cells (Summerfiled et aL, 
2009). These studies clearly demonstrate that FMDV is taken up at a low level by 
DCs and in pigs this is enhanced by immune complex formation with FMDV specific 
antibodies. A study published by Robinson et aL, (2011) demonstrates a similar 
result for bovine dendritic cells. Tissue culture adapted viruses which bind and infect 
via heparin sulphate structures (Jackson et aL, 1996) also show enhanced uptake by
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DCs. The susceptibility of the different subsets of DCs to FMDV infection and the 
subsequent affect on DC interaction with other cells remains unclear (Bautista et aL,
2005). In a study carried out by Harwood et aL, (2008) FMDV non-structural viral 
proteins and double-stranded RNA can be detected for up to 24 hours post-infection 
in porcine denritic cells. In addition, small quantities of virus are released between 2 
and 8 hours post-infection. The authors also show that transfected infectious copy 
genome leads to the production of progency virus, albeit for a limited time, in 
porcine moDC. A recent study by Robinson ef aL, (2011) described the interaction of 
FMDV with bovine moDC. Again low level infection of moDC occurred with 
integrin binding virus but this was greatly enhanced by the presence of FMDV 
specific antibody and shown to utilize CD32 (FcyRII) for cellular uptake The 
authors also clearly show productive infection and cell death of moDC and as a 
consequence of this, reduced capacity of infected DCs to stimulate T cell 
proliferation. This data is in contradiction of the data generated for porcine MoDCs 
as these cells were shown not to support viral replication and were still capable of 
antigen presentation.
1.12.2 FMDV antagonism of the host innate immune response
FMDV has been shown to antagonise the host innate response in most mammalian 
cells by inhibiting the induction of anti-viral molecules at both the translational level 
(Guzylack-Piriou, et aL, 2006) and the transcriptional level (de los Santos et aL,
2007; Wang et aL, 2010), interfering with the secretory pathway (Moffat et aL, 2005, 
2007) and inhibiting surface expression of viral proteins (Otrowski et aL, 2005). A 
key component of this antagonism is orchestrated by the FMDV Leader proteinase 
(Lpro) which is coded for at the 5 '-end of the ORF (Robertson et aL, 1985) and 
targets eIF4G, a host translation initiation factor, for degradation (Devaney et aL,
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1988; Medina et al., 1993). Cleavage of eIF4G results in shut off of host cap- 
dependent mRNA translation (Devaney et aL, 1988 and Etchison et aL, 1982) and as 
a consequence of this, blocks expression of type-I IFN (de los Santos, T., et aL,
2006). Lpro also cleaves NF-kB (de los Santos, T., et aL, 2007) and inhibits dsRNA- 
induced type I IFN transcription by orchestrating the degradation of interferon 
regulatory factor 3/7 (Wang et aL, 2010). A recent publication by Wang et aL,
(2011), describes a novel deubiquitinylation function of the shorter Lbpr0 form of the 
protein and clearly shows the dose dependent deubiquitinylation of RIG-1, TBK1, 
TRAF6 and TRAF3, all critical components in the induction pathway of IFN-p. It 
has been shown that a genetically engineered FMDV lacking the Lpro, has an 
attenuated phenotype in cell culture (Chisangaram et aL, 1999) and in susceptible 
animals (Brown et aL, 1996) and this is attributed to the inability to block the 
expression of type-IIFN (IFN-a/p), resulting in IFN induced inhibition of FMDV 
replication. The authors also demonstrated that Lpro is involved in blocking 
immediate-early induction of IFN-p mRNA and IFN stimulated gene products such 
as PKR, OAS and Mx-1 in vitro. This implies a role for Lpro in antagonising the 
innate cellular response to viral infection. Lpro exist in two forms, Lab and Lb with 
similar proteolytic activities (Medina et aL, 1993; Cao et aL, 1995) but it remains 
unknown if the two forms have differing roles in viral replication and pathogenesis 
however it has been demonstrated that the smaller Lb is essential for successful viral 
replication (Cao et al, 1995). FMDV 3Cpro cleavage of the RNA helicase eIF4A, 
which is part of the cap-binding complex, has also been demonstrated (Belsham et 
aL, 2000). 3Cpro can also cleave eIF4G but this occurs later in the infectious cycle 
and at different sites than Lpr0-mediated cleavage (Belsham et aL, 2000).
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1.12.3 Type-1 IFN production during FMDV infection
Non-enveloped viruses such as adenovirus, poliovirus and simian virus 40 (SV40) 
are either weak inducers or fail to induce IFN-a production by pDCs (Feldman et al, 
1994; Palmer et a l, 2000). However, it was noted that polyvalent IgG enhanced the 
capacity of poliovirus to produce IFN-a in vitro (Palmer et aL, 2000). This work 
suggested that for non-enveloped viruses, immune complexes could play a 
significant role in the activation of pDCs and the induction of type-1 IFN expression. 
This hypothesis was examined by Guzylack-Piriou et aL, (2006) for FMDV immune 
complexed virus and the response of porcine pDC. They showed enhanced levels of 
type-1 IFN production when live virus was complexed with immune serum 
compared to virus alone or virus complexed to non-immume serum.
FMDV infection in vivo has recently been shown to lead to an increase in the levels 
of type-1 IFN. Quantitative assays measuring the mRNA expression of IFN-a in 
nasal-associated lymphoid tissue (NALT) of cattle infected with FMDV revealed 
significantly greater levels during the acute disease phase in comparison to 
uninfected animals (Zhang et aL, 2006). In cattle experimentally infected with 
FMDV, tissue-specific profiles revealed significant increases in IFN-a mRNA levels 
in the coronary band and tongue at 1 to 2 dpi, and coincided with increases in viral 
RNA load (Zhang et aL, 2009), though it is unclear if this message was translated 
into protein. Type-1 IFN has also been recorded in the serum of pigs infected with 
different serotypes of FMDV and correlated with the peak of viremia and a transient 
lymphopenia (Nfon et aL, 2010). The observed increase in type-1 IFN during the 
early stages of FMDV infection is believed to limit viral replication and contribute to 
the resolution of viraemia prior to the induction of a specific immune response.
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The presence of type-1 IFN mRNA in FMDV infected tissue and the presence of 
type-1 IFN in serum samples, detected early in infected animals, suggests the 
presence of a population of cells where type-1 IFN is produced in abundance prior to 
cap-dependent translation shutdown . These cells are believed to be pDCs or natural 
interferon producing cells (NEPC). Guzylack-Piriou et al., (2006) concluded that in 
pDCs, antibody complexed to non-enveloped viruses such as FMDV leads to viral 
uptake, an abortive replication and the production of high levels of type-1 IFN. The 
assertion that high levels of type-1 IFNs are produced by pDC in response to the 
TLR9 agonist, CpG, and immune complexed FMDV was used as the basis for the 
model to identify the presence of pDCs in bovine secondary lymphoid tissue.
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1.13 Bovine viral diarrhoea virus (BVDV)
As is the case for FMDV, only pDCs have the ability to produce type-I IFN in 
response to pestiviral infection (Balmelli et al., 2005). The authors describe the 
interaction of porcine pDCs with Classical swine fever virus (CSFV). In this study 
we use BVDV and examine ther interaction of bovine pDCs with this pestivirus. 
Bovine viral diarrhoea (BVD) is an economically important disease of cattle that 
occurs worldwide and is considered endemic in the UK with an estimated 95% of 
cattle herds having been exposed to the virus (Baton et a l, 1998). The etiological 
agent responsible for this disease is bovine viral diarrhoea virus (BVDV), which 
together with classical swine fever virus (CSFV), and border disease virus ((BDV) 
form the genus Pestivirus within the family Flaviviridae. Two additional genera are 
included in the flaviviridae family, the flaviviruses such as yellow fever virus (type 
species),west nile virus, dengue fever and many other human and animal viruses, 
also Hepaciviridae, with a single member, hepatitis C virus (International committee 
on taxonomy of viruses (ICTV)).
BVDV has been classified into two genotypes, BVDV type I (BVDV-1) and BVDV 
type II (BVDV-2: Ridpath et a l, 1994). Becher et a l, (1999) and Vilcek et a l,
(2004) have shown, using genetic typing, that within each genotype of bovine BVDV 
isolates, a number of subtypes exist, with at least 13 genetic subtypes of BVDV-1 
and at least three for BVDV-2. The speculation is that with an increased number of 
isolates being typed, this number is likely to increase. Not only do BVDV subtypes 
differ genetically they have also been shown to differ antigenically with up to tenfold 
differences in antibody titre in cross neutralization assays between subtypes 
(Bachofen et a l, 2008). BVDV-2 isolates were originally distinguished from BVDV- 
I isolates by the loss of a PstI restriction site within the 5’ untranslated region
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(Harpin et al, 1995) and were considered to be more virulent than BVDV-1 isolates 
(Pellerin et al, 1994). However it has since been shown that some BVDV-1 isolates 
are as virulent as BVDV-2 isolates and some type II isolates do not cause overt 
disease (Ellis et a l, 1998).
Within each BVDV genotype, two distinct biotypes have been identified, cytopathic 
(cpBVDV) and non-cytopathic (ncpBVDV), that can be differentiated by their 
effects in tissue culture (Bolin, 1995), with the ncp biotype being more commonly 
isolated from infected animals. cpBVDV isolates have only been isolated from cases 
of mucosal disease and have been shown to originate from ncpBVDV isolates via 
RNA recombination (McClurkin et al, 1985). cpBVDV isolates arise following the 
insertion of host or viral sequence (Thiel et a l, 1993, Meyers and Thiel, 1996; 
Becher, et al, 1998, Tautz et al, 1996; Meyers et al, 1998, Qi et al, 1998), the 
duplication or rearrangement of viral sequence (Meyers and Thiel, 1996) or by the 
deletion of viral sequence (Meyers and Thiel, 1996). CpBVDV isolates are 
associated with the production of the NS3 gene product from the NS2/3 gene, 
however, during the replication cycle, transient production of NS3 in ncp isolates can 
also occur (Lackner et a l, 2004).
1.13.1 Virus genome and biology
BVDV is a small enveloped single-stranded, positive sense RNA virus, with a single 
open reading frame ranging from 12.3 -  16 kb in size, depending on the strain 
(Collett et a l, 1988). The genome codes for a single polyprotein (Fig 1.12(A)) that is 
cleaved both during and post-translationally by host and viral proteases, into its 
constituent proteins (Collett et al, 1988). The viral genome lacks both a 5’ CAP and 
a 3’ polyA structure (Collett et al, 1988, Brock et al, 1992), and is therefore 
translated in a cap-independent manner, by the internal ribosome entry site (1RES)
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spanning the initiation codon within the 5’ untranslated region (Pestova and Hellen, 
1999). The 1RES of Pestiviruses and Hepaciviruses is one characteristic that 
distinguishes them from the remainder of the Flaviviruses such as Dengue fever 
virus, yellow fever virus and Japanese encaphilitis virus (JE), which are believed to 
use ribosomal scanning as a mechanism to commence protein synthesis (Thumer et 
tir/.,2004). BVDV IRESs can recruit 40S ribosomal subunits without the need for 
eukaryotic initiation factors and bind in such a way that the ribosomal P site is placed 
proximal to the initiation codon. Unlike other viruses possessing IRESs, BVDV 
1RES elements bind to the ternary complex eIF2/tRNA/GTP without the need of 
helper proteins, additional initiation factors (Pestova and Hellen, 1999; Sanderbrand 
et al., 2000) or ATP (Hellen and Samow, 2001). Moes and Wirth, (2007) have 
predicted the presence of a pseudoknot in close proximity to the AUG initiation 
codon and have shown that BVDV 1RES translation is dependent on the integrity of 
this structure (Fig 1.12(B)). Mature virions are spherical, around 50nm in diameter 
and contain three virus encoded membrane proteins ((Ems, El and E2) in addition to 
the capsid protein (fig 1.12(C)). The viral RNA is infectious and serves as both 
genome and viral mRNA.
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Figure 1.12 BVDV genome and virion structure.
(A) Representation o f the BVDV genome. Npro is a non-structural protein and 
functions as a protease to cleave itself from the Capsid protein (adapted from 
www.bvd-info.ch). (B) Proposed RNA secondary structure o f the BVDV 5’ UTR 
and 1RES (Moes and Wirth, 2007), (C) Representation o f the structure o f the BVDV 
virion. This representation suggests a very ordered structure but BVDV is quite 
pleomorphic.
(Figure from www.expasy.org/viralzone/).
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1.13.2 Viral replication
A number of putative host cell receptors for BVDV have been described including 
CD46 (Maurer et al., 2004; Krey et al., 2006), large low density lipoprotein (LDL; 
Flores and Donis (1995)), and heparan sulphate (Hulst et a l, 2000). The use of 
heparin sulphate as a receptor for BVDV is believed to be a result of tissue culture 
passage and adaption. The original data describing the use of LDL as a receptor for 
BVDV describes monoclonal antibody induced inhibition of BVDV infection of 
bovine turbinate (BT) cells using an LDL specific monoclonal antibody (Flores and 
Donis, 1995). However a study by Krey et al., (2006), using the same monoclonal 
antibody, reports no such inhibition in madin-derby bovine kidney (MDBK) cells or 
BT cells. They also report the expression of functional LDL on a clone of MDBK 
cells known to be resistant to BVDV infection - cells resistant to infection with 
BVDV (CRIB). The use of CD46 as a cellular receptor for BVDV infection has been 
described (Maurer et aL, 2004; Krey et al., 2006). However, expression of this 
receptor in a normally non-susceptible cell line does not permit BVDV infection, 
suggesting that an as yet unknown co-receptor is necessary for viral internalization, 
which has been shown to involve clathrin dependent endocytosis (Krey et aL, 2005; 
Lecot et al., 2005). Ems has also been shown to interact with glycosaminoglycans 
and may be important in the initial binding events of the virus to the cell (Fetzer et 
aL, 2005; Iqbal et aL, 2000). Following endocytosis, the virus and vesicle 
membranes fuse and the RNA genome is released into the cytoplasm of the cell. This 
naked positive-sense RNA genome is translated into a polyprotein which is 
subsequently cleaved into structural and non-structural proteins both during and post- 
translationally by host and viral proteases (Collett et al, 1988). A negative-sense 
complementary ssRNA is synthesised using the genomic RNA as a template and new
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genomic RNA is synthesized using the negative-sense RNA as a template (Fig 1.13). 
The nonstructural proteins assist in the cleavage and in the replication of positive and 
negative strand RNA. The structural proteins are used to assemble new progeny virus 
and viral assembly takes place in the perinucleur region of the cytoplasm in 
association with either smooth endoplasmic reticulum (SEM) or Golgi membranes. 
Virions bud from the ER and are transported to the Golgi apparatus and progeny 
virus can be seen in vacuoles within the cytoplasm. Virions exit the cell as vacuoles 
fuse with the plasma membrane.
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Figure 1.13 The BVDV replication cycle.
Schematic representation o f BVDV cellular entry, replication strategy, virion 
assembly and release. This viral replication strategy is fairly slow (approximately 8- 
12 hours or longer) in comparison to FMDV (4-6 hours)
Figure from www.bvd-info.ch
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1.13.3 BVDV protein function
The N-terminal protein of BVDV, Npro, is a virally encoded cysteine protease that 
cleaves the N-terminus from the core protein (Wiskerchen et aL, 1991; Rümenapf et 
aL, 1993), however it has been shown to be dispensable for viral replication in 
culture (Tratschin et aL, 1998), therefore, it’s retention in the genome suggests 
possible involvement in other functions. Npro of the closely related classical swine 
fever virus (CSFV) has been shown to be involved in blocking type-1 IFN induction 
(Bauhofer et aL, 2005; Seago et aL, 2007) by targeting IRF-3 for proteasomal 
degradation. Ruggli et aL, (2009) have demonstrated that the specific elimination of 
the IRF-3 degrading function of Npro does not affect virulence of CSFV.
This mechanism appears conserved in pestivirus infection with targeting and 
degradation of IRF-3 also seen in cells infected with BVDV, with the amino terminal 
of Npro implicated in this function (Gil et aL, 2006).
The structural proteins are Capsid, Ems, E l and E2. Capsid (or core) protein locates 
to the cytoplasm of infected cells. Core is incorporated into virions following three 
enzymatic cleavages. It is highly basic polypeptide and little is known about its 
biological properties or its role in virion assembly and structure. However, Murray et 
aL, (2008) have shown that following processing, the capsid or core protein lacks 
secondary structure and is highly disordered, but also that it bound to RNA albeit 
with low affinity and specificity, thereby reflecting it’s mechanism of action in RNA 
packaging and formation of the virion which had been previously described (Donis, 
1995).
Ems is a highly N-glycosylated endoRNase that forms disulphide linked 
homodimers and is an essential structural component of pestiviruses but is also 
secreted in soluble form from infected cells (Rümenapf et aL, 1993; Schneider et aL,
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1993). Ems interaction with double stranded RNA has also been demonstrated (Iqbal 
et al, 2004). However, the RNase activity of Ems is not essential for viral growth in 
vitro. Magkouras et a l, (2008) clearly demonstrated, using transfected cells 
expressing enzymatically active Ems and cells that were persistently infected with 
wild type ncp vims, a role for Ems in degrading extracellular but not intracellular 
dsRNA. They demonstrated the inhibition of induction of type-1 IFN in response to 
extracellular pI:pC and suggest that Npro and Ems are non-redundant IFN 
antagonists in pestiviruses, with Ems degrading extracellular dsRNA and Npro 
targeting IRF-3 for degradation. These findings have implications for the ability of 
the vims to become persistent. The blocking of type-1 IFN during viral replication 
and degradation of extracellular RNA may represent a mechanism whereby the 
innate immune responses are inhibited in persistently infected animals (PI) thereby 
providing a viral reservoir for further infection. This is supported by the findings of 
Meyers et a l, (2007), who demonstrated using ANpro and AEms recombinant 
vimses, a role in vivo for both Ems and Npro in the establishment of persistent 
infections. More recently, Mâtzener et al, (2009) have shown that not only does Ems 
degrade dsRNA but also ssRNA at neutral pH. They also demonstrate that more 
dsRNA is present in cells infected with a cytopathogenic strain of BVDV than in 
cells infected with the homologous noncytopathogenic strain and this viral RNA was 
able to stimulate the IFN response in a RIG-I independent manner. They propose that 
the soluble form of Ems may represent a decoy receptor that degrades viral RNA that 
may otherwise trigger the IFN response in uninfected cells.
The two remaining envelope proteins El and E2 are also heavily glycosylated. E2 
forms homodimers present in infected cells and in the virion envelope (Weiland et 
al, 1990). Envelope glycoprotein E2 is the most immunogenic and most variable
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protein of pestiviruses and is the immunodominant protein involved in the generation 
of virus neutralizing antibodies (Deregt et aL, 1998). E l is covalently linked to E2 to 
form hetrodimers which can be detected in infected cells (Rümenapf et a i, 1993;
Wei land et aL, 1990).These hetrodimers are involved in formation of the virion 
structure (Donis, 1995) and are essential for virus entry by binding to the bovine 
CD46 molecule (Maurer et aL, 2004; Ronecker et aL, 2008). The genes encoding 
BVDV E2 and NS2-3 are separated by a sequence that encodes a small hydrophobic 
polypeptide with an apparent molecular mass of 6 to 7 kDa (p7). This protein appears 
to be conserved in pestiviruses (Harada et aL, 2000). Cleavage between the E2 
glycoprotein and p7 has been reported to be mediated by a host signal peptidase and 
occur inefficiently resulting in two E2 species, E2 and E2-p7, in pestivirus infected 
cells. Harada et aL, (2000) have demonstrated that both E2 and p7 are essential for 
the production of infectious virions but the E2-p7 fusion protein is not required. 
Cleavage between p7 and NS2 is also believed to occur via a host signal peptidase 
(Elbers et aL, 1996), which has also been shown to be essential in the generation of 
mature NS2/3 that is required for RNA replication (Harada et aL, 2000). As yet no 
role has been elucidated for the E2-p7 fusion protein during BVDV replication or 
virion formation.
BVDV non-structural proteins include NS2/3, NS4a, NS4b, NS5a and NS5b. Full 
length NS2/3 is produced in ncpBVDV infected cells, however during infection with 
cpBVDV isolates, this is cleaved and NS3 can be detected in infected cells (Donis, 
1995). Analysis of the NS2/3 protein has shown that NS2 has a zinc finger motif and 
NS3 possesses helicase activity as well as a zinc finger domain used to bind and 
hydrolyze RNA (Tamura et aL, 1993). Serine protease activity has also been shown 
for NS3 as it cleaves downstream sites in the viral polyprotein, with the aid of the
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proteinase cofactor NS4a to produce the remaining viral proteins (Xu et al, 1997). 
One role described for NS2/3 ascribes a regulatory role in RNA synthesis and 
morphogenesis of the mature virion. Very early in the infection cycle (before 6 hrs 
p.L), NS2/3 is almost completely cleaved, even in ncp BVDV (Lackner et al, 2004). 
This period corresponds to enhanced levels of RNA synthesis and intracellular 
accumulation. This processing diminishes to undetectable levels by 9 hrs p.i. in ncp, 
but not cpBVDV. A role in virion assembly, possibly by co-localizing capsid protein, 
envelope proteins, and genomic RNA on the endoplasmic reticulum membrane has 
been postulated (Agapov et al, 2004).
The NS4a (plO) protein is a highly conserved sequence 64 a.a. long that acts as a 
cofactor for the serine protease activity of NS3 (Xu et al, 1997). The cofactor 
domain was mapped to the central region and interacts with the N-terminal region of 
NS3 (Tautz et aL, 2000). Mutational analysis demonstrated its importance in 
proteolysis and the maintenance of optimal protein precursor: mature protein ratio, 
essential for efficient RNA replication (Grassmann et aL, 2001). The N-terminal one 
third is hydrophobic and the remainder acidic. Qu et al, (2001) demonstrated that 
NS4b has a role in induction of the cytopathic effect in cell culture. A missense 
mutation in NS4b has been shown to change a cpBVDV to a noncytopathic virus. It 
is also believed likely that NS4b plays a role in BVDV genome replication as BVDV 
NS4b interacts with NS5a and NS5b, the implication being that NS4b is part of a 
complex containing the BVDV replicase proteins (Weiskircher et aL, 2009). Other 
functions for NS4b have been inferred by analogy to hepatitis C virus (HCV). HCV 
NS4b is involved in remodelling host membranes and is membrane bound suggesting 
that it may anchor the virus replication complex to the remodelled membranes. 
Weiskircher et aL, (2009) have also demonstrated that host cell membrane
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rearrangement occurs during BVDV infection and NS4b colocalizes with these 
membranes. The role of NS5a still remains unclear although it has been shown to 
interact with the a-subunit of bovine translation initiation factor El and therefore 
may play a role in replication of the viral genome (Johnson et al, 2001). 
Tellinghuisen et a l, (2006) have shown that BVDV NS5a contains an essential zinc 
binding site similar to that of NS5a of HCV. NS5a of HCV has been shown to be 
involved in numerous interactions with members of the cell signalling apparatus, cell 
cycle regulatory kinases and transcription activation machinery (reviewed in Reyes,
2002). Many of the described interactions block the apoptotic response to persistent 
HCV infection and the remarkable similarity between the proteins from the two 
viruses inevitably leads to speculation of similar roles for BVDV NS5a. Little is 
known about the function of NS5b, although a putative RNA-dependent-RNA 
polymerase function was described by (Donis et al, 1995) and was later confirmed 
by Zhong et a l, (1998). One report by Ansari et al, (2004) ascribes a role in virion 
assembly to NS5b. The authors noted an insertion in the NS5b region that inhibited 
virion assembly but not RNA replication and propose a role in BVDV pathogenesis 
for NS5b.
1.13.4 BVDV -  the disease state
BVDV can infect cattle of all ages and has a significant economic impact due to 
productive and reproductive losses. The disease state induced can range from acute, 
sub-clinical infections of immunocompetent cattle to persistent infection that can 
lead to mucosal disease (MD), which is usually fatal (Fig 1.14). In recent years 
advances in molecular genetics have led to an increased understanding of the wide 
range of clinical diseases associated with BVDV which are discussed below.
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1.13.4.1 Acute infection
Acute disease in susceptible animals can arise from infection with either biotype of 
BVDV however natural disease more generally occurs with noncytopathic strains of 
the virus. Acute BVDV is often an inapparent to mild disease with a range of 
symptoms including a biphasic fever, decreased milk production, transient loss of 
appetite, rapid respiration, excessive nasal secretion, excessive lacrimation, and 
diarrhoea (Merck Veterinary manual, 2008). Clinical signs usually appear 6-12 days 
post infection and last for 1-3 days. A transient leucopenia and lymphoid depletion 
caused by either apoptosis or lymphocyte redistribution, especially severe in 
lymphoid tissues of the intestinal tract, leading to a local immunosuppressive state 
(Wilhelmsen et aL, 1990; Liebler-Tenorio et aL, 2003) has been reported early 
during BVDV acute infections and usually coincides with the onset of clinical 
symptoms. Infections result in a transient viraemia and nasal shedding, though 
acutely infected animals rarely transmit virus within a herd (Niskanen et aL, 2002). 
Bruschke et a l, (1998) demonstrated that lymphoid tissue such as tonsils, lymph 
nodes, spleen and Beyers patches were the predominant site of replicating virus 
during ncpBVDV acute infection, though the virus only replicates to low titres in 
lymphocytes. The authors demonstrate using post mortem samples, that following 
intranasal challenge with ncpBVDV, the virus spreads from the oronasal mucosa and 
tonsils to the regional lymph nodes followed by dissemination throughout the body. 
Virus spread can occur through free virus in the serum or via infected leukocytes, 
with viraemia detectable between 3 and 10 days post infection. The infection is 
brought under control by the development of specific immunity, mediated by a T- 
dependent antibody response and an activation of T-lymphocytes (CD4+ and CD8+ T 
cells). Neutralizing antibody can be detected from approximately two weeks post
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infection and is protective on re-exposure to an antigenically homologous viral 
challenge, however, the kinetics of the lymphoproliferative response vary between cp 
and ncp viruses (Collen and Morrison, 2000). Acute infections with cpBVDV are 
less common and are short-lived, resulting in shorter duration of nasal shedding in 
comparison to ncpBVDV infections (Lambot et aL, 1998). The authors also 
demonstrate that infection with cpBVDV does not result in detectable levels of 
viraemia.
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Figure 1.14: Persistent versus transient infections: BVDV causes two types of 
infection in vivo. Infection of a naive animal with BVDV of either biotype leads to a 
transient (acute) infection that usually causes no or mild clinical symptoms. The 
virus is eliminated by the humoral and cellular immune response leading to lifelong 
protection against that particular strain. In contrast, infection with ncp, but not cp, 
BVDV between the second and fourth month of gestation may lead to persistent 
infection of the foetus. Infection later in gestation may lead to abortion, 
malformation, or to the birth of normal, immunocompetent calves. Persistently 
infected (PI) calves are immunotolerant to the infecting BVDV strain. These animals 
are bom antibody negative and shed large amounts of virus during their entire 
lifetime. If the persisting ncp virus mutates into a cp biotype or if the PI animal is 
superinfected with an antigenically related cp virus, the PI calf will succumb to the 
lethal mucosal disease
Figure from Peterhans et ctl., 2010
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1.13.4.2 Foetal infection and virus persistence
Persistent infection occurs in bovine embryos exposed to ncpBVDV from the 
second to fourth of the 9.5 months of development. Trans-placental infection can 
occur when pregnant animals undergo a transient infection, but virus may also be 
transmitted to the foetus by a persistently infected dam (Duffell and Harkness, 1985; 
Peterhans et aL, 2010). If infection occurs during the early period of embryonic 
development, the immature immune system of the foetus fails to mount an immune 
response to the virus and the animals become immunotolerant to the infecting viral 
strain. The resulting calf is persistently infected and constantly sheds high titres of 
virus, even though it may appear clinically healthy (Barber et aL, 1985; Peterhans et 
aL, 2010). As a consequence, persistently infected cattle can transmit the virus both 
laterally and vertically within the herd. Persistently infected cattle are seronegative 
and exhibit no T cell responses to the persisting virus (Collen et al, 2000).
In persistently infected animals, virus can be detected in all types of leucocytes in 
lymphatic tissues and blood but also in skin and hair roots. Clinically, PI animals 
may show no, or only mild, signs of infection, including intermittent diarrhoea and 
pneumonia. In addition, an increased frequency of infections suggests these animals 
may be immunosuppressed and some animals also show growth retardation. In 
contrast, cpBVDV isolates do not result in persistent infection or immunotolérance, 
even if the foetus is exposed to the virus during the first trimester of gestation 
(Brownlie et aL, 1989). However, viable virus can be isolated from foetal spleen 
tissue at days 5 and 7 post infection and it has been speculated that the different 
outcomes are due to the differing abilities of ncp and cpBVDV to induce IFN in the 
foetus (Charleston et al, 2001). Infection of the dam later in gestation, between 
approximately 79 and 150 days can result in abortion or the birth of a calf with
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central nervous system (CNS) or teratogenic defects (reviewed in Moennig and 
Leiss, 1995). However, if the foetus is exposed to the virus during the last trimester 
of pregnancy, the foetal immune system is sufficiently developed to mount an 
immune response to the virus and the infection is resolved with the development of 
neutralising antibodies (Moennig and Leiss, 1995). The resulting calf is normal, 
immunocompetent and protected from infection with antigenically homologous 
virus.
1.13.4.3 Mucosal disease (MD)
After months or years, mutation of the persisiting virus to cpBVDV may lead to 
persistently infected animals developing mucosal disease which can be lethal and is 
characterised by bloody diarrhoea, fever and in some cases, lesions in the mouth and 
interdigital clefts. Postmortem analyses have described ulcers found in different parts 
of the digestive tract, especially in the Peyer’s patches. A cpBVD virus can be 
isolated in addition to the persisting ncp biotype from animals suffering from 
mucosal disease (MD). Since the ncp and cpBVDV strains isolated from an 
individual animal suffering from mucosal disease are antigenically and genetically 
very closely related, they are referred to as a “ virus pair”  (Howard et aL, 1987; 
Brownlie, 1990). MD can be acute or chronic and it has been postulated that chronic 
MD results from infection with a non-homologous strain of cpBVDV that shares 
some, but not complete, antigenic homology with the persisting strain (Fritzemeier et 
al, 1995). Superinfection of a persistently infected calf with a homologous 
cpBVDV strain or mutation of the persisting ncpBVDV strain within the host can 
lead to mucosal disease with 100% mortality (Brownlie et aL, 1984; Kummerer et 
aL, 2000). Attenuated cpBVDV, passaged in porcine or rabbit cell lines has been 
widely used as a vaccine strain (reviewed in Bolin, 1995). However, in herds with PI
animals, recombination between the persisting ncp strain and the modified cpBVDV 
vaccine strain has resulted in the development of MD (Ridpath and Bolin, 1995; 
Becher e/tf/., 2001).
It was originally believed that severe disease only occurred during cases of MD 
resulting from superinfection of a persistently ncpBVDV infected animal with 
cpBVDV. However, this has been challenged in a more recent publication that has 
suggested that biotype specificity in relation to disease severity may need to be re­
assessed, as infecting biotypes do not necessarily correlate with virulence in acute 
infection (Ridpath et al, 2006). What has been established is that BVDV strains 
associated with severe acute BVDV are all ncp in nature upon culture with epithelial 
cells (Ridpath et al, 2006). However, the authors demonstrate that the same, 
evidently non-cytopathic virus will induce apoptosis and necrosis in PBMC both in 
vitro and in ex vivo PBMC from infected cattle (Ridpath et al, 2006). The authors 
therefore propose an expansion to the number or viral biotypes to three, to include a 
lymphocytopathic biotype that can induce a cytopathic effect in lymphocytes but not 
epithelial cells, which would correlate with high virulence in acute infections in vivo 
(Ridpath et al, 2006).
1.14 The immune response to BVDV
BVDV has the ability to cross the placenta of susceptible pregnant animals (Bolin, 
1990) and cause a variety of foetal infections (Brock et a l, 2003) providing clear 
evidence of the success of BVDV in the evasion of the host immune system. A 
transient immunosuppression occurs in acutely infected animals (Potgieter, 1995) 
and BVDV has been shown to infect cells pivotal in control of both the innate and 
acquired immune response (Glew et al, 2003). These cells include granulocytes, 
macrophages, antigen-presenting myeloid cells, CD4+ and CD8+ T-lymphocytes and
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B cells. Analysis of the immune response to BVDV infection is complicated by the 
fact that the interactions of BVDV with the immune system are strain specific with 
differing outcomes depending on not only on genotype and biotype but also the 
virulence of the viral isolate.
1.14.1 The innate response to BVDV infection
Much of the data generated in characterising the innate immune response to BVDV 
has been generated from in vitro experiments in monocyte derived dendritic cells 
(MoDC) or macrophages. Infection of alveolar macrophages in vivo or in vitro with 
either noncytopathic or cytopathic BVDV biotypes has been shown to lead to 
depressed phagocytosis, decreased Fc and complement receptor expression and a 
reduction in microbiocidal activity as well as a reduction in release of chemotactic 
factors (Welsh et a l, 1995; Lui et al., 1999; Peterhans et al., 2003). Adler et al., 
(1996) demonstrated that bone marrow derived macrophages cultured in vitro with 
either biotype of BVDV became productively infected resulting in a reduction in 
their capacity to produce TNFa in response to Salmonella dublin or 
lipopolysaccharide (LPS). Franchini et al., (2006) demonstrated that although the 
levels of TLR mRNA remained constant in ncpBVDV infected macrophages, 
ncpBVDV infection lead to an enhanced production of nitric oxide upon TLR2 and 
TLR4 stimulation. This suggests that BVDV infection may modulate some TLR 
mediated functions in the innate immune response but not others and that these 
effects are dissociated from mRNA expression. It has been demonstrated that only 
ncpBVDV but not cpBVDV infection of macrophages primes the cells for enhanced 
production of nitric oxide (NO) in response to LPS (Adler et al., 1994), and this 
along with a decrease in the levels of superoxide anion and TNF may contribute to 
immunosuppression (Potgieter 1995, Adler et al., 1997). Macrophage infection with
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BVDV also leads to other immunosuppressive effects including the stimulation of 
prostaglandin E2 (PEG2) synthesis (Welsh and Adair 1995; Van Reeth and Adair,
1997), the induction of IL-1 inhibitors (Jensen and Schultz, 1991), and a decrease in 
cytokine induced chemotaxis (Ketelsen et aL, 1979). cpBVDV infection of 
macrophages leads to the release of soluble factors capable of inducing apoptosis in 
uninfected macrophages and epithelial cells (Adler et aL, 1997). The ability of 
cpBVDV to induce apoptosis of uninfected cells surrounding infected macrophages, 
possibly due to release of soluble factors, is believed to play a role in the pathology 
observed in lymphoid tissue during mucosal disease (Teichmann et a l, 2000).
1.14.1.1 Bovine viral diarrhoea virus and interferon
In vitro infection of bovine cells of many origins with cpBVDV results in the 
production of type-I IFN, whereas ncp BVDV does not. Infection of MDBK cells 
with cpBVDV, has been shown to result in PKR activation, eIF2a phosphorylation, 
NF-kB activation and translation inhibition (Gil et al, 2006), providing a further 
indication of the ability of this virus biotype to activate anti-viral pathways. 
However, ncpBVDV infection did not produce similar effects even following 
stimulation with other viruses capable of inducing type-1 IFN, suggesting that 
ncpBVDV has evolved additional mechanisms to prevent PKR activation (Gil et al, 
2006).
NcpBVDV readily establishes persistent infections in bovine cell lines in vitro 
(Ohmann and Babiuk, 1988). It is known that BVDV is sensitive to IFN treatment, 
and IFN can suppress the spread and replication of the virus, however the results of a 
study by Ohmann and Babiuk (1988), demonstrated that it could not cure the 
infection. Later experiments confirmed these results and revealed that pre-treatment 
of either PBMC or foetal bovine muscle cells with up to lx l0 3IU/ml IFN-a resulted
in almost, but not complete inhibition of infection, following culture with BVDV 
(Sentsui eZ a/., 1998).
Specific differences in the type-1 interferon response to in vitro infection of 
macrophages, monocytes and moDCs, with either cpBVDV or ncpBVDV have been 
reported. Infection of macrophages in vitro with cpBVDV but not ncpBVDV 
resulted in the production of type-I IFN (Adler et al, 1997). A subsequent report by 
Glew et al, (2003) concurred with this as monocytes and monocyte-derived-DCs 
were shown to respond to the cp but not the ncp virus by producing IFN. 
Subsequently, ncpBVDV infection was demonstrated to block the induction of type- 
1 IFN by dsRNA in both haematopoietic (Schweizer and Peterhans, 2001, Glew et 
al, 2003) and non- haematopoietic cells (Baigent et al, 2002) however prior 
infection with ncpBVDV does not block a cellular response to exogenous type-I IFN 
(Baigent et al, 2002). More recent publications examining this mechanism using not 
only BVDV but also classical swine fever virus (CSFV), another pestivirus, 
demonstrate these viruses encode active blocks to type-I IFN induction (Charleston 
et a l, 2001; Schweizer & Peterhans, 2001; Baigent et a l, 2002; Ruggli et a l, 2003). 
The Npro protein of both BVDV and CSFV are shown to play a crucial role in this 
process, by blocking the function of IRF-3 ( Baigent et a l, 2002, 2004; Horscroft et 
a l, 2005) and targeting this protein for proteasomal degradation (Seago et a l, 2007). 
Gil et al, (2006) used BVDV viruses with engineered mutations in the Npro gene to 
show that it was a structural component of Npro that was essential for IFN 
antagonism, rather than the catalytic ability of the protein, although the mechanism 
for this inhibition was not determined. CSFV Npro has recently been shown to limit 
type-I IFN induction in pDCs by interacting with IRF-7 and reducing the levels of 
this protein. An intact Zn-binding domain on the Npro protein is needed for the
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interaction with both IRF-3 and IRF-7 (Fiebach et a l, 2011). The authors also 
demonstrate that infection with CSFV but not a virus with engineered mutations in 
Npro impairs the ability of pDCs to produce type -I IFN in response to CpG (TLR9 
agonist) and avian influenza H5N1 infection (Fiebach et a l, 2011).
The interferon response in vivo following ncpBVDV infection is different to that 
described in vitro. Charleston et a l, (2002) demonstrate that infection of post natal 
cattle with ncpBVDV resulted in elevated serum type-I IFN for approximately eight 
days. The authors also report a biphasic IFN-y response detected in serum between 
days 1-14 post infection although the cellular sources of type-I and type-II following 
BVDV infection were not identified. The production of early IFN-y could possibly 
be due to the proposed role for type-1 IFN stimulation of CD8+ T cells to produce 
IFN-y in a non-antigen specific manner (Pien et a l, 2002). Alternatively, early IFN-y 
production could have been dependent on NK cells as reported for other viral 
infections (Orange and Biron, 1996; Hussell and Openshaw, 1998). Later studies 
with CSFV and purified populations of porcine pDCs suggests that these cells play a 
crucial role in the production of type-1 IFN following CSFV viral infection, which is 
enhanced in animals that had previously been immunized (Balmelli et a l, 2005) and 
would be ideal candidates as the cells responsible for the production of type-1 IFN in 
cattle following BVDV infection. There is a report of type-I IFN being produced 
from cells derived from lymphoid tissue in response to ncpBVDV in vitro. These 
cells had characteristics consistent with pDCs but were not chacterised in detail 
(Brackenbury et a l, 2005). The detection of type-I IFN in serum during ncpBVDV 
infection coincides with the onset of leucopenia suggesting it may have a role to play 
in this process. However, it is possible that lymphocyte redistribution is occurring 
with targeting of lymphocytes to regional lymph nodes, resulting in a decline in the
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number of circulating lymphocytes reported for other systems (Gresser et al, 1981, 
Riffault et a l, 1996), including CSFV (Summerfield et al, 2006).
Another pestivirus protein Ems has also been reported to have an inhibitory effect 
on type-1 IFN expression. Recombinant Ems protein, expressed in insect cells, has 
been shown to inhibit dsRNA-induced IFN production via a mechanism dependent 
upon its RNase activity (Iqbal et al, 2004). The authors demonstrate that the protein 
acts to inhibit the dsRNA IFN-inducing signalling pathway as assessed by a lack of 
activation of NK-kB and production of IFN-p. Moreover, the protein was shown to 
degrade dsRNA at low pH, indicating its possible function in endosomal 
compartments within the cell.
1.14.2 The adaptive immune response to BVDV
In general, BVDV infections are resolved quickly, with the generation of neutralising 
antibodies detectable from approximately 14 days post infection (Collen and 
Morrison, 2000). In comparison to the antibody response seen in many acute viral 
infections, the initial antibody titre is relatively low but continues to rise until 10-12 
weeks post challenge (Howard et al, 1985, 1989). Passively acquired antibody to 
BVDV has been shown to be effective in protecting against respiratory shedding 
following BVDV challenge with an isolate from an outbreak of respiratory disease, 
although protection was dose dependent (Howard et al, 1989).
The neutralising antibody response is mainly directed against the structural protein 
E2, (Silva-Krott et al, 1994) with relatively few antibodies directed against El 
suggesting it is likely to be a minor antigenic site or internal component of the virion 
(Potgieter et al, 1995). Howard et al, (1985) demonstrated that following BVDV 
infection, high titres of specific neutralising IgGl and IgG2 antibodies could be 
detected in adult cows, with the predominant isotype being IgGl, and colostrum fed
94
calves had a far higher ratio of IgGl to IgG2-speciflc neutralising antibodies. In 
cattle, a study by Estes et aL, (1996), demonstrated that IgGl production is 
associated with a Th2 CD4+ T cell response in vitro. It has therefore been postulated 
that the T cell cytokine response to BVDV infection is of a TH2 bias and therefore 
not optimal for viral clearance. A further study carried out by Lambot et aL, (1998) 
compared the antibody response generated by groups of calves infected with 
antigenically homologous ncp or cp isolates of BVDV. Calves infected with 
ncpBVDV developed a neutralising antibody response of a greater magnitude, 
detectable 1-2 weeks earlier than in calves exposed to cpBVDV. In the animals 
infected with ncpBVD, virus was recovered from nasal secretions and lymphocytes 
during the first 28 days of infection, whereas the cp isolate was only detected in 
nasopharyngeal swabs at fewer time points during this period indicating less viral 
shedding. However, this may be due to increased exposure to antigen caused by 
enhanced viral replication or dissemination in ncpBVDV infected cattle compared to 
the limited replication in cpBVDV infected animals as a consequence of IFN 
production.
1.14.2.1 The cell mediated immune response to BVDV
The importance of the cell-mediated immune response (CMI) is emphasized by the 
strong correlation of disease severity with degree of lymphopenia. It may be 
surmised that depletion of T cells of the thymus, spleen, and lymphoid tissue also 
corresponds to disease progression and severity. The available evidence to date 
suggests that cell-mediated immunity is required to resolve BVDV infection, as 
antibody alone is insufficient to clear infection (Howard et aL, 1989). In vivo 
depletion of CD4+ T cells results in an extended period of viral shedding and 
viraemia, enhanced viral replication and a delay in resolution of acute infection
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following challenge with ncpBVDV (Howard et aL, 1992). In this study depletion of 
either CD8+ or WC1+ (yÔTCR+) T cell subsets did not result in increased 
susceptibility to infection. Antibody production in response to this acute ncpBVDV 
infection was not detectable until 2-3 weeks post infection. However, enhanced viral 
replication in CD4+ depleted calves was noted preceding the detection of neutralising 
antibodies in control animals, suggesting that CD4+ T cell mediated protection was 
cell mediated rather than just assistance for B cell antibody production (Howard et 
ai, 1992). One other possibility is the loss of CD4+ pDCs and therefore IFN 
production in response to viral infection allows greater levels of viral replication 
prior to antibody production.
Differences in the kinetics of specific lymphocyte proliferation exist when 
comparing the response to ncpBVDV and cpBVDV. Specific lymphocyte 
proliferation is detected earlier in response to cpBVDV than to ncpBVDV in cattle 
challenged with either biotype (Collen and Morrison, 2000; Lambot et al, 1998). 
Specific proliferation by PBMC in response to the infecting virus strain in vitro was 
detected by 21-28 days following infection with cpBVDV, whereas a specific 
response to ncpBVDV was delayed until 56 days post infection (Collen and 
Morrison, 2000). yôTCR+ T cells do not appear to play an important role in 
immunity to BVDV, however this T cell subset was demonstrated to be reduced in 
the circulation of persistently viraemic calves (Howard et al, 1990) but the cause of 
this is unknown. Data presented by Collen and Morrison (2000) demonstrated that 
following acute infection, specific proliferation by PBMC to ncp or cpBVDV could 
only be detected following the resolution of viraemia. A study carried out by 
Larsson and Possum (1992) reported that live but not heat-inactivated BVDV 
induced proliferation in PBMC from cattle sero-positive to the virus. However, a
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further study by Collen et aL, (2002), clearly shows that culture with heat- or UV- 
inactivated ncpBVDV can induce significant, specific proliferation in PBMC from 
cattle immune to BVDV. CD4+ T cells were shown to recognise virus-infected and 
protein-pulsed APCs, whereas CD8+ T cells recognised only virus-infected APCs. 
This study also determined that a memory CD4+ T cell response to BVDV is strain 
cross-reactive and MHC restricted (Collen et al, 2002). This series of experiments 
revealed that the T cell repertoire was biased towards conserved regions within NS3 
and E2 and that two of the regions identified in E2 were adjacent to B cell epitopes 
(Collen et aL, 2002), which had previously been defined in viral escape mutants 
using monoclonal antibodies (Paton et aL, 1992). A previous study by the same 
group examining the CD4+ responsiveness (lymphoproliferation) of persistently 
infected cattle to peptides demonstrated immunotolérance at the level of the cell 
mediated response (Collen et aL, 2000). Glew and Howard (2001), used BVDV- 
infected monocytes isolated from a persistently infected calf to demonstrate that both 
CD4+ and CD8+ T cells are activated in seropositive calves, indicating that both arms 
of the adaptive immune response are employed in response to BVDV exposure and 
memory T cells are generated. Several peptide regions in the viral polyprotein have 
been identified as regions that could serve as candidates for presentation on bovine 
MHC I alleles (BoLA-Al 1, -A20, -HD1, and -HD6) that appear to correspond to the 
C, Ems, E2, and NS2-3 regions (Hegde and Srikumaran, 1996; Chase et aL, 2004). 
Rhodes et aL, (1999) presented data demonstrating that CD8+ T cells from BVDV- 
immune cattle proliferate and produce IFN-y in response to ncpBVDV infected 
monocytes, however, the cytolytic ability of these cells was not assessed. They 
demonstrated that CD4+ T cells from BVDV-immune cattle produce a B cell growth 
factor (BCGF) when cultured with infected monocytes which correlated with low
97
levels of IL-2 and IFN-y production. CD8+ T cells proliferated specifically in 
response to BVDV-infected monocytes and produced IL-2 and IFN-y with 
undetectable BCGF. From their data, the authors concluded that CD8+ T cells were 
capable of acting as anti-viral effectors against virally infected cells and that CD4+ T 
cells provide help for antibody production to limit viral spread via a TH2 response, 
stimulating B cell antibody production. However, this is in contrast with the study 
carried out by Howard et aL, (1992), which suggested a role for CD4+ cells in the 
cell mediated immune response as well as antibody production. A further study by 
Beer et aL, (1997) indicated a role for MHC-restricted cytotoxic activity in response 
to ncpBVDV, although whether this was class I or II restricted was not determined. 
Further evidence of the importance of the cell mediated immune response against 
BVDV was described by Endesley et aL, (2003). In this study T-cell mediated 
immune responses were reported to be associated with protection against virulent 
challenge without sero-conversion, in calves that were exposed to either modified 
live virus (MLV) vaccine or challenge virus in the face of high circulating maternal 
antibody (Endsley et aL, 2003).
The generation of memory cells of both subsets (CD4+ and CD8+) was shown to 
occur, as antigen-specific cytotoxic lymphocyte (CD8+) activity (Beer et aL, 1997) 
and mixed Th1/Th2 responses were observed in PBMC cultures of convalescent 
cattle (Rhodes et aL, 1999). Taken together the available information suggest a 
response where CD4+ T cells have a helper function in mounting the humoral 
response required to reduce systemic viral spread during the acute phase of infection, 
but that both CD4+ and CD8+ memory is established, and respond with expansion of 
both Tr2 and ThI activity upon secondary exposure.
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1.15 BVDV induced immunosuppression
BVDV is known to have immunosuppressive effects on cells of both the innate and 
adaptive immune response (fig 1.15) which permits colonisation and replication by 
opportunistic pathogens. It has been reported that Mycobacterium paratuberculosis 
(PPD) and M. bovis (BCG) recall immunological responses were temporarily 
inhibited when the animal had recently been vaccinated with MLV BVDV (Thoen 
and Waite, 1990) or acutely infected with ncp BVDV (Charleston et aL, 2001). In the 
latter study the authors clearly demonstrate that acute ncpBVDV infection leads to a 
period of transient leucopenia and a suppression of the recall response to BCG 
antigen in in vitro cultures that persisted for up to two weeks post infection. The 
authors also determined that the effect ncpBVDV was having on proliferation during 
in vitro cultures was not a direct effect of the virus itself, but suggest that this was 
due to conditioning of the cells in vivo by an as yet undetermined mechanism that 
prevented their response in a subsequent in vitro assay (Charleston et aL, 2001). 
Infection by important bovine viral pathogens such as bovine respiratory syncytial 
virus (BRSV) can be potentiated by concurrent BVDV infection. BRSV has been 
shown to gain a foothold during the delays in the antibody response (Graham et aL, 
1998). Dual infection with bovine respiratory syncytial virus (BRSV) and BVDV has 
been shown to result in longer viral shedding and a delayed detection of BRSV- 
specific antibody in comparison to animals infection with BSRV alone (Elvander et 
ah, 1998). Challenge experiments have demonstrated enhanced pathogenesis of 
BRSV (Brodersen and Kelling, 1998) and bovine rotavirus (BRV) (Kelling et aL,
2002) infections when co-inoculated with BVDV. Clearly, the fact that BVDV 
suppresses induction of type I IFN could lead to exacerbation of concurrent viral 
infections normally cleared by an early IFN response (Peterhans, et aL, 2003).
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Concurrent infection with BVDV and bacterial pathogens such as Salmonella dublin 
or S. typhimurium resulted in protracted bacteraemia with the former and raised body 
temperatures and increased faecal bacterial shedding with the latter (Wray et al, 
1987).
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Figure 1.15 Immunosuppressive mechanisms of BVDV
Acute BVDV infections can result in immunosuppression of cattle. The importance 
of BVDV-induced immunosuppression is that it increases the host's susceptibility to 
other pathogens. The mechanism of immunosuppression of BVDV infection is 
multifactorial leading to down regulation of various receptors, cytokines and 
signalling molecules (highlighted in red) and upregulation of other parts of the 
immune system (highlighted in green). Specific aspects of the interaction of BVDV 
with the immune system such as IFN production have been shown to be biotype- 
specific.
Adapted from http://www.bvdvinfo.ch/veterinarians/immunosuppression.html
Institute of Veterinary Virology, University of Bern.
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The mechanism of this early immunosuppression during BVDV infection is likely to 
be extremely complicated involving not only infection of cells of the immune 
system, but altered cytokine profiles as a result of this infection. The infection of 
immune cells crucial to innate immunity can lead to altered function, representing 
another means of rendering an animal immunosuppressed and more susceptible to 
bacterial and viral opportunists. This was clearly seen in cp and ncp BVDV infected 
macrophages whose ability to respond to LPS with TNF-a (Adler et aL, 1996) and to 
respond to PMA with superoxide anion production (Adler et aL, 1994) was 
significantly impaired. MLV BVDV vaccination was shown to inhibit neutrophil- 
mediated antibody-dependant cellular cytoxicity (Roth and Kaeberle, 1983). 
Inhibition of phytohaemogluttinin (PHA)-induced proliferation of PBMC by 
cpBVDV was attributed to reduced IL-2 production (Atluru et aL, 1990) stemming 
from reduced IL-1 secretion by infected monocytes and inhibiton of mRNA 
production. This block in IL-1 activity and the antiproliferative effects of BVDV 
infection was confirmed in a further study by Jensen and Schultz (1991). However, 
IL-2R expression is maintained in cells infected with both biotypes (Hou et aL,
1998).
Several studies have demonstrated BVDV infection of leukocytes. One of the first 
demonstrations of viral antigen in PBMCs defined the frequency of infection at 5- 
36% (Bielefeldt-Ohmann et aL, 1987) with B cells being permissive to infection 
without viral replication. This was later confirmed by Lopez et aL, (1993), with 
productive viral replication only detected in monocytes and T cells expressing 
BoCD4, B0CD8 and y 6-TOR, but not B cells. However, in a study of leukocyte 
subsets permitting viral replication by Sopp et aL, (1994) using an antibody to the 
NS3 protein and FACS analysis reported B cells comprised 11% of cells positive for
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BVDV NS3 protein, with yô-T cells (11%), CD2+ T cells (23%), and (35%) 
monocytes also exhibiting fluorescence. Flow cytometric analysis of PBMCs from a 
persistently infected animal quantified the frequency of infection to be 3-21%, and 
determined this method to be suitable for diagnostic purposes (Qvist et aL, 1990). 
Mononuclear cells also stained positive for BVDV antigen in lymph nodes 
(Wilhelmsen et aL, 1990) and monocyte-derived macrophages expressed 20-30% 
viral antigen upon examination (Chase et aL, 2004). cpBVDV has also been 
demonstrated to induce apoptosis in monocytes in vitro (Lambot et al, 1998) 
however, monocyte-derived DC have been shown to be resistant to this effect, even 
though a significant proportion of the cells become infected (Glew et al,. 2003). In 
addition the cp virus was also shown to induce apoptosis in CD8+, CD4+ and 
WCl+yÔ+ T cells in cultures with monocytes (Lambot et al, 1998).
Antigen presentation by cells of the innate immune system is another function 
impacted by BVDV infection, both directly and indirectly. PBMCs isolated from 
calves acutely infected with a highly virulent type II BVDV demonstrated reduced 
expression of surface MHC II and B7 molecules compared to uninfected controls 
(Archambault et aL, 2000), but MHC I and B4 (CD 19) expression, and phagocytic 
capability were unaffected. However, ncpBVDV-infected PBMCs isolated from a 
persistently infected calf were able to promote proliferation of CD4+ and CD8+ 
memory T cells derived from a seropositive MHC-matched calf (Glew and Howard, 
2001) suggesting MHC IIAPC function is primarily affected during acute infection 
of naïve animals but in PI calves, APC function is relatively normal. Boyd et aL, 
(2004) reported that the mechanism of endocytosis in infected monocytes appeared 
to be unaffected by biotype, but phagocytic responses were inhibited by a cp and two 
highly virulent ncpBVDV strains compared to two avirulent ncp strains (Chase et aL,
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2004). Importantly, monocytes and monocyte-derived dendritic cells (DC) are both 
permissive to both biotypes of BVDV, but DC are resistant to apoptosis when 
infected with cpBVDV (Glew et aL, 2003).
Many mechanisms contribute to the immunosuppression seen early during 
ncpBVDV acute infection. However, the work described by Charleston et aL, (2001) 
suggests that the effect ncpBVDV infection was having on proliferation was not 
directly attributable to infection of PBMC but rather to some form of conditioning, 
possibly of antigen presenting cells, leading to an inhibition of T-cell proliferation. 
The mechanism of this conditioning is yet to be described.
Interestingly, althought these RNA viruses use different receptors, predominantly 
integrins for FMDV and CD46 (plus an as yet unidentified co-receptor) for BVDV, 
both viruses are believed to activate the TLR7 pathway in pDCs leading to the 
production of interferon. FMDV does not directly infect pDCs but gains access via 
Fc receptor mediated uptake when complexed to antibody, whereas BVDV will 
directly infect these cells. In other cell types such as mucosal epithelial cells, the 
production of IFN in response to FMDV is shut off due to the action of Lpro. 
Similarly for BVDV the N -  terminal protease Npro disrupts the interferon pathway 
by targeting IRF3 for proteasomal degradation.
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1.16 Project Aims
Plasmacytoid dendritic cells have been isolated and characterised from a number of 
species, but not from cattle. These cells have been shown to play a crucial role in the 
production of interferon in response to viral infection, especially in response to 
viruses that have evolved complex mechanisms of either evading or blocking the 
interferon response in other target cells.
The aims of this project are:
• To characterise bovine plasmacytoid dendritic cells
• To examine the interaction of these cells with foot and mouth disease virus 
(FMDV)
• To examine the interaction of these cells with bovine viral diarrhoea virus 
(BVDV)
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Chapter 2: The characterisation of bovine plasmacytoid denritic cells
2.0 Introduction
Type-I interferons (alpha/beta interferons [IFN-a/p]) are the main innate cytokines 
that are able to induce a cellular antiviral state, thereby limiting viral replication and 
disease pathology. Plasmacytoid dendritic cells (pDCs) play a crucial role in the 
control of viral infections, especially in response to viruses that have evolved 
mechanisms to block the type-I IFN signal transduction pathway. Many types of cells 
are capable of producing type-I IFN, but the “natural type-I IFN-producing cells” 
(NJPC), also known as pDCs, produce very high levels of type-I IFN in response to 
infection with enveloped viruses (Fitzgerald-Bocarsly and Feng. 2007.). 
Nonenveloped viruses induce very little, if any, type-I IFN in pDCs (Feldman et 
a/., 1994.; Palmer et al., 2007). However, it has been shown that antibodies 
complexed to non-enveloped viruses such as FMDV lead to viral uptake, abortive 
replication, and the production of high levels of type-I IFN in porcine pDCs 
(Guzylack-Piriou, et aL, 2006). pDCs have been isolated and characterized from a 
number of species, including humans, mice, and pigs (Asselin-Paturel et al. 2001; 
Facchetti et al. 1989.; Grouard et al. 1997; Nfon et al., 2010; Summerfield et al.,
2003), but not from cattle. Pascale et al., (2008) have identified and partially 
characterized these cells in sheep and pigs.
In this chapter we set out to isolate bovine pDCs from tissue using density gradient 
centrifugation and cell sorting techniques. We also examine the level of serum type-I 
interferon from cattle infected with FMDV which had been selectively depleted of 
specific cell populations. Immune complexed FMDV was used as a tool to help in 
the identification of pDCs from mesenteric lymph nodes of uninfected cattle.
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2.1 Materials and methods
2.1.1 Growth of FMDV Stocks
Seed stocks of the wild-type isolate OIK (Kaufbeuren)-Cad2 were a kind gift from 
Dr Lucy Robinson, Pirbright Laboratory. 01K-Cad2 was propagated initially in 
primary bovine thyroid cells (BTY) (Central Services Unit (CSU), Pirbright 
Laboratory, UK) to maintain the virus’ integrin-binding specificity. Cell monolayers 
were washed once with PBS (Invitrogen, UK) before adding 3ml virus stock diluted 
1:6 in viral growth medium (VGM) (DMEM (Invitrogen, UK), 1% Adult bovine 
serum, lOOIU/ml penicillin, 100pg/ml streptomycin and 2.5pg/ml amphotericin B). 
Flasks were incubated at 37°C for 30 minutes to allow virus adherence, then a further 
7ml VGM was added and flasks were incubated on a tilting rack at 37°C until 
cytopathic effect (CPE) was evident under the light microscope. Supernatants were 
collected and underwent a freeze thaw cycle at -70°C, before clarifying by 
centrifugation (250 X g for 3 minutes). Aliquots of this seed virus were used to 
infect baby hamster kidney (BHK)-21 cells (ATCC) as above to produce the working 
stock of virus.
2.1.2 Titration of FMDV by plaque assay
BHK-21 cells were grown to approximately 90% confluency in 6 well plates in 
complete DMEM. (DMEM, 10% adult bovine serum, 100 KJ/ml penicillin, lOOpg/ml 
streptomycin). A series of tenfold dilutions of virus were prepared in phosphate 
buffered saline (PBS) and lOOpl per well of each dilution was added to PBS pre­
washed BHK cell monolayers. The virus was allowed to adsorb to the monolayer for 
15 minutes at 37°C, 5% CO2 prior to the addition of 3ml per well of molten Eagles 
overlay (0.6g indubiose (Ciphergen Biosystems Inc., Guildford, UK)) dissolved in 
25ml dHzO added to 75ml Eagles overlay (CSU, Pirbright, UK), 5ml tyrptose
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phosphate broth (TPB), 1ml BVDV free foetal calf serum (PCS; Autogen Bioclear, 
Wiltshire, UK. Catalogue number S0415 batch 318A), lOOIU/ml penicillin and 
100pg/ml streptomycin at 37°C). The overlay was set at room temperature prior to 
plates being transferred to 37°C, 5% CO2 for 24 hours. Plaques were visualized by 
the addition of 3ml per well of methylene blue solution (10% of 1% (w/v) methylene 
blue in ethanol, 10% formaldehyde, 80% PBS) and incubating for 6 to 24 hours at 
room temperature before removing the overlays and rinsing. Plaque forming units 
(PFU) per ml were calculated by counting the individual plaques formed in each well 
and averaging that number across triplicate wells. This average was divided by the 
volume of the virus stock that was applied to each well (in ml) to give the PFU for 
that dilution. The values calculated for each dilution were then averaged to give the 
final PFU/ml.
2.2 Preparation of lymphoid tissue cell suspensions
Mesenteric lymph nodes or retropharyngeal lymph nodes were harvested from naive 
male Holstein Friesian animals, (3 to 18 months of age), cut into small pieces under 
sterile conditions using scissors and placed onto muslin immersed in PBS. Cells were 
released from the tissue by pressing gently through the muslin using the barrel of 
10ml syringe. Cell suspensions were then underlayed with histopaque (density 1.083, 
Sigma-Aldrich, UK) and centrifuged at 1200 X g, for 20 minutes at 18°C (Fisher 
Scientific accuSpin 3R) to remove dead cells and debris. Cells from the gradient 
interface were collected into clean tubes and washed three times with calcium and 
magnesium free PBS.
2.3 Isolation of Peripheral Blood Mononucleur Cells (PBMC) from whole blood
Heparinised blood was collected from individual animals and diluted 1:1 with PBS. 
Thirty milliliters of diluted blood was underlayed with 10ml of histopaque 1083 and
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centrifuged at 1200 X g, for 20 minutes, at 18°C (Fisher Scientific accuSpin 3R). 
Cells were harvested from the gradient interface and washed three times in calcium 
and magnesium free PBS.
2.4 Collection of pseudo afferent lymph and isolation of cells
Pre-scapular lymph nodes were surgically removed and 2 months later, cannulas 
inserted to allow the collection of pseudo-afferent lymph from individual cattle 
(Hope et aL, 2006). Pseudo-afferent lymph was diluted 1:1 with PBS and underlayed 
with 10ml of histopaque 1083. The gradients were centrifuged at 1200 X g. for 20 
minutes at 18°C (Fisher Scientific accuSpin 3R).Cells were harvested from the 
gradient interface and washed three times in calcium magnesium free PBS.
2.5 Optiprep (lodixanol) enrichment of large low density cells
Enrichment for large low density cells was carried out using a previously published 
protocol used to isolate dendritic cells from mouse splenic lymphocytes with a few 
minor changes (Ruedl et aL, 1996). Following isolation of live cells over histopaque 
(1083) gradients, 1x109 cells were resuspended in lOmls of 15% optiprep solution 
(Axis-Shield, Kimbolton, UK), diluted in Hanks balanced salt solution (HBSS 
(Sigma, Poole, UK)). The 15% solution was then overlayed with lOmls of 11.5% 
optiprep solution, diluted in (0.88% Nad, ImM EDTA, 0.5% BSA, lOmM HEPES) 
or (PBS, 0.5% BSA). Finally the gradient was overlayed with 6mls of HBSS. 
Gradients were centrifuged at 600 X g for 30 minutes at 18°C (Fisher Scientific 
accuSpin 3R) and the cells from the interface (the large, low density cells containing 
dendritic cells, monocyte / macrophages and large activated lymphocytes) were 
harvested and washed a further three times in PBS. These cells will subsequently be 
referred to as large low density cells (LED). Cells were then sorted using midiMACS 
LS columns (Miltenyi Biotec, Germany) and the sorted populations analyzed by
immunostaining and flow cytometry or cultured to examine the induction of type-I 
inteferon following stimulation with virus, virus antibody complexes or type A CpG 
(tlrl-hoDNA, Invivogen, San Diego).
2.6 Magnetic cell sorting of large low density cells using Miltenyi (MACS) 
technology
The midiMACS columns were prepared by flushing through twice with MACS 
column buffer (PBS, 2% adult bovine serum) prior to use. These columns were kept 
at 4°C until required. All solutions were kept cold throughout this procedure.
Isolated LLD cells were counted and 3 x 108 cells used for each depletion 
procedure. Cells were incubated with the appropriate monoclonal antibodies (Table 
2.2.4-1) diluted in PBS to a concentration of 1 jag/ml for purified antibody or 1:10 
dilution of tissue culture supernatant, for 15 minutes on ice. These cells were then 
centrifuged at 500 X g for 5 minutes at 8°C (Fisher Scientific accuSpin 3R). The 
supernatant was discarded and the cells were washed three times in 15ml of MACS 
column buffer. Cells were resuspended in residual MACS buffer and lOOpl of 
MACS IgGl beads added. After 15 minutes on ice the cells were washed as 
described above. Cells were finally resuspended in 6ml of MACS column buffer, 
split into two and passed through two separate MACS LS separation columns, the 
flow through collected, pooled and passed through a third column to remove any 
remaining positively labelled cells. The remaining cell population was collected from 
the column flow through by centrifugation as described above, the supernatant 
discarded and cells resuspended in 1ml of complete growth media (DMEM, 10% 
foetal bovine serum, lOOIU/ml penicillin, 100pg/ml streptomycin). Cells were then 
counted and plated appropriately on a 24 well tissue culture plate (Beckton 
Dickinson Labware, New Jersey, USA) in a 500pl final volume for use in LLD assay
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for type-I interferon. Cell population and depletion analysis were carried out using 
monoclonal antibodies and FACS analysis to determine the success of the depletion 
strategy.
2.7 Immuno-staining and flow cytometry
Cells were plated at a concentration of 3 x 105 per well in round bottomed 96 well 
tissue culture plates (Nunc, Roskilde, Germany) in 25pi total volume. Plates were 
centrifuged at 350 X g (Fisher Scientific, accuSpin 3R) for 5 minutes at 8°C. The 
supernatant was flicked off the cell pellets which were gently resuspended in residual 
buffer. Pellets were washed twice in FACS buffer (PBS, 0.5% bovine serum albumin 
(BSA), centrifuged as previously described and resuspended in residual buffer.
The directly conjugated antibodies (table 2.1) were diluted in FACS buffer prior to 
use in staining procedures. Purified antibodies were diluted to Ipg/ml and tissue 
culture supernatants were diluted 1:10. All antibodies had been pre-titrated prior to 
use. Twenty five microlitres of diluted, directly conjugated, antibody was added to 
the relevant wells and incubated for twenty minutes on ice prior to centrifugation as 
previously described and three washes with FACS buffer. Finally, cells were fixed 
with 25pi of 1% paraformaldehyde for fifteen minutes at room temperature, made up 
to 200pl with FACS buffer and transferred to FACS tubes for analysis using a 
Beckton Dickson FACSCalibur and FCS Express software.
Analysis of cell staining was carried out by gating on all live cells in the forward 
scatter FSC / side scatter SSC plots and recorded as gatel. Analysis of individual 
stains was carried out in the appropriate channel for each Alexa Fluor channel.
2.7.1 Direct conjugation of antibodies
Zenon Alexa fluor labeling kits (Invitrogen, U.K.) were used according to 
manufacturer’s protocol to directly label primary antibodies (table 2 .1) for use in
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FACS staining procedures. In summary, Ipg of purified monoclonal antibody orl5pl 
of tissue culture supernatant was labelled using isotype specific Zenon Alexa fluor 
kits (IgGl-488, IgGl-647 or IgG2a-647). Five microlitres of label was added to the 
antibody to give a final volume of 20pl and incubated at room temperature for five 
minutes in the dark. The reaction was quenched by the addition of 5pi of the 
blocking reagent and incubation for a further five minutes in the dark prior to 
dilution for use.
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A ntibody  A n tig en /ce ll , i
Iso ty p e
n o m e n c la tu re  ty p e
S ource U se R e fe ren ce
M M 1A
CC30
CC8
CC21
CCG33
CC149
CC108
CC76
TRT1
TRT3
I LA-16 
BF2
GB21A
2C2
3F7
CD 3 I g G l V M R D ,  USA
CD 4 I g G l IAH
CD 4 l g G 2 a IAH
C D 2 1 I g G l IAH
C D 1 4 I g G l IAH
C D 1 7 2 a l g G 2 b IAH
M H C  II I g G l IAH
C D 4 5R B I g G l IAH
T u r k e y
r h i n o t r a c e i t i s I g G l IAH
v i r u s
T u r k e y
r h i n o t r a c e i t i s l g G 2 a IAH
v i r u s
C D l l c I g G l ILRAD
I F N -a IgM IAH
6 - c h a i n
r e c e p t o r
lg G 2 b V M R D
A n t i  o v i n e  
N P 4 6 ;  NK 
ce l ls
I g G l
U n i v e r s i t y  o f  
E d i n b u r g h
I s t i t u t o
Z o o p r o £ l a t t i c
o
F M D V  3A lg G 2 a
S p e r i m e n t a l e
d e l l a
L o m b a r d i a  e 
d e l l ’E m il ia ,  
B r e s c i a ,  I ta ly  
( I n s t i t u t e  
Z o o p r o f i l a t t i c  
o
F M D V 2 C  l g G 2 a
d e l l a  
L o m b a r d i a  e 
d e l l ’Em il ia ,  
B r e s c i a ,  I ta ly
M C S  D a v is ,  W .C . , e t  a l . 1 9 9 3 .
FACS, IF B e n s a i d ,  A. e t  al . ,  1 9 9 1
M C S ,  FACS, H o w a r d  e t  al. ,  1 9 8 9
M C S, FACS N a e s s e n s  e t  al . ,  1 9 9 0
M CS, FACS S o p p  e t  a l „  1 9 9 6
M CS, FACS H o w a r d  e t  al . ,  1 9 9 9
FACS H o w a r d  e t  al. ,  1 9 9 1
FACS, IF H o w a r d  e t  al. ,  1 9 9 1
FACS, IF C o o k  e t  a l „  1 9 9 3
FACS, IF C o o k  e t  al. ,  1 9 9 3
M C S, FACS H o w a r d  e t  al . ,  1 9 9 7
IF B r a c k e n b u r y  e t  al . ,  2 0 0 5
FACS, M C S  B r o d e r s e n  e t  al . ,  1 9 9 8
A k in d  g i f t  f r o m  Dr
FACS, M C S  T i m o t h y  C o n n e l l y  f r o m  t h e  
U n i v e r s i t y  o f  E d i n b u r g h
IF D e  D ie g o  e t  al . ,  1 9 9 7
IF A k i n d  g i f t  f r o m  E. B r o c c h i
Table 2.1. Mouse monoclonal antibodies used for magnetic cell sorting (MCS), 
fluorescence Activated Cell Sorting (FACS) analysis and immunofluorescence 
(IF).
• TRT -  Turkey Rhinotracheitis virus
• MCS -  MACS cell sorting
• FACS -  fluorescence activated cell staining
• IF - immunofluorescence
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2.8 Assay for type-I IFN production by large low density (LLD) cells
LLD cells were isolated as previously described and the total population or a 
population enriched by selective depletion were plated on to 24 plate tissue culture 
plates (Beckton Dickinson Labware, New Jersey, USA) at 1 x 106 -  5 x 106 cells per 
well in SOOpl final volume of complete growth media (DMEM, 10% adult bovine 
serum, lOOIU/ml penicillin, 100pg/ml streptomycin). In these experiments, FMDV 
OIK Cad2, was used at an M.O.I. of 3. Antiserum harvested on day 0, day5, or day 
13 from cattle infected with FMDV O UKG 34/2001, were used either singly or to 
form immune complexes at a dilution of 1:10 in virus. Immune complexes were 
allowed to form by incubation at room temperature for 30 minutes. Unmethylated 
CpG dinucleotides (500pM tlr-hodna, Invivogen, San Diego), a known TLR9 
agonist, were used as a positive control for the stimulation of type-I interferon (Krug 
et al, 2001). Virus, immune complexes or CpG were added to the appropriate wells 
of the 24 well plated and incubated overnight at 37°C in 5% CO2. Supernatants were 
harvested, centrifuged to remove cellular debris, and either placed at -80°C for 
storage or assayed for the production of type-I interferon.
2.9 Gel electrophoresis and Western blotting.
Large low density cells and depleted populations (1 xlO6 per well) were treated as for 
the IFN production assay. After 24 hours of treatment cells were lysed directly in 
reducing sample buffer (100 mM Tris/HCl (pH 6.8), 4% SDS, 0.2% bromophenol 
blue, 20% glycerol, 200 mM (3-mercaptoethanol). Proteins were separated by SDS- 
PAGE gel electrophoresis (10% acrylamide) and transferred to nitrocellulose 
membranes (Hybond-C Extra; Amersham Biosciences) using a wet blotting 
procedure. Membranes were blocked with 5% (w/v) dried skimmed milk in PBS 
containing 0.5% Tween 20. The membrane was then probed with primary antibodies;
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Mouse anti-y-tubulin (T6557, Sigma) at 1:1000 dilution and rabbit anti-IRF-7 (ab, 
Abeam) diluted to 1 jig/ml in PBS, 5% (w/v) dried skimmed milk, 0.5% Tween 20. 
Bound primary antibodies were detected by horseradish peroxidise-conjugated anti­
mouse or anti-rabbit antibodies (Southern Biotech) again diluted to 1:1000 in PBS, 
5% (w/v) dried skimmed milk,0.5% Tween 20and visualized using a Pierce 
SuperSignal West Pico chemiluminesent substrate kit (Fisher Scientific, 
Loughborough, U.K. ) and processed with a Kodak RP X-OMAT machine .
2.10 MDBK-t/2 culture and reporter assay for type-I IFN
The MDBK-t/2 cell line (Madin Derby bovine kidney cells stably transfected with 
the human Mxl gene promoter fused to chloramphenicol acetyltransferase (CAT) 
reporter (Mx-CAT) were cultured in complete culture medium (DMEM, 10% FBS 
(AutogenBioclear, Wiltshire), lOOIU/ml penicillin, 100pg/ml streptomycin and 
lOpg/ml blasticidin). Six well tissue culture plates (Becton Dickinson Labware, New 
Jersey USA) were set up and grown to approximately 90% confluence, media 
removed and cells washed twice with PBS. Samples from the LLD cell assay were 
added to the monolayer (at varying dilutions) at 200pl/well, SOOpl of Assay medium 
was added to each well (DMEM, 2% FBS, lOOIU/ml penicillin, lOOpg/ml 
streptomycin and lOpg/ml blasticidin).Threefold dilutions of recombinant bovine 
interferon (Novartis, Basle, Switzerland) starting at 90IU/ml, were plated in 
duplicate, at 200pl per well, plus 800pl of assay medium. Plates were incubated for 
24 hours at 37°C in 5% CO]. Samples were then removed, cells washed twice with 
PBS and lysed in 1ml of lysis buffer from the CAT ELISA kit (Roche Diagnostics 
GmBH, Germany). Lysates were either stored at -80°C or assayed immediately for 
CAT expression following the manufactures instructions.
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Results were analyzed using Microsoft Excel software, sample values were 
calculated from standard curve of known concentrations of type-I interferon.
2.10.1 Chloramphenicol acetyltransferase (CAT) ELISA
A CAT ELISA kit supplied by Roche was used to indirectly measure IFN 
production. 2 0 0 jli1 of each standard or cell sample extract was added directly to the 
anti-CAT microtitre plates in duplicate, sealed and incubated for 1 hour at 37°C. The 
samples were then removed and the wells rinsed five times for 30 seconds with 
250pl per well of the kit washing buffer. 200pl per well of anti-CAT DIG 
(digoxigenin) was added to each well, the plates were sealed and incubated for 1 
hour at 37°C. The plates were rinsed five times as previously described, prior to the 
addition of 200pl per well of anti-DIG POD (digoxigenin conjugated to peroxidise). 
The plates were sealed and incubated for 1 hour at 37°C. The solution was removed 
and the plates rinsed 5 times with washing buffer as previously described. 200pl per 
well of the POD substrate was added and the plate incubated at room temperature to 
allow colour development. ELISA plates were read at an absorbance 405nm 
(reference wavelength: 490nm) using a Dynex MRXII ELISA reader and Revelation 
V4.25 software.
Log transformed values for the IFN standards were used to generate a standard curve 
to allow quantification of the levels of IFN in each sample.
2.11 Statistical analysis
Statistical analysis was carried out using Minitab 16 (Minitab Ltd, Coventry, U.K.) 
statistical analysis programme. Levels of type-1 interferon (IFN) produced in vitro 
by large low density cells (LLD), or pDCs were log transformed and analysed using 
general linear models (ANOVA) with tissue and cell source/antigen as fixed effects.
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Model selection proceeded by stepwise deletion of non-significant terms (as judged 
by F-tests) starting from a model including tissue, cell source/antigen and an 
interaction between these factors.
A model was designed by Dr Simon dubbins from the Mathematical Biology group 
at The Pirbright Institute to analyse significance of the levels of type-I IFN produced 
in vivo by CD4 and non-CD4 depleted animals in response to FMDV infection. To 
capture the observed rise and fall in type-I IFN levels (y) over time (f) the starting 
point was a curve y(f)==(/+a/'exp(-cf), where the tb term relates to the initial rise and 
the exp(-cf) term relates to the subsequent fall. However, the curve was 
reparameterised so that the model parameters had a clear biological meaning. In the 
reparameterised model changes in type-I IFN levels (y) over time (t) were described 
by the function,
y(ZL) = ô + a
vPy
exp
where ô is the baseline IFN level, a  is the maximum increase in IFN above baseline, 
p is the time at which maximum IFN level occurs and y is the time before (after) the 
maximum IFN level at which the maximum rate of increase (decrease) in IFN level 
occurs. Parameters for each animal were estimated by fitting the above curve to the 
data using the method of least-squares. Estimates for each animal were then 
compared using Kruskal-Wallis tests to identify significant (PO.OS) differences 
amongst CD4-depleted and non-CD4-depleted animals.
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2.12 Results
2.12.0 Isolation of bovine pDCs
Preliminary experiments were carried out to prepare and to titrate FMDV stocks for 
use in this study and to compare tissue sources for the isolation of the cells capable 
of producing high levels of type-I IFN in response to a known TLR9 agonist. Initial 
experiments to compare the levels of type-I IFN generated in response to virus alone 
or virus -  immune antibody complexes were also carried out to ascertain if a type-I 
IFN response could be generated in response to FMDV by a population of cells that 
could be enriched by density gradient centrifugation.
2.12.1 Virus titration by plaque assay
Seed virus stocks of OiK Cad2 were propagated and titrated as described in the 
materials and methods to give a working stock.
Plaque forming units (PFU) per ml were calculated by counting the individual 
plaques formed in each well and averaging that number across triplicate wells. This 
average was divided by the volume of the virus stock that was applied to each well 
(in ml) to give the PFU for that dilution. The values calculated for each dilution were 
then averaged to give the final PFU/ml.
Both negative and positive controls worked as expected, with the control virus -  
previously titred at 4 X 107 pfu/ml -  giving a titre of 4.17 X 107pfu/ml in this assay. 
The new working stock virus was calculated to have a titre of 4.15 x 107pfu/ml, and 
was used in all subsequent experiments. (Table 2.2)
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Virus dilution 
factor 
Known OiK  
cad2
Plaque count PFU/ml Mean PFU/ml 
per dilution
Virus
concentration
PFU/ml
10"J
10"4
10"5
63.00
55.00
46.00
6.3 x l0 v
5.5 xlO7
4.6 xlO7
5.5 xlO7
10"6
7.00
5.00
5.00
7.0 xlO7
5.0 xlO7
5.0 xlO7
5.7 xlO7
10'7
0.00
3.00
1.00
0.00 
3.0 xlO7 
l.OxlO7
1.3 xlO7
10'8
0.00
0.00
0.00
PFU/ml 4.17xl07/ml
Test O iK cad2
10"
10‘4
10"5
42.00
52.00
43.00
4.2 xlO7
5.2 xlO7
4.3 xlO7
4.6 xlO7
10‘6
4.00
2.00 
5.00
4.0 xlO7
2.0 xlO7
5.0 xlO7
3.7 xlO7
1 0 7
1.00
2.00
1.00
l.OxlO8 
2.0 xlO8 
l.OxlO8
1.3 xlO8
(values similar to 
negative control)
10 8
0.00
0.00
0.00
PFU/ml 4.15 x 107/ml
PBS control
1
0
10
0
5/ml
Table 2.2: Virus titration by plaque forming assay
Virus titrations on BHK cell monolayers gave a final titre of 4.15 x 1 (f pfu/ml for the 
new working stock of OiK Cad 2 (FMDV).
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2.13 Comparison of cell sources for type-I IFN producing cells
Plasmacytoid dendritic cells are a rare subtype of circulating dendritic cells found in 
the blood as well as in peripheral lymphoid organs, which are capable of secreting 
high levels of type-I IFN when activated. They are described as plasma cell- like and 
having low density (Lennert and Remmele, 1958). In this preliminary set of 
experiments, we decided to carry out a comparison of different tissues as a source of 
these IFN producing cells.
Bovine retropharyngeal lymph nodes and mesenteric lymph nodes from two separate 
animals and alveolar macrophages from one animal, were used as cell sources of 
large low density cells. White cell suspensions were isolated and debris removed by 
centrifuging over a histopaque 1083 cushion prior to lodixanol (Optiprep) density 
gradient separation (material and methods 2.5 -  2.7).
The cells harvested from the iodixanol gradients were plated at 5 x 106 per well in 
500pl of assay medium and incubated for 18 hours, either alone, with virus, with 
immune complexes formed by incubating virus with either, day 0 (naïve serum), day 
5 post challenge serum (predominantly IgM), day 13 post challenge serum 
(predominantly IgG) or with CpG. Virus was used at an multiplicity of infection 
(m.o.i.) of 3 and immune complexes were formed by diluting antiserum 1:10 in virus. 
The supernatants from these assays were harvested and used to induce expression of 
Mx-CAT, an interferon responsive promoter-reporter, in the MDBK t/2 stable 
reporter cell line (material and methods 2.10). Following 24 hour incubation, cells 
were lysed and assayed for CAT expression using the ROCHE ELISA kit (material 
and methods 2.10.1)
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Figure 2.1: Type-I IFN production -  tissue comparison
The levels o f type-I IFN produced by large low density cells isolated from 
mesenteric lymph node (MLN), retropharyngeal lymph node (RPLN) and alveolar 
macrophage (AM) were compared, following incubation with virus, FM DV-immune 
complexes with naïve serum (0), day 5 post challenge serum (5), day 13 post 
challenge serum (13) or CpG using the Mx-CAT reporter assay. Data shown 
represents the average o f duplicates from two animals (brown and green).
1 2 1
A dilution series of recombinant bovine type-I IFN of known concentrations were 
used to set up standard curves and allow direct comparison between samples. The 
results show similar IFN production profiles for cells isolated from both mesenteric 
and retropharyngeal tissue with a much smaller quantity produced from alveolar 
macrophages. The large quantity of type-I IFN produced in response to day 5 and 13 
post challenge immune serum complexed to virus and CpG stimulation in cells 
isolated from lymph tissue, encouraged us to believe that plamacytoid dendritic cells 
were present within the population of cells isolated from the lymph nodes. 
Comparison of the data sets for the lymph nodes from individual animals suggested 
that the quantity of type-I IFN produced by large low density cells (LTD) from 
animal to animal is variable but the overall profile is similar, with immune 
complexed FMDV and CpG stimulation leading to high levels of type-I IFN 
expression. Enrichment of pDCs should help reduce the large variation in the data 
recorded from animal to animal and standardise the number of pDCs in each assay. 
The production of interferon in response to day 5 post challenge serum immune- 
complexed virus, where the predominant antibody was known to be IgM, could 
either be a result of low level IgG present within the serum sample or may be an 
effect of complement mediated uptake.
Statistical analysis of the data generated was not possible as the values generated by 
individual animals varied too much and only two data sets were collected for this 
preliminary experiment. (Figure 2.1)
Plasmacytoid denritic cells, in other species, are known to express the FCyRl 1 
(CD32) and to be responsive to CpG, a known TLR9 ligand. Guzlack-Piriou et al., 
(2006) were able to show that Fc receptors expressed on porcine pDCs, efficiently
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promoted the uptake of immune complexed FMDV, leading not only to an abortive 
replication but also production of high levels of type-I IFN.
Following these preliminary results and the conclusion that the levels of interferon 
generated from immune complexed virus (MLN -  between 1000IU/ml and 
4000IU/ml; RPLN -  between lOOOIU/ml and 4500IU/ml) from cells obtained from 
mesenteric lymph nodes and retropharyngeal lymph nodes were similar, it was 
decided that for all subsequent experiments, mesenteric lymph nodes would be used 
as a source of cells from secondary lymphoid tissue. This decision was taken as the 
quantity of lymph nodes available from this tissue was much higher and provided a 
larger quantity of start material to isolate pDCs. Virus, day 13 immune serum-FMDV 
complexes (IC) and CpG would be used to assay for presence of cells producing 
large quantities of interferon.
2.13.1 Lymph node, blood and pseudo-afferent lymph comparison
Isolation of plasmacytoid dendritic cells from other sources such as blood and 
afferent lymph have been described for other species such as pig (Summerfield et al., 
2003), and sheep (Pascale et al., 2008). In this set of experiments we compare 
mesenteric lymph node, blood and pseudo-afferent lymph for the presence of cells 
able to secrete large amounts of type-I IFN in response to appropriate stimuli. 
Samples were collected from three different animals for each tissue source for 
comparison. Large low density cells were isolated from mesenteric lymph nodes as 
already described. To isolate these cells from blood and pseudo-afferent lymph, the 
procedure was modified slightly (see material and methods 2.2 -  2.5). lodixanol 
(Optiprep) gradient separations of large low density cells were carried out as 
previously described. For this preliminary comparison, no further depletion or 
enrichment procedures were carried out. Rather, due to the lower number of cells
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recovered from blood and pseudo-afferent lymph, the isolated large low density cells 
(LLD) were plated at 1 x 106 cells per well for each tissue source and the type-I 
interferon induction assay carried out as previously described.
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Figure 2.2: Lymph node, blood and pseudo-afferent lymph comparison
Comparison o f the quantities o f type-I interferon generated in response to virus, 
FMDV-immune complexes or CpG by equivalent numbers (1 x 106) o f large low 
density cells isolated from bovine mesenteric lymph nodes, pseudo-afferent lymph or 
blood from three animals. Each experiment was repeated three times and the data 
statistically analyzed using ANOVA general linear models. Cells isolated from 
mesenteric lymph nodes either contain more pDCs or these cells are more responsive 
than those isolated from the other tissues.
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Significantly higher quantities of IFN were observed in LLDs isolated from 
mesenteric lymph nodes compared with those isolated from pseudo-afferent lymph 
(PAL) or blood (p<0.05). Individual comparison for the effect of FMDV-immune 
complexes, show there is a significant difference in the quantity of type-I IFN 
between mesenteric lymph node (MLN) and blood (p=0.005), MLN and pseudo- 
afferent lymph (p=0.017), but no significant difference between blood and pseudo- 
afferent lymph (p=0.524).
In cells isolated from each animal, type-I IFN was produced in response to FMDV - 
immune complexes and CpG, with the highest concentration produced by cells 
isolated from mesenteric lymph nodes. The quantities of type-I IFN generated by 
equivalent numbers of cells from blood and pseudo-afferent lymph were comparable. 
These data suggested that the population of pDCs or NfPC, may be higher in 
secondary lymphoid tissue than in blood or pseudo-afferent lymph or perhaps more 
responsive to immune complexed virus and led to the decision that all the remaining 
experiments would be carried out using cells isolated from mesenteric lymph nodes.
2.14 Enrichment of cells producing type-I IFN
Plasmacytoid dendritic cells in both human and mice have been characterised as 
lineage negative for the majority of common myeloid markers (reviewed by 
Shortman and Liu, 2002). However these cells do express some lymphoid markers 
such as CD4. It is known that these cells do not express the T-cell co-receptor CDS. 
Nor do they express CD21, otherwise known as CR2. CR2 is involved in the 
complement system and can bind iCSb (inactive derivative of C3b), CSdg, or C3d 
and is expressed on B cells and follicular dendritic cells. CD21 activates B- 
lymphocytes and can also bind IFN-a (Delcayre et al., 1991).
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CD 14 is expressed in two forms, either as a phospholipid anchored membrane 
protein expressed by monocytes, macrophages, neutrophil granulocytes and myeloid 
dendritic cells, but not pDCs, or as a soluble form. This soluble form is believed to 
be derived from the membrane bound form or can be directly secreted from 
intracellular vesicles (Kirkland and Viriyakosol, 1998; Tapping and Tobias, 2000) 
Membrane anchored CD 14 acts as a co-receptor (along with the TLR4 and MD-2) 
for the detection of bacterial lipopolysaccharide (LPS) (Kitchens, 2000). As CDS, 
CD21 and CD 14 are not expressed on pDCs, a selective depletion of cells expressing 
these markers was carried out to determine if we could enrich for the population of 
cells producing high levels of type-I IFN. Each antibody used to perform the 
depletion has previously been characterised (see table 2.1) and similar approaches 
facilitated the enrichment of pDCs from porcine blood and sheep lymph 
(Summerfield et al., 2003; Guzylack-Piriou et al., 2006; Pascale et al., 2008).
2.14.1 Depletion of lineage specific cell populations
Large low density cells were isolated from bovine mesenteric lymph nodes as 
previously described. Cells expressing CD3, CD 14 or CD21 were removed from the 
population using magnetic cell sorting techniques (see methods 2.6). The remaining 
cell population collected from this procedure, as well as the mesenteric lymph node 
starting material and the large low density cells, were plated at 1 x 106 cells per well 
and the type-I interferon induction assay carried out. Supernatants generated from 
this experiment were assayed by Mx-CAT reporter assay and CAT ELISA as 
previously described (Fig 2.3.1).
Immuno-staining and FACS analysis were carried out on the three populations of 
cells to confirm the depletion of the selected populations (see material and methods 
2.7). Directly conjugated monoclonal antibodies (see material and methods 2.7.1),
were diluted in FACS buffer prior to use in staining procedures. Purified antibodies 
were diluted to 1 pg/ml and tissue culture supernatants were diluted 1:10. Stained 
cells were transferred to FACS tubes for analysis using a Beckton Dickson 
FACSCalibur and FCS Express software (Fig 2.3).
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Figure 2.3: Enrichment of cells producing type-I IFN
FACS analysis o f expression o f CD3, CD 14 and CD21 from mesenteric lymph node 
starting material (total cells), large low density cells (LLD) and the selectively 
depleted population, (representative o f three experiments). LLD cells were isolated 
from total starting material using density gradient separation. Depleted cells were 
then isolated from the LLD population using monoclonal antibodies and Miltenyi 
MACS magnetic heed depletion. All popupations were then subject to 
immunofluorescence with antibodies to CDS (T cells), CD 14 ( monocytes/ 
macrophage) and CD21 (B cells and some dendritic cells) and secondary goat anti 
m ouse-IgGl-488 labelling. All cell populations were analysed using a gated cell 
population to exclude dead cells and devris. Data analysis o f the o f the cell 
populations present during each stage o f the sequential enrichment, clearly shows 
that the majority o f the lineage positive cells targeted, CDS , CD21+ and CD14+ were 
successfully removed using the Miltenyi MACS magnetic sorting technology.
129
total cells large low selectively depleted
density cells cell population
6000-j ----------------------  ----------------------  ----------------------
5000 
z  4000  
1  3000 
-  2000  
1000 
0
c e l l  s o u r c e  I a n t ig e n
Figure 2.3.1: Sequential enrichment of type-I IFN producing cells
Type-I IFN generated by equivalent numbers o f cells from mesenteric lymph node 
starting material (MLN), large low density cells (LLD) and a selectively depleted cell 
population (CD3, CD 14, CD21 depleted) for three animals, following stimulation 
with FMDV, FM DV-immune complexes (IC) and CpG. Density gradient separation 
and selective depletion enriches for the population o f cells producing large quantities 
o f type-I IFN in response to FMDV-immune complexes and the TLR9 agonist CpG. 
There was a significant interaction between tissue and cell source/antigen (T,=0.02). 
There were no significant effects (P=0.109) o f tissue, however there were significant 
effects o f source (pO.OOl)
o
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Comparison of untreated cells showed no significant differences (p>0.05). Virus 
treated cells showed a significant difference between depleted and LLD (p=0.05) but 
no statistically significant difference between depleted and MLN (p=0.3) or LLD 
compared to MLN (p=0.47). Cells treated with immune complexes showed 
significant differences in depleted compared to LLD (p=0.0014), depleted compared 
to MLN (pO.OOl), and LLD compared to MLN (pO.OOl).
Further examination of the data revealed that there was an increase in the level of 
type-I IFN when cells isolated from the gradient were treated with virus alone. This 
effect suggests that the large low density cells include a population of cells that 
produce low levels of interferon in response to virus alone. This effect is abrogated 
when the population is depleted of CD3+, CD21+ and CD14+ cells.
This analysis suggests that the cell type responsible for the production of large 
quantities of type-I IFN is progressively enriched by density gradient separation and 
the removal of specific lineage positive cell subsets and suggests that uptake of 
FMDV- immune complexes via Fc receptors on these cells leads to the production of 
large quantities of IFN.
2.14.2. Selective depletion of NK and yd  cell Tcells +/- CD4+ non -T  cell 
populations
Sequential enrichment of the large low density cells by the removal of specific 
lineage positive cells clearly shows a significant enrichment in the cell type 
responsible for the production of type-I IFN. Following the successful use of the 
Miltenyi MACS sorting technology to achieve this, it was decided to target further 
cell populations using lineage specific markers (figure 2.4).
FACS analysis of cell populations were analysed by gating on the total cell 
population in each sample excluding cellular debris or dead cells (Gate 1). Individual
staining profiles were then examined in the appropriate channel for the fluorescence 
label (FL1- Alexa Fluor 488 staining; FL2- PE staining, FL4 -  Alexa Fluor 647 
labelling). This gating strategy was used for all subsequent experiments.
Natural killer cells (NK), a morphologically distinct subset of lymphocytes referred 
to as large granular lymphocytes, can be identified using monoclonal antibodies to a 
surface expressed protein NKp46. This protein was identified by Sivori et a l, (1997) 
and is expressed on both resting and activated natural killer cells. NK cells play a 
crucial role in immunity to intracellular pathogens and can be activated by 
interferons or macrophage- derived cytokines, however, they have not been 
implicated in the production of type-I IFN in response to viral infections.
Bovine gamma delta (yÔ) T-cells, another subset of T-lymphocytes have been shown 
to constitute a high percentage (20-50%) of peripheral blood mononuclear cells 
(PBMC) (Hein and Mackay, 1991), although they represent only a minor subset in 
peripheral lymph nodes (Walcheck and Jutila, 1994). Both of the abovementioned 
cell types are capable of secreting high levels of type-II IFN (IFN-y), which has 
limited anti-viral effects but can potentiate the effects of type-I IFNs ( reviewed in 
Schroeder et a l, 2004).
Monoclonal antibodies to NKp46 (Grl3.1) and to the TCRô-chain on y8 T-cells 
(GB21A) were included in the monoclonal antibody cocktail containing antibodies 
targeting CD3 (MM1A), CC21 (CD21) and CCG33 (CD 14) to be used for depletion. 
The depletion procedure was carried out as previously described with the exception 
of the addition of magnetic beads to both IgGl and IgG2a+b being added following 
primary antibody incubation. Following the primary depletion, CD4+ cells were 
depleted using the magnetic cell sorting techniques already described and a 
monoclonal antibody specific for bovine CD4 (CC8). This was carried out to
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ascertain if the cell population enriched for were indeed CD4+ non-T cells, described 
as plasmacytoid dendritic cells in the literature (Guzylack-Piriou et al., 2004), (Fig 
2.4.1(A)). Western blot analysis of IRF-7 expression on the depleted population was 
also carried out, as this protein is constitutively expressed by pDCs and is up- 
regulated in response to viral infection (Fig 2.4.1(B)).
A single experiment to examine selective depletion of individual cell lineages was 
carried out to confirm that the depletion strategy, involving more than one round of 
magnetic cell sorting, was indeed producing accurate results and did not impair the 
capacity of the cells to produce type-I IFN following stimulation (figure 2.4.2).
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Figure 2.4: Selective depletion including NK, yô T-cells +/- CD4+ non-T cells
FacsCalibur analysis o f large low density cells before and after depletion o f 
specifically targeted cells populations. Miltenyi MACS magnetic sorting technology 
in combination with monoclonal antibodies successfully depleted targeted cell 
populations including T-cells (CDS -(M M 1 A)). Sub-populations o f T-cells (CD4 
(CC8), yô -  (GB21A) and NK cells -  (G rlS .l)), monocytes, macrophages, neutrophil 
granulocytes and some dendritic cells (CD 14 -  (CCG33)), B-cells and follicular 
dendritic cells (CD21 -  (CC21)).
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Figure 2.4.1 Type-I IFN generated following selective depletions and IRF-7 
expression
(A) Data shown for three animals. Depletion o f CD3+, CD14+, CD21+, NK and y§ T 
cells significantly enriched type-I IFN production in response to FM DV-immune 
complexes (IC) (p<0.05) or CpG (p<0.05). Depletion o f CD4+ cells almost 
completely abolished type-I IFN production in response to the same stimuli. There 
was no significant interaction between depletion status and cell source/antigen 
(f=0.735), but there were significant effects (.PO.OOl) o f both these factors. In 
particular, significantly lower IFN levels were observed in CD4 depleted large low 
density cells (LLDs) compared with those o f other depletion statuses ((pO .0223).
(B) Western blot analysis o f the level o f IRF-7 in a CD3+, CD 14% CD21+, NK and 
y§ T cell depleted cell population following stimulation with immune serum, FMDV 
(V), FMDV-immune complexes (IC) or CpG. Levels o f IRF-7 increased in response 
to FMDV-immune complexes or CpG, but not in response to virus alone or immune 
serum. IRF-7 could not be detected in LLD prior to depletion enrichment.
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Results of this analysis show there was no significant interaction between depletion 
status and cell source/antigen (P=0.735), but there were significant effects (PO.OOl) of 
both these factors. In particular, significantly lower IFN quantities were observed in 
CD4 depleted LLDs compared to other depleted populations. In addition, the quantities 
of IFN were significantly higher in LLDs stimulated with IC or CpG compared with 
non-stimulated (cells or those stimulated with serum or virus alone. Individual 
comparisons between groups show there is no significant difference in the level of type- 
I IFN produced when comparing non-stimulated cells, CD4 depleted cells compared to 
depleted (p=0.229), CD4 depleted cells compared to LLD (p=0.212), and depleted 
compared to LLD (p=0.998)). Individual comparisons between the groups for FMDV 
treated cells show there is a significant difference between CD4 depleted cells compared 
to depleted (p=0.0223) and CD4 depleted cells compared to LLD (p= 0.019). When 
individual comparisons were made for immune complexes (IC) stimulated cells, a 
significant difference was seen in the level of type-I IFN produced by depleted 
compared to CD4 depleted cells (p=0.0006), as was the case for CD4 depleted cells 
compared to LLD (p=0.0019). Again, individual comparisons between the groups show 
a significant difference in the level of type-I IFN produced in response to CpG. CD4 
depleted cells compared to Depleted (p=0.013), CD4 depleted cells compared to LLD 
(p=0.027).
Over all these results confirm that the cell type responsible for high level type-I IFN 
production in response to immune complexes and CpG are CD4+ non-T cells. This is in 
agreement with the data published for pDCs isolated in other species. This data also 
confirms that the depletion strategy, leaving behind a naïve cell population that has been 
significantly enriched for pDCs is appropriate in the identification of these previously 
uncharacterised bovine cells.
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Figure 2.4.2: Selective depletion of individual cell populations.
Analysis o f type-I IFN production by large low density cells selectively depleted of 
individual cell lineages. Large low density cells (LLD) were individually depleted o f 
specific cell populations using monoclonal antibodies to CD3 (MM1 A), CD 14 
(CCG33), CD4 (CC8) and CD21 (CC21). These data are representative o f two 
individual experiments and clearly show that CD4 depletion alone reduced the ability o f 
large low density cells to produce type-I IFN in response to both FM DV-immune 
complexes (IC) and CpG.
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2.15 In vivo depletion of CD4 cells in cattle and the effect on type -1 IFN 
production
The anti-CD4 monoclonal antibody (CC8) used to selectively deplete CD4+ LLD cells 
from the enriched pDC population (see figures 2.4,2.4.1 and 2.4.2) was successfully 
used by Juleff and co-workers, along with the monoclonal antibody IL-A11, to deplete 
circulating CD4+ cells in calves prior to infection with FMDV (Juleff ef a l t 2008). 
However, this study focussed on the role of CD4+ T-cell-independent antibody 
responses in the resolution of FMD. In order to gain insight into the affect CD4+ cell 
depletion has on the production of type-I IFN during the early stages of FMDV 
infection in vivo, serum samples from days (0,1,2,3,4,5,6,7) days post infection (dpi), 
taken during this previous study were analysed for type-I IFN (Fig. 2.5). Serum samples 
from these animals were compared to samples generated from either isotype matched 
control treated animals, CD8 depleted animals or TCR yô depleted animals, using the 
MDBK Mx-CAT reporter assay. Analysis of the significance of the levels of type-I IFN 
produced in vivo by CD4 and non-CD4 depleted animals was carried out using a model 
designed by Dr. Simon dubbins (Mathmatical biology group. The Pirbright Institute) 
(see material and methods 2.11)
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Figure 2.5: CD4 in vivo depletion of cattle and the effect on type -1 IFN production
Analysis o f serum type-I IFN responses in cattle specifically depleted o f CD4+cells as 
compared to CD8+ceils and TCRyô+cells and control antibody.
Serum samples (0,1,2,3,4,5,6,7) days post infection (dpi) taken during this previous 
study were analysed for IFN using the Mx-CAT reporter assay. For each calf, a peak o f 
type-I IFN production was observed between 1 to 4 dpi. In comparison to all six calves 
not depleted for CD4+, three o f the four CD4+ depleted calves exhibited a lower peak 
o f type-I IFN production. There were significant differences between CD4-depleted and 
non-CD4-depeleted cattle in terms o f  the maximum increase in IFN above baseline 
(T>=0.04), but not in terms o f the baseline IFN level (P=0.21), the time at which the 
maximum IFN level occurred (P=0A3), or the time at which the maximum rate o f 
increase occurred (P=0.55). In agreement with the in vitro depletion studies presented 
above, these results show a positive correlation between the presence o f bovine CD4+ 
non-T cells and the production o f type-I IFN.
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2.15.1 Positive selection of CD4+ cell populations
Depletion of CD4+ cells resulted in a significant reduction of type-I IFN both in vivo 
and in vitro. Summerfield et al., (2006) describe the positive selection of a 
CD4+/CD172a+ cell population from porcine blood that retain the ability to produce 
type-I IFN when activated. Other researchers have reported that receptor cross-linking 
using the Miltenyi magnetic beads inhibits the type-I IFN pathway (Fanning et al., 
2006). They show that cross-linking of the CD4 receptor prevents IRF-7 translocation 
to the nucleus, a possible explanation for the reported inhibition of type-I IFN 
production. In order to ascertain if we could purify bovine pDCs still capable of 
producing type-I IFN, we decided to positively select CD4+ cells, following depletion 
of CD3+, CD14+ and CD21+ cells, using the Miltenyi MACS magnetic sorting 
technology. These cells were then subjected to the same treatment regime as that 
previously described for IFN induction in depleted cell populations. (Fig: 2.6).
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Figure 2.6 Positive selection of CD4+ cells and the effect on type -1 IFN production.
Large low density cells (LLD) were isolated as previously described (material and 
methods). The resulting cell population was depleted o f CD3+, CD14+ and CD21+cells 
using Miltenyi MACS sorting technology (depleted).
A further separation o f CD4+/" cells was carried out and both populations assayed for 
their ability to produce type- IFN in response to FMDV-immune complexes and CpG 
oligodeoxynecleotides. The positively selected CD4+ population did not produced type-I 
IFN in response to either CpG or FMDV - immune complexes.
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In agreement with the data published by Fanning et al, (2006), we found an inhibition 
of type-I IFN production in CD4+ positively selected cells using the Miltenyi MACS 
magnetic sorting technology.
2.15.2 Type-I IFN production by FACS Aria sorted CD3-, CD4+ cells
As the Miltenyi MACS sorting technology appeared to compromise the ability of 
positively selected pDCs to produce type-I IFN in response to FMDV-immune 
complexes and CpG, we decided to attempt FACS ARIA cell sorting as an alternative. 
To obtain CDS', CD4+ cells that had not been positively selected using Miltenyi MACS 
sorting technology, we double stained large low density cells with fluorescently labelled 
monoclonal antibodies to CDS (Alexa fluor 405) and CD4(Alexa Fluor 488) and 
collected the CDS', CD4+ fraction using FACS ARIA cell sorting (Gate 2: Fig 2.7a).
The positively selected cells were then compared to large low density cells and a 
population of cells depleted of specific cell populations using the Miltenyi MACS 
sorting technology (Fig 2.7b), for the ability to produced type-I IFN in response to 
FMDV-immune complexes and CpG oligodeoxynecleotides (Fig 2.8).
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Figure 2.7: Comparison of FACS ARIA sorted CD3 , CD4+ cells and the selectively 
depleted population generated by MACS sorting.
(a) FACS ARIA positive selection o f CD3 , CD4+ cells following immune-staining 
with CD3-Alexa fluor 405, and CD4-Alexa fluor 488. CD3-, CD4+ cells were 
positively selected by electronically gating on the specific cell population. Cells 
were collected to examine their ability to produce type-I IFN in response to FMDV- 
immune complexes and CpG oligodeoxynucleotides stimulation.
(b) MACS depleted cell populations. Large low density cells were depleted o f CD3+, 
CD14 , CD21+ and CD1 lc+ cells using Miltenyi MACS sorting technology for 
comparison with FACS ARIA sorted cells. The above populations were assayed for 
type-I IFN production in response to FMDV-immune complexes and CpG.
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Figure 2.8 Type-I IFN production by FACS Aria sorted CD3", CD4+ cells
Large low density cells were compared to a CD3+, CD14+, CD21+, CD 11 c+ depleted 
cell population and a CDS", CD4+ FACS ARIA positively selected cell population (Gate 
2) for their ability to produce type-I IFN in response to FMDV-immune complexes and 
CpG oligodeoxynucleotides.
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The selectively depleted population retain the ability to produce type-I IFN in response 
to both CpG and FMDV immune-complexes however the FACS ARIA positively 
selected cells were compromised in their ability to produce type-I IFN.
These results confirm previous observations that using this particular antibody to CD4 
(CC8), positive selection of bovine pDCs still able to produce type-I IFN in response to 
appropriate stimuli is not feasible. Positively selected cells lose their ability to produce 
type-I IFN in response to FMDV immune complexes and CpG, a phenomenon that had 
been previously described by Fanning et al., (2006), involving receptor cross-linking. 
The mechanism of the inhibition of IFN production by FACS ARIA selected cells has 
not been explored and may be due to either receptor ligation triggering cell signalling 
events or possibly pressure effects of the ARIA sorting system damaging the cells or 
leading to stress induced signalling, activation and maturation of the pDCs. This would 
result in a reduced capacity to produced type-I IFN in response to immune-complexes 
or CpG. Depletion of selective populations using the MACS magnetic sorting 
technology that leave pDCs untouched, remains the preferable method of isolation for 
these cells.
2.15.3 C D llc expression on the surface of cells producing type-I IFN in response to 
immune complexed FMDV and CpG oligodeoxynucleotides.
GDI 1c, also known as the integrin alpha X chain protein, when combined with the beta 
2 chain (ITGB2) forms a leukocyte-specific integrin referred to as inactivated-C3b 
(iC3b) receptor 4 (CR4). This protein is commonly regarded as a myeloid lineage 
marker, expressed highly on most dendritic cells, monocytes, macrophage and 
neutrophils. However, the expression of this protein on pDCs of different species is 
variable. Murine pDC express GDI le (Asselin-Paturel., et al., 2001; Bjorck et al., 2001; 
and Nakano et al., 2001), whereas human pDC are negative for this myeloid marker
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(Grouard et al., 1997), as are ovine pDC (Pascale et al., 2008). Porcine pDC have been 
reported as low positive for C D llc expression (Summerfield et al., 2003), however a 
recent publication by Calzada-Nova et al. (2010) showed this molecule to be absent 
from porcine pDC.
Due to the ambiguity of C D llc expression in other species we decided to investigate 
its expression on the surface of bovine pDCs. As previously described, LLD cells 
isolated from bovine lymph nodes were first depleted of CD3+, CD14+ and CD21+ cell 
populations. Further magnetic cell sorting was performed to separate the constituent 
CD1 lc+ and CD11c"cell populations (Fig.2.9). The CD1 lc+ and CDllc" cell 
populations were then incubated with FMDV, FMDV antibody immune complexes or 
CpG and the resulting supernatants assayed for type-I IFN (Fig. 2.10).
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Figure 2.9: Separation of C D llc+ and C D llc"cell populations using Miltenyi
MACS technology.
Large low density cells were isolated and depleted o f specific cell populations as 
previously described. A further separation to isolate CD1 lc +/ " cell populations was 
carried out by incubating cells with a monoclonal antibody to CD1 le  (ILA -16). Cell 
populations were collected and analysed for both depletion and positive selection by 
FACS staining and analysis. FACS analysis was carried out on all populations by gating 
on all cells, excluding dead cells and celluar debris (previously described on p i 29 and 
132) and examining individual staining profiles in the FL1 channel (Alexa Fluor -488).
147
d e p l e t e d  c e l l  d e p l e t e d  d e p l e t e d
p o p u l a t i o n  (C D 1 1 c + ) (C D 1 1 c -)
1 0 0 0 0  -I
8000  "
6000  "
40 0 0  "
2 0 0 0  -
«3 Ifl3■c0> +oO >uE oE EO (3 O
D
c e l l  s o u r c e  / a n t i g e n
Figure 2.10: Production of biologically active type-I IFN from C D llc+/" cell 
populations following incubation with FMDV immune complexes or CpG 
oligodeoxynucleotides.
Large low density cells depleted o f CD3, CD 14, CD21, expressing cell populations 
(depleted), followed by depletion or positive selection o f CD1 lc +. CD1 lc + [mDCs] and 
CD lie" [pDCs] cells were assayed for their capacity to produce type-I IFN in response 
to FMDV-immune complexes (IC) and CpG. Tissues from three animals were 
processed. Cells were stimulated as previously described. In comparison to the GDI lc+ 
cells, the GDI 1c" cells produced significantly more type-I IFN in response to both 
FMDV immune complexes and CpG (p=0.0077 and p= 0.0123 respectively). These 
results clearly indicate the enriched population o f bovine pDCs to be within the GDI 1c" 
population.
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The data generated in this series of experiments confirms that bovine pDCs are CD! 1c" 
cells. This is in agreement with the data generated for the majority of other species 
investigated. There is a discrepancy between the results reported by two different 
groups for the expression of C D llc  on porcine pDCs. In one publication, porcine pDCs 
were shown to be CD11c low (Summerfield et al., 2003). These results were generated 
using an anti-human C D llc monoclonal antibody that had previously been 
characterised as recognising a porcine protein with similar molecular weight to human 
CD11c but having a different cellular distribution on porcine cells to that seen on 
human cells (Dominguez et al., 2001), and may be one possible explanation of the 
different results published by the two groups (Summerfield et al., 2003; Calzada-Nova 
et al., 2010).
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2.8 Discussion
In this chapter the enrichment of a bovine cell population that is lineage negative, CD4+, 
and corresponds to the pDC populations described for other species. pDCs are described 
as large low density cells and our initial experiments comparing tissue distribution 
indicated that higher numbers are present in bovine secondary lymphoid tissue as 
compared to blood or pseudo-afferent lymph. The sequential enrichment of pDCs by 
density gradient centrifugation and selective depletion of specific populations of cells, 
initially defined the phenotype of bovine pDCs to be CD3", CD 14", CD21", NKp46", 
TCRS-chain-  (expressed on yS -  Tcells). This is in agreement with the data published 
by Pascale et al. (2008), describing the phenotype of ovine pDCs. In our hands, 
experimental depletion of CD4+ cells, in vitro, significantly reduced the level of type-I 
IFN produced. Likewise, in three of four cattle depleted of CD4+ cells we observed a 
significant reduction in the level of serum type-I IFN during the early stages of FMDV 
infection. Interestingly, the depletion of CD4+ cells, which resulted in the profound 
reduction in circulating type-I IFN, had no adverse effect on the magnitude or duration 
of clinical signs, induction of neutralising antibodies or clearance of virus from the 
circulation (Juleff et al., 2009). The pattern of type-I IFN expression in vivo is 
consistent with in vitro observations. Even though virus is present in blood, type-I IFN 
is not induced until, presumably, T-independent antibodies are produced and immune 
complexes form. The timing of type-I IFN induction after the development of 
neutralising antibodies also suggests this cytokine does not play a major role in 
controlling infection but may have a role to play in developing immunological memory. 
In contrast, exogenous IFN has a potent effect when administered prior to infection (Wu 
et al., 2003).
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In all species where pDCs have been characterised, it is now generally accepted these 
cells are CD4+ non-T cells, and that their depletion would be expected to significantly 
reduce the type-I IFN response to viral infection and known TLR7/9 agonists. To date, 
in vivo studies examining the effects of pDC depletion on type-I IFN production have 
been mainly restricted to the murine model and demonstrated by depletion of pDCs 
using cell specific monoclonal antibodies other than anti-CD4. Asselin-Paturel et al., 
(2001) demonstrated that in vivo depletion of pDC in mice, using a monoclonal 
antibody specific for murine pDCs, led to a significantly reduced capacity to produce 
IFN-a in response to CpG. Similarly, Barchet et al, (2005) have shown, using a 
MyD88_/_ mouse model, that the IFN-a response to TLR7 agonists in vivo, are 
completely absent. Using the monoclonal antibody, anti-mPDCA-1 to deplete pDCs in 
vivo, they showed that the levels of serum IFN-a produced in response to known TLR7 
agonists, G-U rich oligoribonucleotides (ORN), are significantly reduced and that pDCs 
are entirely responsible for the type-I IFN produced. Two TLRs have so far been 
identified in pDC that respond to viral infection, TLR7 and TLR9. TLR7 is a receptor 
for ssRNA and is involved in the recognition of RNA viruses such as influenza virus 
(Diebold et a l, 2004), whereas TLR9 recognizes CpG motifs found in the genome of 
DNA viruses such as herpesviruses (Hochrein et a l, 2004). In a more recent 
publication, Zhang et a l, (2008) cloned and expressed porcine TLR7 cDNA in HEK293 
cells and have shown that ORN found in FMDV activated NF-kB and induced the 
expression of IFN-a via TLR7. Taken together these data suggest a role for the 
endosomal RNA receptor, TLR7, in the initiation of type-I IFN production in pDC in 
response to FMDV. This hypothesis is supported by the findings of Guzylack-Piriou et 
a l, (2006) which describe the inhibition of IFN-a production in porcine pDC by the 
administration of chloroquin, which neutralizes the acidic environment of endocytic
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vesicles, but not with leupeptin, ruling out the involvement of lysosomes. Their results 
also suggest the involvement of an RNA receptor associated with endocytic 
compartments, such as TLR7, though further studies are required to clarify this 
mechanism. The differential expression of CD11c has the potential to differentiate cDCs 
and pDCs in mixed cell populations. CD llc, also known as the integrin alpha X chain 
protein, when combined with the beta 2 chain (ITGB2) forms a leukocyte-specific 
integrin referred to as inactivated-C3b (iC3b) receptor 4 (CR4). This protein is 
commonly regarded as a myeloid lineage marker, expressed highly on most dendritic 
cells, monocytes, macrophages and neutrophils. However, the expression of this protein 
on pDCs of different species is variable. Murine pDCs express CD11c (Asselin-Paturel 
et al., 2001; Bjorck., 2001; Nakano et al., 2001), whereas human pDCs are negative for 
this myeloid marker (Grouard et al., 1997; Soumelis et al., 1997), as are ovine pDCs 
(Pascale et al., 2008). Porcine pDCs have been reported as positive for C D llc 
(Summerfield et til., 2003), however a recent publication by Calzada-Nova et al., (2010) 
showed this molecule was not present on porcine pDCs. Here, in agreement with the 
majority of the data published for other species, we show that bovine pDCs do not 
express CD 11c.
An important study carried out by Diebold et. al., (2003) indicated that other cells of 
the immune system can be induced to produce large amounts of type-I IFN if given the 
appropriate stimulus. They demonstrated that conventional CD1 lc+ murine DC were 
able to produce large quantities of type-I IFN following poly I:C transfection and that 
the induction of type-I IFN did not involve signalling through TLR-3 but was in part 
dependent upon protein kinase R (PKR). Hidmark et al., (2005) demonstrated that 
murine bone marrow derived cDCs were able to produce up to 50,000 lU/ml of IFN-a/p 
in response to a genetically engineered Semliki forest virus (SFV) that was capable of
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fusing with the DCs but was replication deficient. The induction was shown to be 
directly dependent upon the ability of the virus to fuse with the cells, indicating that 
induction of IFN was not simply occurring due to the extracellular engagement of the 
virus particle.
Ciavarra et al., (2005) published some interesting results suggesting that cells other 
than antigen presenting cells (APCs) were capable of producing a level of interferon 
that could be detected in the circulation of mice in response to vesicular stomatitis virus 
(VSV). They used a mouse challenge model to demonstrate in mice depleted of antigen 
presenting cells using liposome encapsulated clondrate, circulating interferon could still 
be detected even though pDCs had been removed. To further confirm this finding, the 
authors depleted pDCs using a monoclonal antibody (mPDCA-1), shown to specifically 
recognise mouse pDCs and thus they concluded that a cell type other than pDCs 
produce IFN-a/p in response to VSV infection of mice. An earlier experiment carried 
out by Eloranta and Aim (1999) demonstrated that following immunisation of mice 
with UV-inactivated herpes simplex virus, cells within the spleen responded by 
producing detectable IFN by immunohistochemistry, localising to the marginal zone. 
The phenotype of the IFN-a producing cells was determined as being non-DC on the 
basis of their lack of expression of MHC class II or CD llc. The majority of the IFN- 
producing cells were shown to express sialoadhesin, which is specifically expressed by 
metallophillic marginal zone macrophages, however, only a small minority of the IFN-a 
producing cells were identified as being marginal zone macrophages, leaving the 
identity of the IFN producing cells in doubt (Eloranta and Aim, 1999).
There is still a level of debate as to whether non-pDC can produce equivalent quantities 
of IFN in response to an appropriate stimulus as those seen for pDCs. There are reports 
of extremely high levels of IFN being produced by non-pDC (Diebold et. al. 2003,
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Hidmark et. al, 2005). Subsequently, a direct comparison experiment performed by Ito 
et. al, (2006), using pDCs, C D llc+ DC and monocyte derived DC derived from the 
same human donor and challenged by seven different toll-like receptor agonists found 
that maximal IFN production by the pDCs was several hundred times more than that of 
other cell types tested in respect to any of the stimuli. This experiment does not take 
into account other routes of IFN induction such as the cytosolic RIG-I/MDA5 pathway 
utilised by many cell types other than pDCs. It is believed that pDCs preferentially use 
the TLRs in recognition of infection however this is not the case for all cells.
The importance of pDCs and their ability to rapidly secrete large quantities of IFN-a in 
response to many viral infections has been well documented. pDCs can induce high 
levels of type-I IFN in response to many viruses irrespective of the state of 
infectiousness. The coronavirus, transmissible gastroenteritis virus (TGEV) is an 
example of where live or inactivated virus can stimulate equally well (Charley et al., 
1991). Herpes simplex virus is yet another example, where the state of infectiousness is 
irrelevant to the induction of type-I IFN (Ankel et al., 1998). Both the aforementioned 
viruses are enveloped and the induction of type-I IFN is stimulated by their glycosylated 
viral envelope proteins. In contrast, in vitro studies indicate that pDCs have a limited 
capacity to, or fail to respond to many non-enveloped viruses directly (reviewed in 
Fitzgerald-Bocarsly et al., 2007). To date, there is no explanation of the differing 
responses to enveloped and non-enveloped viruses, though the differing mechanisms of 
cell entry could possibly result in different sub-cellular localization and processing.
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Chapter 3: The phenotype of bovine plasmacytoid dendritic cells and their 
interaction with Foot and Mouth Disease virus.
3.0 Introduction
Many types of cells are capable of producing type-I IFN, but the “natural type-I IFN- 
producing cells” (NIPC), also known as plasmacytoid dendritic cells (pDCs), produce 
very high levels of type-I IFN in response to infection with enveloped viruses 
(Fitzgerald-Bacarsly and Feng, 2007). Nonenveloped viruses induce very little, if any, 
type-I IFN in pDCs (Feldman et al., 1994; Palmer et al., 2000). However, it has been 
shown that antibodies complexed to nonenveloped viruses such as FMDV lead to viral 
uptake, abortive replication, and the production of high levels of type-I IFN in porcine 
pDCs (Guzylack-Piriou et al., 2006). FMDV has been shown to antagonize the host 
innate response in mammalian cells by inhibiting the induction of antiviral molecules at 
both the translational level (Guzylack-Piriou et al., 2006) and the transcriptional level 
(de Los Santos et al., 2006; Wang et al., 2010), interfering with the secretory pathway 
(Moffat et al., 2005; Moffat et al., 2007) and inhibiting surface expression of viral 
proteins (Ostrowski et al., 2005). A key component of this antagonism is orchestrated 
by the FMDV leader proteinase (Lpro), which targets the host translation initiation 
factor eIF4G for degradation (Medina et al., 1993; de Los Santos et al., 2007) and, as a 
consequence, blocks de novo protein synthesis and the production of type-I interferons 
(alpha/beta interferons [IFNs-a/p]) (Devaney et al., 1988). Lpro also disrupts NF-kB (de 
Los Santos et al., 2007) and inhibits double-stranded RNA (dsRNA)-induced type-I IFN 
transcription by orchestrating the degradation of IFN regulatory factor 3/7 (IRF-3/7) 
(Wang et al., 2010). Mason et al., (1997) have shown that a genetically engineered 
FMDV lacking Lpro has an attenuated phenotype in vitro and in vivo. This is attributed 
to the inability to block the production of type-I IFNs, which inhibit FMDV replication 
(Chinsangaram et al., 2001). In vitro studies show that FMDV has the capacity to target
the innate immune response. Although detailed in vivo studies on this subject are 
lacking, FMDV infection in vivo has recently been shown to lead to an increase in the 
levels of type-I IFN in porcine serum (Nfon et aL, 2010). Quantitative assays measuring 
the mRNA expression of IFN-a in nasal mucosa-associated lymphoid tissue (NALT) of 
cattle infected with FMDV revealed significantly greater levels during the acute disease 
phase than in uninfected animals (Zhang et aL, 2006). In cattle experimentally infected 
with FMDV, tissue-specific profiles revealed significant increases in IFN-a mRNA 
levels in the coronary band and tongue at 1 to 2 days post-infection, coinciding with 
increases in the viral RNA load (Zhang et aL, 2009), though it is unclear if this message 
was translated into protein. Type-I IFN has also been detected in the sera of pigs 
infected with different serotypes of FMDV and has been correlated with the peak of 
viraemia and a transient lymphopenia (Nfon et aL, 2010). The observed increase in 
type-I IFN levels during the early stage of FMDV infection is believed to limit viral 
replication and to contribute to the resolution of viraemia prior to the induction of a 
specific immune response.
In the previous chapter we show that the cells producing IFN in response to virus- 
immune complexes are a lineage negative cell population that are positive for CD4 
expression. In this chapter we expand the description of the phenotype of bovine pDCs 
and examine their interaction with FMDV in more detail.
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3.1 Materials and Methods
All cell isolation procedures and biological assays for IFN were carried out as 
previously described in chapter 2 material and methods
3.1.1 Direct conjugation of antibodies 
Already described (see material and methods 2.7.1)
3.1.2 Immuno-staining and flow cytometry
Already described (see material and methods 2.7)
3.2 Immunofluoresence and confocal microscopy
Cells from the depletion enriched population, following stimulation, fixation and 
immunofluorescent staining, were examined by microscopy using a (Leica DMRXA2) 
confocal microscope.
3.2.1 Preparation of coverslips
13mm coverslips were placed in a 24 well plate and ethanol washed prior to being 
incubated with 500pl per well of adult bovine serum (ABS) for 2 hours. This was 
carried out to encourage the adherence of non- adherent cells. The ABS was removed 
immediately prior to the addition of the cell suspension in complete growth media. Cells 
were allowed to adhere over night before use.
3.2.2 Stimulation of adherent cells for the production of type 1 IFN
Coverslips of adherent cells from the depleted LLD population had the media removed 
and 500pl of fresh media added prior to the addition of CpG (2pM final concentration), 
either alone or in the presence of Brefeldin A (5pg/ml final concentration). CpG 
stimulated cells treated with brefeldin A, were incubated for 4 hours at 37°C, 5% CO2, 
the media removed and the cells fixed in ice cold 100% methanol for 20 minutes,
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followed by 30 seconds in ice cold acetone. The coverslips were transferred to a fresh 
24 well plate containing 500pl per PBS, for staining.
3.2.3 Fixation of adherent cells on coverslips for type -1 IFN staining
Coverslips in 24 well plates had growth medium removed and were washed three times 
with calcium magnesium free PBS. Five hundred microliters of ice cold 100% methanol 
was added to each well and the cells incubated on ice for 20 minutes. The coverslips 
were then individually collected and immersed for 20 seconds in ice cold acetone prior 
to being placed into a fresh 24 well plate containing 500pl per well of calcium 
magnesium free PBS.
3.2.4 Fixation of adherent cells for cell surface and /or internal staining
Cells were fixed using 4% paraformaldehyde (PFA) for 20 minutes at room 
temperature. Following fixation, the cells were washed three times with PBS. Where 
appropriate, the cells were then permeabilized using 0.1% (v/v) NP40 in PBS and 
incubated for 20 minutes with shaking at room temperature (RT). Cells were the washed 
three times with PBS and blocked in PBS, 0.5% BSA prior to use.
3.2.5 Immunofluorescence on fixed cells on coverslips
All monoclonal antibodies used for immunofluorescence were used at a concentration 
of lpg/ml or in the case of tissue culture supernatants at a dilution of 1:10. Primary 
antibodies were diluted in PBS, 0.5% BSA prior to use. Five hundred microliters of 
antibody were added to the appropriate cover slips and incubated for 30 minutes at 
room temperature. Coverslips were then washed three times with PBS. Five hundred 
micoliters of Isotype specific Alexa fluor dye conjugated secondary antibodies diluted 
1:500 in PBS, 0.5% BSA were added to the appropriate wells and incubated for 30 
minutes at room temperature. Coverslips were washed three times with PBS prior to 
counterstaining with 4’,6-diamidino-2-phenylindole (DAPI) diluted 1:10,000 from a
5mg/ml stock. Coverslips were incubated for 15 minutes at room temperature, washed 
three times with PBS and finally wash with sterile filtered de-ionized water. Cover slips 
were then mounted using ProLong Gold anti fade reagent mounting medium (Invitrogen 
Molecular probes, Paisley, U.K.)
3.2.6 Ultraviolet (UV) inactivation of FMDV
Foot and mouth disease virus (FMDV) was inactivated by placing the required volume 
in the bottom of a sterile petri dish or tissue culture plate to a depth of no more than 
2mm and placed on ice. The virus was exposed to UV radiation using an 8W UV lamp, 
emitting at 254nm, placed 10cm above the plate for 15 minutes or 30 minutes. The 
resulting virus preparation was then checked for inactivation by the World Reference 
Laboratory Virus Diagnosis Groups using their standard protocol (SOP 011-5).
3.2.7 Empty Capsids
O serotype empty capsids prepared by Dr Alison Burman were a kind gift, supplied at a 
concentration of 0.05pg/ml, which is equivalent to 6.25 x 109 particles/ml (King et aL, 
2009) The empty capsids were used both alone and to form immune complexes as 
previously described in the assay for type-1 IFN induction by large low density cells 
(see sections 2.8,2.10 and 2.10.1)
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Results
The data generated in the previous chapter confirmed bovine pDCs to be lineage 
negative and CD4+ cells in agreement with the phenotype described for other species 
(Asselin-Paturel., et aL, 2001; Bjorck et aL, 2001; and Nakano et aL, 2001; Grouard et 
aL, 1997; Summerfield et aL, 2003; Pascale et aL, 2008; Calzada-Nova et al. 2010).
3.3 Fluorescence Activated Cell sorting - phenotyping of bovine pDCs.
Using the data generated by the depletion studies as a starting point, the initial cell 
phenotype was found to be CD3", CD4+, CD14", CD21", CD11c, NKp46‘, TCRyô'. To 
further elucidate the cell phenotype, it was decided to use total large low density cells 
for staining purposes, gating on the CD4+, CD3" population and examining the surface 
expression of various other surface molecules.
CD 172a, also known as src homology 2 domain-containing phosphatase substrate-1 
(SHPS1), signal-regulatory protein a  (SIRPa), and P84, is a transmembrane 
glycoprotein involved in receptor tyrosine kinase coupled signalling pathways. It 
belongs to Ig superfamily and is primarily expressed on cells of the monocyte 
/macrophage lineage, granulocytes, dendritic cells and neurons. CD 172a is a substrate 
of activated receptor tyrosine kinases (RTKs). The interaction of the CD 172a 
intracellular domain with src homology 2 domain-containing phosphatase (SHP)-l and 
SHP-2, is involved in negative signalling in the regulation of leukocyte adhesion and 
transmigration, macrophage fusion and phagocytosis, and T cell activation, (Brooke et 
aL, 1998; Latour et aL, 2001). This protein is recorded as being expressed at low level 
on the surface of porcine pDCs (Summerfield et aL, 2003) and ovine pDCs (Pascale et 
aL, 2008). Using a monoclonal antibody specific for bovine CD 172a (see table 2.1), we 
examined the CD3", CD4+ population for expression of this molecule. We also stained 
this cell population for expression of MHC II, which is expressed on only a few
specialized cell types, including B cells, macrophages and dendritic cells, all of which 
are antigen presenting cells (APCs).
CD45RB is a single chain type-I membrane glycoprotein expressed on leukocytes 
including thymocytes, T cell subsets, B cells, monocytes/macrophages, granulocytes, 
and dendritic cells. CD45RB has been shown to enhance both T cell receptor and B cell 
receptor signalling mediated activation. This molecule is reported to be expressed on 
ovine pDCs, another ruminant (Pascale et al., 2008) and was therefore included in the 
screen on bovine pDCs. FACS analysis ws carried out on a population of cells that had 
been gated to exclude dead cells and debris. A gate (Gate 2) was used to select CD4+, 
CDS- cells and surface expression of other cell surface proteins on this population were 
analysed using pre-labelled monoclonal antibodies.
3.4 FACS ARIA analysis of bovine pDC phenotype.
We examined the expression of cell surface proteins known to be expressed on pDCs in 
other species using direct antibody labelling and FACS ARIA analysis. Monoclonal 
antibodies were labelled using Zenon Alexafluor labelling kits (Table 3.1) and diluted in 
a single pool to give a final concentration of lpg/ml of each. Large low density cells 
were isolated as previously described (see materials and methods 2.5). Cells were 
stained with pre-labelled antibodies (see materials and methods 2.7.1), fixed in 1% 
paraformaldehyde (PFA) and analyzed using a FACS ARIA cell sorting machine by a 
skilled operator (Mr Paul Sopp). The CD3", CD4+ cell population was selected and 
staining profiles for the remaining antibodies recorded (Fig 3.1).
Cells were initially gated (Gate 1) to exclude dead cells and debris. Subsequently, the 
population of CD4+, CD3- cells were gated (Gate 2) and surface expression of cell 
surface proteins known to be expressed in other species analysed using pre-labelled 
monoclonal antibodies.
Antibody Isotype Label Spectrum Excitation/
Emission
MM1A (CD3) IgGl Alexafluor 405 Blue 402/42Inm
CCS (CD4) IgG2a Alexafluor 488 Green 495/519nm
CC108(MHC II) IgGl Alexafluor 750 APC Near infrared 650/775nm
CC76 (CD45RB) IgGl Alexafluor R-PE Red 496/578nm
CC149(CD172a) IgGl Alexafluor 647 Far red 650/668nm
ILA-16(CDllc) IgGl Alexafluor 750 APC Near infrared 650/775nm
Table 3.1: Direct labelling of monoclonal antibodies for FACS ARIA analysis
Zenon Alexa fluor labeling kits (Invitrogen, U.K.) were used according to 
manufacturer’s protocol to directly label primary antibodies for use in FACS staining 
procedures. In summary, Ipg of purified monoclonal antibody or 15pl of tissue culture 
supernatant was labelled using isotype specific Zenon Alexa fluor kits (IgG1-488, 
IgGl-647 or IgG2a-647).
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Fig 3.1. FACS ARIA analysis of cell surface phenotype of CD3", CD4+ cells (bovine 
pDCs).
LLD cells were stained with monoclonal antibodies to CD3, CD4, MHC-II, CD45RB, 
CD 172a and CD11c. FACS ARIA characterisation o f the surface phenotype o f bovine 
pDCs (A). CDS", CD4+ gating (gate 2) from large low density cell population. (B) 
Monoclonal antibody staining on total large low density cell staining (red) and on CDS", 
CD4+ gated cells (black), isotype controls in blue. Cumulative data from reporter assays 
and FACS analysis defines bovine pDC cell phenotype as CDS', CD4+, MHC IIlow, 
CD45RB+, CD172aIowand C D llc".
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3.5 FACS phenotype generated by individual stains on CD3-, CD4+ cell 
population.
To confirm the results of the data generated by the FACS ARIA staining protocol, it 
was decided to check the expression of individual proteins on the CD3", CD4+ cell 
population. Once again large low density cells were isolated as previously described. 
This population was used in the staining procedure to enable direct comparison between 
the FACS ARIA generated data and data from this experiment. Monoclonal antibodies 
were directly labelled using the Zenon Alexafluor labelling kits.
A monoclonal antibody to the FCyRII was also included in this staining procedure as 
work carried out by other researchers (Guzylack-Piriou et. aL, 2006) and the results of 
our own initial experiments confirmed Fc receptor mediated uptake of FMDV by pDCs. 
Cells were stained as previously described (see material and methods 2.7), fixed using 
1% paraformaldehyde and then analysed using a BD FACScalibur. The data was 
analysed using FCS Express software.
In agreement with the data generated by the FACS ARIA protocol, the cell phenotype 
was found to be CDS', CD4+, CD172a+, MHC IIlow, GDI 1c, CD45RB+ and CD32+ (Fig 
3.2).
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Figure 3.2 FACS phenotype of CD3", CD4+ cells.
Analysis generated by triple staining procedure using monoclonal antibodies to CDS, 
CD4 and monoclonal antibodies to other individual cell surface proteins. Top row 
depicts the staining profile generated by total large low density cells (LLD) and second 
row shows the staining profile for CDS", CD4+ cells.
FACS analysis defined the cell phenotype as: CDS , CD4+, CD172a+, MHC II+, CD11c", 
CD45RB+ and CD32+
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3.4 Immunostaining and confocal microscopy on bovine pDG
Large low density cells depleted of CD3+, CD14+, CD21+, CD1 lc+, NKp46+ and 
TCRyô"1" cell populations were isolated as previously described and adhered to FCS 
treated glass coverslips (see material and methods 3.2.1) for analysis of interferon 
induction and cell surface staining to confirm FACS generated phenotypic analysis.
CpG oligodeoxynucleotides (2pM) were used to induce type-I IFN production by the 
pDCs. Cells were treated for either 2 or 4 hours in the presence or absence of Brefeldin 
A (5pg/ml final concentration) and then fixed and permeabilised for intracellular 
staining (see material and methods 3.2.3; 3.2.4; 3.2.5).
Where both internal and external staining were required, cells were incubated with the 
primary and secondary antibodies to cell surface proteins and fixed with 2% 
paraformaldehyde prior to permeabilisation and internal staining.
Monoclonal antibodies to CD4, CD45RB and type-I IFN were used to confirm the 
phenotype of the isolated cells and their response to stimulation with the TLR9 agonist 
CpG oligodeoxynucleotides (Fig 3.3).
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Figure 3.3: Confocal images of immunostaining on bovine pDC
Panel (A) Bovine pDCs stained for type-I IFN production following stimulation with 
CpG oligodeoxynucleotides. Left hand panels show DIC images taken 2 hours (i, 
iii), after stimulation or 4 hours (v) in the presence o f Brefeldin A and stimulation 
with CpG. Right hand panels (ii, iv, and vi) show type-I IFN staining o f the same 
cells (green). (B) Type-I IFN (green) internal staining and CD4 (red) surface staining 
following 16 hour stimulation with CpG. (C) pDC stimulated for 16 hours with CpG 
were immunostained for CD45RB (green) and CD4 (red) surface expression. (D) 
pDC stimulated for 16 hours with CpG were immunostained with an IgM isotype 
control (green). (E) pDC stimulated for 16 hours with CpG were immunostained 
with an IgGl isotype control (red).
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IResults of the immunostaining and confocal microscopy go some way to confirming 
the cell phenotype generated by FACS and the in vitro stimulation assays.
Treatment of cells with Brefeldin A, retained type-I IFN in the ER and made it 
possible to obtain images of type-I IFN staining. Collecting images of cells that had 
not been treated with Brefeldin A was difficult as the type-I IFN released into the 
media by stimulated cells bound to the cell surface of all cells on the coverslip. Panel 
(B) confirms the presence of cell surface CD4 and high levels of intracellular type-I 
IFN expected to be seen in pDCs. Surface staining for CD4 and CD45RB clearly 
show that the pDCs retain these proteins on the cell surface following stimulation but 
also show that following stimulation, pDC morphology, becomes more like 
conventional dendritic cells.
The cumulative evidence of the in vitro type-I IFN assays, reduction in production 
of type-I IFN in vivo in CD4 depleted animals, FACS phenotyping and confocal 
microscopy, defines the cell phenotype for bovine pDCs to be: CD3", CD4+, CD 14', 
CD21', C D llc,N K p46', TCRyô', CD45RB+, CD172a+, MHC II+ andCD32+. This 
phenotype-Is in agreement with the phenotype of pDCs described for other species 
including sheep (Pascale et aL, 2008) and pig (Calzada-Nova et aL, 2010) and to the 
best of our knowledge is the first description of bovine pDCs.
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3.5 The interaction of bovine pDCs with FMDV
The epithelial cell tropism of FMDV is well established and its inability to replicate 
in monocytes and macrophages has been described (Rigden et aL, 2002). The 
formation of immune complexes and Fc mediated uptake has also been shown to 
enhance the capacity of macrophage to destroy the virus (McCullough et aL, 1988). 
However, it has been shown in vitro, that human polyvalent IgG enhanced the 
capacity of poliovirus to induce IFN-a in PBMC (Palmer et aL, 2000), as did 
immune complexes of coxsackie virus B (Hober et aL, 2001). IFN-a induction in 
pDCs following Fc mediated FMDV immune complex uptake has also been 
demonstrated in pigs by Guzylack-Piriou et al. (2006). The authors have shown in 
the pig, that type-I IFN production by pDC in response to FMDV requires immune 
complexes and replication competent virus. Having determined FMDV immune 
complexes are also required for the production of type-I IFN by bovine pDCs, we 
decided to investigate the requirement of live virus. To do this, immune complexes, 
made using live FMDV OiK, UV- inactivated OiK or empty capsids (Oi Manisa), 
were incubated with enriched pDC populations from two animals (in triplicate) and 
the levels of type-I IFN generated were determined using the Mx-CAT reporter 
assay. Repeated experiments clearly show a requirement for live virus in the 
induction of type-I IFN, as immune complexes formed with UV inactivated virus or 
empty capsids were unable to elicit type-I IFN production (Fig 3.4). Furthermore, 
after incubation with live virus-immune complexes, CD4+non-T cells exhibiting 
expression of the non-structural protein 3A were observed, suggesting that 
replication was initiated within these cells (Fig 3.5).
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Figure 3.4: Induction of type-I IFN by bovine pDCs requires live virus
Large low density cells depleted o f CD3, CD 14, CD21, CD11c, Nkp46, and TCRyô 
expressing cell populations were used to determine the requirement o f replication 
competent virus in the induction o f type-I IFN following immune complex uptake. 
Inactivated virus (IV), inactivated virus immune complexes (IV-IC), live virus (V), 
live virus immune complexes (IC), empty capsids (EC) and empty capsid immune 
complexes (EC-IC) were incubated with pDCs. IFN was only induced in cells treated 
with live virus immune complexes suggesting the viral replication has a role to play 
in the induction o f IFN following Fc mediated uptake. Graph represents results 
generated from cells isolated from two separate animals (brown and green).
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Statistical analysis shows that there is a significant difference (pO.OOOl) between 
empty capsid immune complexes (EC-IC) and inactivated virus immune complexes 
(IV-IC). Values for type-I IFN production for both samples are very low and the 
difference probably reflects a minute level of activation of pDCs through means 
other than viral replication as the virus inactivation was tested to ensure complete 
inactivation. There was a significant difference (pO.OOOl) in IFN produced from 
cells stimulated with empty capsid immune complexes or inactivated virus immune 
complexes compared to live virus immune complexes.
The high levels of type-I IFN produced in response to live virus immune complexes 
confirms that at least the initial stages of viral replication are required to induce type- 
I IFN production by bovine pDCs (Fig 3.4).
To further investigate viral replication within bovine pDCs, the depleted cell 
population were added to FCS pre-treated coverslips and allowed to adhere 
overnight before incubating with FMDV immune complexes or complexes formed 
using UV inactivated FMDV (see material and methods) for 4 hours at 37°C. 
Coverslips were then fixed using 2% paraformaldehyde, surface stained for CD4 
expression and finally permeabilised to allow intracellular staining of the FMDV 
non-structural protein 3 A. Staining was visualized by confocal microscopy and 
analyzed using LCS Lite software. The resulting images clearly show both CD4 
external staining and FMDV non-structural 3A protein internal staining in bovine 
pDC, confirming that at least the initial stages of viral replication occur within these 
cells following FcR mediated uptake of live FMDV immune complexes. Cells 
incubated with immune complexes formed with UV inactivated FMDV show only 
external CD4 staining (green) and no internal 3A - (red) staining (Fig 3.5). The 
production of non-structural proteins indicates that viral replication is initiated in
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these cells. Further work would need to be carried out to establish if this a productive 
viral infection leading to the release of virions from bovine pDCs, or if as described 
in other systems this replication is abortive.(Guzylack-Piriou et al., 2006).
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Figure 3.5: Initial stages of FMDV replication in bovine pDCs, following FcR 
mediated uptake of live virus immune complexes.
Panel (A) Bovine pDCs incubated with live FMDV immune complexes for 4 hours, 
and stained for CD4 expression and FMDV non-structural 3A protein production, 
with CD4/green and 3A/red. (B) Bovine pDCs incubated with UV inactivated 
FMDV immune complexes for 4 hour and stained as described for CD4/green and 
FMDV 3A/ red.
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3.6 Discussion
In the previous chapter we characterised the cells responding to FMDV-immune 
complexes to be lineage negative, CD4+ cells. Immunostaining and FACS ARIA / 
FACScalibur analysis further defined the population as CD4+, CD45RB+, MHC II+, 
CD172a+, CD32+ and CD 11c". Confocal microscopy on immunostained pDCs 
following treatment with GpG was carried out to confirm the presence of type-I IFN 
in treated cells and the surface phenotype of those cells. Following activation with 
CpG, pDCs displayed a dendritic cell phenotype, but retained CD4 and CD45RB 
expression on the cell surface.
Porcine pDCs have been demonstrated to produce little, if any type-I IFN in 
response to FMDV in vitro (Guzylack-Piriou et al., 2006). However, this study also 
defined the requirement for FMDV-immune complexes in the activation of porcine 
pDCs and reports the requirement for live virus for this activation to occur. We also 
found that immune complexes of live FMDV were necessary to activate bovine 
pDCs, with immune complexes of UV-inactivated virus or empty viral capsids 
barely able to elicit type-I IFN production. The lack of type-I IFN production by 
FMDV alone, suggests these cells do not express the appropriate receptors to permit 
infection, however, Fc receptor mediated uptake of immune complexes permits the 
virus access to cells that would otherwise be inaccessible. The production of FMDV 
non-structural proteins in these cells following Fc receptor mediated uptake of virus- 
immune complexes confirms that replication is at least initiated within bovine pDCs, 
however, whether this is a productive or abortive infection has not been examined. 
Human pDCs have been reported to express CD32 (FcyRl la) (Means et al., 2005; 
Benitez-Ribas et al., 2006). Means et al., (2005) showed DNA-containing immune 
complexes (ICs) within lupus serum (SLE-ICs), but not protein-containing ICs from
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other autoimmune rheumatic diseases, could stimulate pDCs to produce cytokines 
and chemokines via a cooperative interaction between TLR9 and FcyRIIa (CD32). 
Similarly, human pDCs exhibit weak expression of CD32, but not other Fc receptors 
such as CD 16 and CD64 (Lui et al., 2009). Porcine pDCs have also been reported to 
express CD32. Balmelli et al., (2005) describe co-localization of CD32 with classical 
swine fever virus (CSFV) in polarized structures in “immune pDC” and ascribe the 
immune complex formation to cytophilic antibodies bound to FcyRIIa. Guzylack- 
Piriou et al., (2006) reported the ligation of CD32 by FMDV immune complexes in 
porcine pDCs. We also detected FcyRIIa expressed on a CD4+/CD3~ cell 
populations from bovine mesenteric lymph nodes and have shown that antibody 
mediated uptake of replication competent virus in immune complexes are required to 
initiate the production of type-I IFN in these cells.
The mouse homologue of human pDCs was identified and characterised as Ly6C+, 
B220+, C D llc low, CD4+ and MHC class II+ (Asselin-Paturel et al, 2001). An 
important difference between these cells in humans and mice is that mouse pDCs did 
not express the IL-3 receptor (CD 123) and were not responsive to IL-3 stimulation 
(Asselin-Paturel et ah, 2001). A common feature of pDCs from both of these 
species is that they express TLR-7 and TLR-9 and are both able to produce large 
quantities of type-I IFN in response to stimulation via these receptors. Viral infection 
of human or mouse pDCs in vitro results in high levels of type-I IFN production. In 
vivo infection of mice with murine cytomegalovirus (MCMV) resulted in over 
2000units/ml IFN-a in the serum, however this was abrogated when the pDCs were 
depleted (Asselin-Paturel et ah, 2001) indicating that in mice, they are the major 
type-I IFN producing cells in vivo. An important feature in identifying pDCs in all 
species is that they produce type-I IFN in response to non-infectious agents and
175
human pDCs were shown to do this is response to UV-inactivated herpes simplex 
virus (Siegal et al, 1999).
The porcine homologues of pDCs have also been described as being capable of 
producing type-I IFN in response to non-infectious viral material (Riffault et al, 
1997). Their phenotype was described as being non-T, non-B, MHC class II+, CD4+, 
CD36+ and they are non-phagocytic and non-adherent (Riffault et al, 1997). 
Porcine pDC were subsequently characterised in more detail and were found to be 
positive for SWC3 (SIRPa, a porcine SIRP family member; a marker of myeloid 
cells), CD 14' and expressed low levels of MHC class II and CD80/86 in relation to 
other porcine DC (Summerfield et al, 2003). They have also been shown to produce 
type-I IFN in response to UV-inactivated transmissible gastroenteritis virus (TGEV) 
in vitro (as had previously been demonstrated in v/vo; Riffault et al, 1997). Porcine 
pDCs were induced to increase their expression of MHC class II and CD80/86 
following culture with IL-3, although as reported in this study, they did not appear to 
be as specialised in stimulating a T cell response as other porcine DC (Summerfield 
et al, 2003). In pigs, pDCs have been shown to localise to mucosal sites and produce 
IFN in response to TGEV infection, their migration attributed to viral replication 
within enterocytes (Riffault et. al, 2001). The authors demonstrate that during this 
infection, the vast majority of the cells migrated to the small intestine and could be 
seen secondary lymphoid tissue including the lamina propria, peyers patches and 
accumulated in the mesenteric lymph nodes (Riffault et. al, 2001).
Human CD4+ C D llc-  CD3-  cells isolated from tonsils, corresponding to pDCs 
express CD45RA, but not other lymphoid or myeloid markers. They have been 
shown to undergo rapid apoptosis in culture, unless rescued by IL-3. Further addition 
of CD40-ligand results in their differentiation into cells with the morphology of
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mature interdigitating dendritic cells after 6 days of culture with IL-3 and CD40- 
ligand and they express low levels of myeloid antigens CD 13 (functions as an 
aminopeptidase enzyme) and CD33 (a transmembrane receptor expressed on cells of 
myeloid lineage that binds sialic acid; Grouard et. al, 1997). The authors also 
showed that prior to culture, pDCs were incapable of stimulating a naïve T cell 
response, however, the cells acquired the ability to simulate a T cell proliferative 
response following culture with IL-3 and CD40L.
Mouse pDC morphology did not change following culture with IL-3 and CD40L and 
in fact only 10% of the cells remained viable (Asselin-Paturel et. al, 2001). 
However the same authors then showed that stimulation with IFN or infection with 
herpes simplex virus (HSV) enhanced their rate of survival and increased their 
expression of MHC class II, CD40 and CD86. Morphologically, these activated 
PDCs were larger and had a more irregular shape than freshly isolated cells, similar 
to the change observed in human pDCs following culture with CD40L and IL-3 
(Grouard e ta l,  1997; Asselin-Paturel e ta l,  2001).
In summary, the phenotype of bovine pDCs has been defined as CD3", CD 14",
CD21", NKp46~, TCR5", CD 11c", CD4+, CD45RB+, MHC i f ,  CD172a+ and 
CD32+.
This is the first description of a bovine cell phenotype that corresponds to and 
behaves as pDCs described for other species. Also, the initiation of type-I IFN 
production by these cells in response to FMDV requires immune complex formation 
and at least the initial stages of viral replication (Reid et a l, 2011).
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Chapter 4: The interaction of bovine viral diarrhoea virus (BVDV) with bovine 
plasmacytoid dendritic cells (pDC)s
4.0 Introduction
As previously described in the introduction, the BVDV genome encodes four 
structural (C, Ems, E l, and E2) and eight non-structural proteins (NS; Npro, P7, NS2, 
NS3, NS4A, NS4B, NS5A, and NS5B) (Donis, 1988; Thiel, 1991; Meyers, 1996; 
Collett, 1988). The main differences in genomic organization between ncp and cp 
BVDV are rearrangements in the NS2/NS3 region of the genome. cpBVDV arises by 
a variety of mechanisms, such as cellular RNA insertions, deletions and by RNA 
recombination of ncpBVDV (Qi, 1992; Tautz, 1994; Ridpath,1995). The cp 
phenotype has also been characterized by unrestrained genome replication and a 
reduced ability of the infected cell to prevent a type-I interferon (IFN) responses to 
double-stranded RNA (dsRNA) (Lackner et a l, 2004; Lackner et a l, 2005; reviewed 
in Peterhans et a l, 2010).
Only Pestiviruses within the Family Flaviviridae have a non-structural (NS) protein 
at the N-terminus of their polyproteins. The autoprotease, Npro has proteolytic 
properties and cleaves itself from the capsid protein between Cysi68 and Sen69 of the 
polyprotein (Stark, 1993). The essential amino acids for the proteolytic activity of 
Npro have been shown to be Cys69, His49, and Glu22 (Rumenapf, 1998).
Attenuated BVDV viruses have been made by deleting or mutating Npro (Tratschin, 
1998; Meyers et a l, 1997; 2007). The growth kinetics of a BVDV chimeric virus in 
which the Npro region was replaced with the hepatitis C virus (HCV) NS3 gene, 
substituting the Npro enzymatic activity with a serine protease, were similar to the 
wild-type BVDV. However, the growth kinetics and replication of an Npro-null 
BVDV virus (entire Npro region deleted) were much lower than the wild-type 
BVDV but still viable (Lai, 2000). A further study carried out by Meyers et a l.
(2007) determined that four amino acids at the 5’ end of the Npro protein (MELF) 
needed to be retained to maintain acceptable growth characteristics of their Npro 
deletion mutant virus, resulting in only slight growth retardation compared to wild 
type virus. These recombinant viruses were made from a New York 1993(NY’93) 
BVDV-2 isolate and are the viruses used in this study.
Interferon regulatory factor-3 (IRF-3), an essential antiviral signalling molecule, is 
a member of the interferon regulatory transcription factor (IRF) family, which is 
important in IFN regulation and development of the immune system. IRF-3 is 
expressed in a variety of cells, including mature DCs. IRF-3 is found in an inactive 
cytoplasmic form and is post-translationally-modified following virus infection by 
protein phosphorylation. This virus-dependent phosphorylation of IRF-3 alters 
protein conformation leading to the translocation of IRF-3 from the cytoplasm to the 
nucleus. Phosphorylation also stimulates DNA binding with IRF-3, and increases 
IRF-3 transcriptional activation and primary activation of IFN-responsive genes 
leading to the production of type I IFN and the establishment of early innate 
immunity (Hiscott, 1999; Gabriele, 2007). In both BVDV and classical swine fever 
virus (CSFV), the amino-terminal cysteine protease, Npro, prevents the production 
of type-I IFN by suppressing levels of IRF-3 to avoid host antiviral responses 
(Horscroft, 2005). Even though IRF-3 can translocate from the cytoplasm to the 
nucleus in CSFV and BVDV-infected cells, Npro blocks IRF-3 binding to DNA and 
targets the protein for proteasomal degradation (Baigent et a l, 2002; Hilton et a l, 
2006; Seago et a l, 2007). However Npro does not seem to affect the levels of IRF-3 
mRNA and the autoprotease activity of Npro is not required for IFN inhibition 
(Hilton, 2006; Seago et a l, 2007).
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Despite the ability of pestiviruses to block type-I IFN in the majority of host target 
cells, type-I IFN can be detected in serum samples from infected animals early in 
infection with ncpBVDV. For classical swine fever virus (CSFV), the cells 
responsible for producing large quantities of IFN have been identified as pDCs 
(reviewed in McCullough et al., 2009). It is believed that the constitutive expression 
of another interferon regulatory factor, IRF-7, in these cells allows the production of 
the large quantities of IFN in response to viral infection prior to the action of Npro. 
Here we seek to confirm the interaction of BVDV with bovine pDCs and to examine 
the IFN response to infection using both a wild type (XIKE A) and an Npro deletion 
mutant virus (XIKE A ANdN).
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4.1 Materials and methods
All cell isolation procedures, biological assays for IFN and CAT ELISAs were 
carried out as described in previous chapters.
4.1.1 Growth of BVDV stock virus
BVDV XIKE A or BVDV ANdN recombinant viruses kindly supplied by Dr. Gregor 
Meyers (Meyers et a l, 2007) were added to a sub-confluent calf testes cell 
monolayer (CTe) in a T175 flask (BD Biosciences) that had been washed previously 
with pre-warmed PB Sa (Invitrogen). After incubation for one hour, CTe 
maintenance media (Dulbecco’s modified eagles medium (DMEM), 2% FBS 
(previously tested for BVDV antigen and antibody, AutogenBioclear, Wiltshire), 
0.25% lactalbumin hydrolysate (LAH), 0.17% sodium bicarbonate, 30mM MgCl2, 
lOOIU/ml penicillin, 100pg/ml streptomycin, 25U/ml nystatin) was then added to the 
flasks and they were left for a further three days. Flasks were then freeze-thawed at 
-70°C to lyse the cells and the remaining lysate was removed using a cell scraper 
(Coming Inc, New York, USA). Lysates were then pooled and centrifuged at 1500 x 
g for 10 minutes, after which the supernatants containing the infectious virus 
particles were removed, aliquoted and stored at -70°C. Viral supernatants were then 
titrated on CTe cells by plaque assay to determine infectivity.
4.1.2 Plaque assay for titration of non-cytopathic Bovine Viral diarrhoea Virus 
(BVDV)
Calf testes cells (CTe) were grown in Dulbecco’s modified eagles medium (DMEM), 
10% FBS (previously tested for BVDV antigen and antibody, AutogenBioclear, 
Wiltshire), 0.25% lactalbumin hydrolysate (LAH), 0.17% sodium bicarbonate,
30mM MgCE, lOOIU/ml penicillin, 100pg/ml streptomycin, 25U/ml nystatin.
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24 well plates with confluent monolayers were used to titre each virus stock.
A log dilution series of each virus was prepared in 2% maintenance media (media as 
described above with the exception of 2% FBS rather than 10%). The growth media 
was removed from each plate and lOOpl of the virus dilution series applied in 
quadruplicate to the appropriate wells, media alone was used as a negative control. 
Plates were then incubated for 1 hour at 370C, 5%C02. A 1% agarose overlay was 
prepared by melting 2% low melting point agarose in water and adding an equal 
volume of twice strength (2X) maintenance media. This was maintained at 40°C 
until ready to use.
Following the 1 hour incubation of virus and cells, the inoculum was removed and 
1ml of the overlay was added to each well, this was allowed to cool for 
approximately 10 minutes or until set before incubating for 72 hours at 37°C, 5% 
C 02.
To stain cells for the presence of BVDV antigen, the agarose plugs were carefully 
removed and the monolayer washed gently in PB Sa (Invitrogen). Cells were the 
fixed in 80% acetone for 10 minutes at room temperature, The actone was then 
removed and the monolayer dried at 37°C for 10-15 minutes. Non -specific binding 
sites were blocked by the addition of 200pl per well of PBSa, 10% FBS for 1 hour at 
room temperature. Monolayers were washed three times with PBSa prior to the 
addition of 200pl per well of the primary antibody (8.12.7 mAb, gifted by Dr. E 
Dubovi, Cornell University, U.S.A.) at a dilution of 1:5000 in PBSa. Again, cell 
monolayers were incubated for 1 hour at room temperature, the antibody removed 
and the monlayers washed a further three times. 200pl of goat anti mouse HRP 
(Southern Biotech) secondary antibody was added at a dilution of 1:500 to each well, 
the monlayers were incubated for a further hour, the antibody was removed and
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monolayers washed three times. Each well was then stained with 3-amino-9- 
ethylcarbazole (AEG). AEG was dissolved in dimethylformamide (DMF) at a 
concentration of 17.33mg/ml to create a working stock. For each plate 115pl of stock 
AEG was added to 5 ml of 0.05M sodium acetate, pH 5.0, 2.5pl of 30% hydrogen 
peroxide (H2O2). 200pl per well was added and incubated at 37°C.
Plaques were counted at the appropriate dilution that gave a reasonable number. The 
titre was calculated using the following formula:
e.g. No of plaques @ 10'5 from each of the replicate wells XI0 H OOpI aHHerh Yin5 
Number of wells (4 wells)
4.2 Acid treatment of samples to destroy virus (and acid labile IFN)
Samples generated from large low density cells or pDCs incubated with BVDV were 
treated with 2M HC1 to reduce the pH to 2 for 24 hours. 2M NaOH was added to 
adjust the pH back to 7 prior to assay by the MDBK Mx-CAT reporter assay and 
CAT ELISA (methods described 2.10,2.10.1). This had previously been shown to be 
sufficient to destroy BVDV (Depner et a l, 1992). This method also destroys acid 
labile IFN (Kugel et a l, 2011).
4.2.1 Comparison of type I and type III IFN standards on Mx-CAT reporter 
assay
The MDBK Mx-CAT reporter assay and CAT ELISA (described in 2.10, 2.10.1) 
were used to compare the ability of IFN alpha and IFN lambda to induce Mx gene 
expression. Log dilutions of recombinant bovine IFN-a and murine IFN-X (IL-28B; 
as no bovine recombinant protein available) were prepared in maintenance media 
(DMEM, 2% foetal bovine serum, lOOIU/ml penicillin, lOOpg/ml streptomycin).
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200pl per well of each standard plus 800pl of maintenance media was added to the 
appropriate wells of the MDBK Mx-CAT reporter cells in duplicate. Plates were 
incubated for 24 hours at 37°C, 5% CO2. Cell monolayers were lysed and samples 
assayed by CAT ELISA. Standard curves of Mx induction were prepared to compare 
the ability of the different IFN preparations to induce the reporter.
4.3 Trizol extraction of RNA
Trizol reagent (ambion, cat. no. 15596-018) was used to extract total RNA from cells 
(pDC) following virus infection. 1ml of Trizol reagent was added directly to the 
wells of a 24 well tissue culture plate containing treated cells in 500pl final volume 
of media. Each well bottom was scraped to ensure all cells were collected. Samples 
were placed in cryotubes and either frozen at -80°C for later use, or the RNA 
extracted immediately.
1ml of each homogenised sample was incubated at room temperature for 5 minutes. 
All samples were then centrifuged at 12,000 x g for ten minutes at 4°C to pellet 
protein prior to RNA isolation. Samples were transferred to fresh tubes prior to the 
addition of 200pl of chloroform (Sigma-Aldrich). The tubes were capped tightly and 
shaken vigorously for 15 seconds and incubated at room temperature for 3 minutes. 
Samples were then centrifuged at 12,000 x g for 15 minutes at 4°C. The clear 
aqueous phase at the top of the tube was collected and the chloroform extraction 
procedure repeated. 500pl of 100% isopropanol (VWR International Ltd.) was added 
to each tube and incubated for 10 minutes at room temperature to precipitate RNA. 
Samples were then centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant 
was removed, 1ml of 75% ethanol (VWR International Ltd) added to each tube and 
the samples vortexed briefly to resuspend the RNA pellet. Tubes were centrifuged at 
7500 x g for 5 minutes at 4°C, the supernatant discarded and the pellet air dried for
10 minutes. The RNA pellet was resuspended in 30pl o f RNase free water and 
heated to 60°C for 15 minutes. Samples were then stored at -80°C for use in further 
applications.
4.3.1 Primers for RT-PCR and alignment
F2 5’-AACCAGCGACATGGCCC-3’
3F 5’-ACTCATCCCTGGGCCACA-3’
R1 5’-TCAGACACTGGTCTCCGC-3’
F3 5’-ATGCTGACGACCGTGGC-3’
F4 5’-CCTTTGAAGACTCGTTCTTGCC-3’
F5 5’-CTGCAGGCCTTCAAGACG-3’
F6 5’-CTGCAGAACATCCACTCCAAG-3’
R2 5’-GCTTGGAGTGGATGTTCTGCA-3’
IL-28B
F4
1 10 20 30 40 50 60 70 80 90 100 110 120 130I----------- *------------♦------------♦------------♦------------♦------------♦------------♦----------- ♦------------♦------------♦------------♦------------♦------------1
ATGGCCCCGGGCTGCACGCTGGTGCTGGTGCTGflTGCTGflCGflCCGTGGCGCTGflGCHGGflCBGGflGCRGTTCCTGTGCCCTCTGCCCCCAGGGCCCTCCCflCCTGCCAGGGGCTGCCflCGTGGCCCRGT
HTGCTunCunCCGTBGC
F2
C onsensus
AACCRGCGACATGGCCC
IL-28B
F4
FG
TCAAGTCTCTGTCCCCTCAAGAGCTGCAGGCCTTCRRGACGGCCAGGGATGCCTTTGRAGRCTCGTTCTTGCCARAGGACTGGGRCTGCAGCACCCRCCTTTTCCCCAGGACCCGGGACCTGAAGCACCT
CCTTTGAAGRCTCGTTCTTGCC
CTGCRGGCCTTCRAGACG
261 270 280 290 300 310 320 330 340 350 360 370 380 390
GCRGGTGTGGGAGCGCCCTGTGGCTCTGGAGGCAGAGCTGGCCCTGACACTGACGGTCCTGGRGGCCATGGCTARCTCATCCCTGGGCCACAGCCTGGAGCAGCCCCTTCTCACGCTGCAGAACATCCAC
CTGCAGAACATCCAC
TGCAGAACATCCAC
ACTCATCCCTGGGCCRCA
391 400 410 420 430 440 450 460 470 480 490 500 510 520
TCCRRGCTCCRGGCCTGTGTCCCRGCTCAGCCCRCRGCRAGCTCCRGGCCCCGGGGCCGCCTCCACCRCTGGCTGCRCCGCCTCCAGGRGGCCCGGARGGRGTCCCRGGRCTGCCTCGRRGCCTCTGTGR
TCCRRG
TCCAAGC
521 530 540 550 560 570 580 588
IL-28B TGTTCAACCTCCTCCGCCTCCTCACCCGGGACCTGAAATGTGTTGCCAGCGGAGACCAGTGTGTCTGA 
F4
GCGGAGACCRGTGTGTCTG
Figure 4.1 RT-PCR prim er alignment
Alignment o f forward and reverse primers used to isolate, clone and sequence bovine 
IL28B (IFNX3).
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4.3.2 DNase digestion of RNA samples to remove genomic contamination
RNA isolated from infected/ treated/ or uninfected cells was treated with DNase 
Turbo (Invitrogen) to remove any contaminating genomic material.
12.5pl of each RNA sample was placed in a clean tube. 1.5pl of DNase Turbo buffer 
(X10) was added to each. 1 pi of DNase Turbo enzyme was added and tubes 
incubated at 37°C for 30 minutes. Following incubation Ipl of inactivation reagent 
was added to each reaction and incubated for 5 minutes at room temperature. Tubes 
were then centrifuged at 10,000 X g for 1.5 minutes and the supernatant transferred 
to a clean tube to be stored at -80°C. Sample concentration was determined by 
nanodrop technology.
4.3.3 Reverse transcriptase polymerase chain reaction (RT-PCR)
RT-PCR reactions to amplify type III IFN mRNA were carried out using a one-step 
RT-PCR kit (Bioline Reagents Ltd), or a Superscript III kit (Invitrogen).
4.3.3.1 Bioline RT-PCR reactions were carried out as per manufacturer’s protocol. In
brief, reactions for each tube were set up as follows:
Reagent volume final concentration
2X One step RT-PCR 
buffer 25ul IX
One step enzyme mix 2ul N/A
Forward primer (5uM) 2ul 200nM
Reverse Primer (5uM) 2ul 200nM
RNA Sample l-10ul User determined. (lOOpg to 2ug recommended)
RNase inhibitor lul
2X reaction buffer
10 units
MgCl2 containing 3mM MgC12. 1.5mM (unless adjusted byHowever additional Mg2+ 
may be required
user)
DMSO (recommended) 2.5ul 5%
DEPC treated water up to final volume of 50ul N/A
Final volume 50ul
186
The PCR was carried out using an Eppendorf Mastercycler and the following 
programme: step temperature time
1 42°C 30 min
2 95°C 2 min
3 | 95*C 30 sec
4 570C 30 sec 35
720C
cycles
5 30 sec
6 72°C 10 min
7 4°C hold
4.3.3.2 Superscript III cDNA amplification
A Superscript III reverse transcription kit (Invitrogen) was used for first strand 
synthesis of cDNA from 500ng of total RNA, according to manufacturer’s protocol. 
The PCR was carried out using an Eppendorf Mastercycler Reactions were set up as 
follows:
Denature RNA+Primer+dNTPs(l Oui)
65°C for 5 minutes
i'
place on ice for at least 1 minute
Anneal OIigo(dT)2o or GSP Random Hexamers
Add 1 Oui cDNA Synthesis Mix Add lOul cDNA Synthesis Mix
,  I
2S C for 10 minutes
cDNA Synthesis 50oC for 50 minutes cDNA Synthesis Mix:
Terminate reaction 85°C for 5 minutes lOxRT butler 2
25mM MsCh 4
Remove RNA Add lul o f RNase H 0..1M DIT 2
37°C for 20 minutes RNaseOUT I
Superscript IH RT 1
PCR Amplification Remove 2ul aliquot for PCR final volume KM
(up to lOul may be used)
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4 3.3.3 PCR amplification from Superscript III generated cDNA
PCR reactions for each sample were set up as follows:
Reagent Volume
1 OX Reaction buffer 5ul
25mM MgC12 3ul
lOmM dNTPs lul
Forward Primer (5uM) 2ul
Reverse Primer (5uM) 2ul
Taq Polymerase lul
Template 2ul
DEPC Water 34ul
final volume 50ul
PCR amplification was carried out using an Eppendorf Mastercycler and the 
following programme:
step temperature time
1 95°C 10 min
2 95*C 30 sec
3 : 57°C 30 sec 35
1 72°C
cycles
4 30 sec
5 72°C 5 min
6 4°C hold
PCR reactions were either run immediately on agarose gels or stored at -20°C prior 
to use.
4.3.4 Agarose gel electrophoresis
Agarose powder (genetic analysis grade; Fisher) was used to make either 1% or 2% 
agarose gels by dissolving in IX TAB (40mM Tris, 20mM acetic acid, and ImM 
EDTA, pH 8.0) and heating in a microwave on full power for 1 min 30 seconds. The 
melted agarose was allowed to cool before adding lOpl of a 5mg/ml solution of 
ethidium bromide. Gels were poured, and allowed to set before samples were added
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along with a molecular weight marker. Gels were run at a constant 100V for an 
appropriate period and imaged under UV light using a Biorad transilluminator and 
Gel Doc software. If appropriate, specific bands were excised from the gel for DNA 
extraction prior to cloning.
4.3.4.1 Extraction of DNA from agarose gels
DNA was purified from agarose gels using a Qiagen QIAQuick gel extraction kit in 
line with the manufacturers’ protocol. Briefly, the DNA fragment was excised from 
the agarose gel with a clean, sharp scalpel. Three volumes of buffer QG to one 
volume of gel was added to each tube. The tubes were then incubated at 50°C until 
the gel had dissolved. 1 gel volume of isoproanol was added to each sample and 
mixed thoroughly. QIAquick spin columns were placed into a 2ml collection tubes, 
the samples applied to allow DNA to bind to the membrane and then centrifuged at 
17,900 X g for 1 minute at 4°C. The flow through was discarded from the collection 
tube and the spin column centrifuged for a second time at 17,900 X g for 1 minute at 
4°C. Again the flow through was discarded and the spin column placed back in the 
collection tube. To wash, 750pl of buffer PE was added to each tube which was then 
incubated for 2 minutes at room temperature and then centrifuged for 17,900 X g for 
1 minute at 4°C. The flow through was discarded and the samples centrifuged as 
previously described for a second time to remove residual wash buffer. QIAquick 
spin columns were placed into clean collection tubes. To elute the DNA, 50pl of 
water was added to the centre of the membrane of each tube and the tubes 
centrifuged at 17,900 X g for 1.5 minutes at 4°C. The resulting DNA concentration 
and purity was assessed by nanodrop prior to use.
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4.3.5 Cloning of RT-PCR products
PCR products were cloned into a TA vector pcDNA3.1/V5-HisTOPO (Invitrogen) 
according to m anufacturers’ instructions.
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Figure 4.2 TA cloning vector structure and sequence o f the multiple cloning sites.
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“The plasmid vector is supplied linearised with single thymidine (T) overhangs for 
TA cloning and has topoisomerase covalently bound to the vector (this is referred to 
as an activated vector). Taq polymerase has a nontemplate-dependent terminal 
transferase activity that adds a single deoxyadenosine (A) to the 3 ' ends of PCR 
products. The linearised vector supplied in this kit has single, overhanging 3 ' 
deoxythymidine (T) residues.This allows PCR inserts to ligate efficiently with the 
vector. Topoisomerase I from Vacpinia virus binds to duplex DNA at specific sites 
and cleaves the phosphodiester backbone after 5’- CCCTT in one strand (Shuman, 
1991). The energy from the broken phosphodiester backbone is conserved by 
formation of a covalent bond between the 3’- phosphate of the cleaved strand and a 
tyrosyl residue (Tyr-274) of topoisomerase I. The phospho-tyrosyl bond between the 
DNA and enzyme can subsequently be attacked by the 5’- hydroxyl of the original 
cleaved strand, reversing the reaction and releasing topoisomerase”, (method by 
Shuman, 1994).
The cloning reaction was set up as follows:
Reagent Volume
PCR product 2ul
Salt solution lul
sterile water 5ul
TOPOTAxector lul
final \  ohuip 6 ul
The reactions were mixed gently and then incubated for 5 minutes at room 
temperature before being placed on ice till needed for bacterial transformation.
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4.3.5.1 Bacterial transformation
Chemically competent TOP 10 E. coli (supplied in TOPO TA kit, Invitrogen) were 
as follows: 2pl of TOP 10 E. coli was added to ligation reactions and mixed gently. 
The reaction tubes were then incubated on ice for 30 minutes prior to being heat 
shocked at 42°C for 30 seconds. The reactions were immediately placed back on ice 
and 250pl of room temperature SOC medium added. The tubes were capped and 
incubated horizontally at 37°C for 60 minutes, on an orbital shaker (200rpm).
50pl of the transformation reaction was then spread onto pre-warmed agar (CSU, 
Pirbright) plates containing 50pg/ml ampicillin. Plates were then incubated 
overnight at 37°C and the resulting colonies picked for miniprep analysis.
4.3.5.2 Miniprep and plasmid DNA purification
Single colonies from agar selection plates were used to inoculate 3ml of LB broth 
(CSU, Pirbright) containing 50pg/ml ampicillin selection. Cultures were incubated 
for 16 hours at 37°C, with vigorous shaking. Bacterial cells were harvested by 
centrifugation at 6800 X g in a accuSpin 3R centrifuge (Fisher scientific, 
Loughborough, UK) for 3 minutes at room temperature. All traces of bacterial media 
were removed by inverting the centrifuge tubes and allowing the media to drain 
completely. Plasmid DNA was purified using a QIAprep Miniprep kit (QIAGEN, 
Crawley, UK) according to manufactures instructions.
Bacterial cell pellets were resuspended in 250pl of kit buffer PI and transferred to 
microcentrifuge tubes. Next, 250pl of kit buffer P2 was added and mixed thoroughly 
by inverting the tubes 4-6 times. At this point the solution becomes viscous due to 
bacterial cell lysis. Finally, 350pl of kit buffer N3 was added to each tube and the 
solutions mixed thoroughly by inverting the tubes 4-6 times. This neutralisation step 
leads to the formation of a white precipitate. Eppendorf tubes were then centrifuged
at 17,900 X g for 10 minutes to remove the precipitate. The supernatants from each 
tube were then applied to the QIAprep spin columns that had been placed in 
collection tubes and centrifuged for 1 minute at 17,900 X g. The flow through was 
discarded and the columns washed with 500pl of kit buffer PB. Tubes were again 
centrifuged at 17,900 X g for 1 minute. Each column was washed a second time with 
750pl of kit buffer PE and centrifuged as described. The flow through was discarded 
and the tubes centrifuged again as previously described to remove any residual wash 
buffer. Finally, spin columns were placed into fresh collection tubes, 50pl of sterile 
water added to the centre of each column and the tubes allowed to stand for 1 minute 
prior to centrifugation as previously described. The resulting DNA preparations were 
checked for purity and concentration using a nanodrop 8000 spectrophotometer 
(Thermo Scientific, Waltham, USA). DNA preparations were checked by restriction 
enzyme digest to confirm the presence of the insert.
4 3.5.3 Restriction enzyme digest
Restriction enzyme digests were set up as follows:
Reagent Volume
1 OX Buffer 2ul
10XBSA 2ul
DNA lOul
Ennzyme(s) lul(X2)
water 4ul
final volume 2 Oui
Reactions were incubated at 37°C for 1 hour. 5pl of loading buffer (40% sucrose, 
100 mg Orange G in DEPC water, in 50ml total volume) was added to each tube 
prior to agarose gel electrophoresis to visualise resulting bands (see material and 
methods 4.3.4).
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4.4 Sequencing of PCR products
Sequencing reactions were carried out using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems (catalogue number 4337455))
4.8pL of df^O and 1.8pL of plasmid DNA were added to 0.5mL micro centrifuge tubes 
(one per sample), heated at 94°C for 3 minutes and then placed on ice.
The samples were briefly centrifuged, placed back on ice and the following added to 
each sample: 1.0 pi of primer, 1.9 pi of buffer, 0.5 pi of enzyme.
Samples were transferred to an Eppendorf Mastercycler and run on a program of 24 
cycles of:
Temperature Time Cycles
96°C 10 seconds
50°C 5 seconds x 24
60°C 4 minutes
2.5 pL of EDTA (lOOmM) was added to 1.5mL microcentrifuge tubes (1 per sample). 
Samples were added to the EDTA. Seventy microlitres of ethanol (100%) was added to 
each sample and briefly vortexed prior to being centrifuged at 17,900 X g for one hour 
at 4°C. The supernatant was removed and 500 pL of ethanol (70%) was added to each sample 
The samples were again centrifuged at 17,900 X g for 10 minutes at 4°C. The supernatant 
was removed whilst avoiding disturbing the pellet and samples were air dried in a 
microbiological safety cabinet. Once the samples were dried to ensure the removal of all 
the ethanol, the pellets were resuspended in 20pl of Hi-Di fonnamide (Applied Biosystems, 
catalogue number 4311320) for 10-15 minutes in the dark. The dark. Sequencing reactions 
were analyzed using a A B I3730 capillary sequencer (Applied Biosystems, Life 
Technologies Ltd., Paisley, UK). Results were visualised with Chromas Software 
(Technelysium Pty Ltd, Australia).
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4.4.1 Primers and probes for qPCR
Primers and probes were synthesised by Sigma Aldrich (Dorset, England).
Primer set for type III IFN :
HQ317919 _F ACTCATCCCTGGGCCACA
HQ317919 _R GCTTGGAGTGGATGTTCTGCA
HQ317919 _probe [6FAM] CCT GGAGCAGCCCCTTCTCACG[BHQ 1 ]
Primer set for internal controls (28S primers and probe):
28S_F GGCGAAAGACTAATCGAACCAT
28S_R CGAGAGCGCCAGCTATCCT
28S_probe [6F AM] AGI AGCTGGTT CCCT CCGAAGTTTCCCT[BHQ 1 ]
p-actin primers and probe:
B-actin_F ACCCAGATCATGTTCGAGACCTT
B-actin_R GTGATGGACTCCGGTGACG
B-actin_probe [6FAM]CCTGTATGCCTCTGGCCGCACC[TAM]
Tyrosine 3-monooxygenase/tiyptophan 5-monooxygenase (YWHAZ) primers 
and probe:
YWHAZ F GATATCTGCAATGATGTACTGTCTCTTTT
YW HAZR TTGAAAATGAAAGGAGACTACTACCG
YWHAZ_probe [6FAM]TGATCCCCAACGCTTCACAAGCAG[TAM]
Note: BHQ1 — Black Hole Quencher-1.
TAM -  Rhodamine as the quencher.
F AM — 6-carboxyfluorescein
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1 10 20 30 40 50 60 70 80 90 100 110 120 130I------♦-------♦------ ♦------ ♦------ ♦------ +------ ♦------ ♦------♦------ ♦------ ♦------ +------ 1
IL28B HTGGCCCCGGGCCGCflCGCTGGTGCTGGTGCTGflTGCTGflCGflCCGTGGCGCTGflGCHGGflCflGGHGCflGTTCCTGTGCCCTCTGCCCCCHGGGCCCTCCCflCCTGCCHGGGGCTGCCHCflTGGCCCRGT 
P1-HQ317919 
R1-HQ317919 
F1-HQ317919
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
131 140 150 160 170 180 190 200 210 220 230 240 250 260I------+------ +-------*------ +------ +------ ♦------ ♦------ 1------ ♦------ ♦------ +------ +------ 1
IL28B TCflflGTCTCTGTCCCCTCflflGflGCTGCflGGCCTTCflflGflCGGCCflGGGflTGCCTTTGflflGflCTCGTTCTTGCCRAflGGRCTGGGflCTGCflGCflCCCflCCTTTTCCCCflGGflCCCGGGflCCTGflflGCflCCT 
P1-HQ317919 
R1-HQ317919 
F1-HQ317919
Consensus  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . ... . . . . . . . . . . . . . . . . . . .
261 270 280 290 300 310 320 330 340 350 360 370 380 390|------♦------ ♦------ +------ ♦-------v------ 1------ ♦------ ♦------ +------ 1------ +------ +------ 1
IL28B GCRGGTGTGGGRGCGCCCTGTGGCTCTGGRGGCRGRGCTGGCCCTGRCRCTGRCGGTCCTGGRGGCCRTGGCTRflCTCRTCCCTGGGCCflCRGCCTGGRGCRGCCCCTTCTCRCGCTGCflGflflCRTCCflC 
P1-HQ317919 CCTGGRGCRGCCCCTTCTCRCG
R1-HQ317919 TGCRGRHCRTCCRC
F1-HQ317919 RCTCRTCCCIGGGCCRCfl
Consensus . . . . . .      actcaLccctgggccaca. . . . . . . . . . . . . . . . . . . . . . . .
391 400 410 420 430 440 450 460 470 480 490 500 510 520
IL28B TCCRRGCTCCRGGCCTGTGTCCCRGCTCRGCCCflCRGCRflGCTCCflGGCCCCGGGGCCGCCTCCRCCRCTGGCTGCflCCGCCTCCRGGRGGCCCGGRRGGflGTCCCRGGRCTGCCTCGflRGCCTCTGTGfl 
P1-HQ317919 
R1-HQ317919 TCCRRGC 
F1-HQ317919
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
521 530 540 550 560 570 580 588
IL28B TGTTCflflCCTCCTCCGCCTCCTCflCCCGGGRCCIGRRflTGTGTTGCCRGCGGRGRCCRGTGTGTCTGR 
P1-HQ317919 
R1-HQ317919 
F1-HQ317919
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . .
Figure 4.3. QPCR prim er and probe alignment for type III IFN (IL-28B).
Primer and probe alignment for the amplification o f type-III IFN giving a product o f 
62 base pairs.
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“When carrying out a qPCR experiment, a fluorogenic probe, complementary to the 
target sequence is added to the PCR reaction mixture. This probe is an 
oligonucleotide with a reporter dye attached to the 5' end (6FAM) and a quencher 
dye attached to the 3' end (BHQ1/TAM). While the probe is not hydrolized, the 
quencher and the fluorophore remain in proximity to each other, separated only by 
the length of the probe and little background fluorescence is observed. During PCR, 
the probe anneals specifically between the forward and reverse primer to an internal 
region of the PCR product. The polymerase then carries out the extension of the 
primer and replicates the template. The 5' exonuclease activity of the polymerase 
cleaves the probe, releasing the reporter molecule away from the close vicinity of the 
quencher. The fluorescence intensity of the reporter dye, as a result increases. This 
process repeats in every cycle and does not interfere with the accumulation of PCR 
product”. (Method explanation from http://sciencesoftware.com).
4.4.2 Generation of type III IFN RNA standards (MEGAscript T7 kit)
A MEGAscript T7 kit (Applied biosystems, catalogue number AM 1333) was used to 
generate RNA transcripts of type-III IFN cloned into pCDNA3.-/V5-His-TOPO (see 
4.3.5). The transcripts were quantified and used to generate a standard curve in 
qPCR reactions.
Plasmid DNA was linearized downstream of the insert using the restriction enzyme 
EcoRY as follows: Reagent Volume
10X enzyme 
buffer 4ul
lOxBSA 4ul
DNA 3 Oui
EcoRV 2ul
final volume 40ul
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The reactions were incubated at 37°C for 1 hour. The linearized template was 
checked on a 1% agarose gel (see material and methods 4.3.4).
Following linearization, the restriction digests were terminated by adding the 
following: 1/20* volume 0.5M EDTA (2pl), 1/10th volume of 3M Na acetate (5pl), 
plus two volumes of 100% ethanol (80pl). The reactions were mixed thoroughly and 
placed at -20°C for 15 minutes. The DNA was pelleted by centrifuging at 17,900 X g 
for 15 minutes. The supernatant was removed, the tubes centrifuged again for 30 
seconds and the residual liquid carefully removed with a fine tip pipette. The DNA 
pellets were resuspended in nuclease free water at a concentration of Ipg/pl. The 
transcription reactions were assembled at room temperature, however, the enzyme 
mix and ribonucleotides were kept on ice until required.
The transcription reactions were set up as follows:
Reagent Volume
ATP solution 2ul
CTP solution 2ul
GTP solution 2ul
UTP solution 2ul
1 OX reaxtion buffer 2ul
linear template DNA lul
Enzyme mix 2ul
Nucleate free water 7ul
Funl \  olume 20ul
The reactions were mixed gently, microcentrifuged briefly and then incubated at 
37°C for 4 hours. Following incubation, Ipl of Turbo DNase was added to each tube 
and incubated at 37°C for a further 15 minutes. RNA recovery was carried out by 
phenol-chloroform extraction and isopropanol precipitation.
To each transcription reaction, 115pl of nuclease free water and 15pl of ammonium 
acetate stop solution was added and mixed thoroughly. An equal volume of phenol-
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chloroform was added (150^1), mixed gently and centrifuged at 17,900 X g for 5 
minutes. The aqueous phase was collected into fresh tubes and 150pl of isopropanol 
added. The tubes were then placed at -20^C for 15 minutes prior to being centrifuged 
at 17,900 X g for 15 minutes at 4°C. The supernatants were carefully removed and 
the RNA was resuspended in nuclease free water. Following quantification by 
nanodrop, RNA standards were stored at -80°C.
4.4.3 RT- qPCR reactions
First strand synthesis of cDNA from RNA samples was carried out using a TaqMan 
reverse transcription kit (Applied Biosystems, catalogue number N805-0234) 
according to the manufacturer’s instructions. Multiples of the reaction volumes 
described below were assembled in a sterile eppendorfs. From this master mix, 9pl 
was added to 6pl of RNA (500ng) in thin walled PCR tubes, for each reaction.
Volume for each
Reagent reaction (ul)
Taqman RT buffer 1.5
MgCl2 3.22
dNTPs 2.93
Random
Hexamers 0.73
RNase Inhibitor 0.25
RT Enzyme 0.37
Total 9
Samples were transferred to an Eppendorf Mastercycler and cDNA synthesis carried 
out using the following PCR programme:
Step Temperature Time
1 48°C 45 minutes
2 95°C 5 minutes
3 4°C Hold
Samples were collected and placed on ice for PCR reaction or stored at -80°C.
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A TaqMan universal PCR master mix (Applied Biosystems, catalogue number 
4304437) was used to set up the PCR reactions, using the cDNA synthesised in the 
initial PCR reaction and qPCR primers and FAM labelled probes (see 4.3.7).
The qPCR master mix reactions were set up as follows in a PCR hood:
Volume for each
Reagent reaction (ul)
2X TaqMan PCR
master mix 12.5
Forward primer 2.25
revgerse primer 2.25
FAM labelled
probe 1
Water 2
Total 20
cDNA samples (5pi) were added to transparent qPCR plates and 20pl o f the master 
mix added to each well. Sterile caps were used to seal each well in use and the plates 
transferred to a MX3000P qPCR machine (Stratagene). Samples were run using the 
following programme:
100
9 5 '
10.00
9 5 *
0 0 : 1 5
7 5-
02:00
5 0 *
25-
S e g m e n t  1 
1 C y c l e
S e g m e n t  2 
1 C y c l e
S e g m e n t  3  
5 0  C y c l e s
Results were collected using MxPro software (Stratagene) and the data analysed 
using Microsoft Excel and Graph Pad PrismS software (Graph Pad Software, La Jolla, 
USA).
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4.5 IFN Omega 1 (-ml) ELISA
A commercial IFN-col ELISA kit was used according to manufacturers’ instructions 
(CUSABIO Biotech Company, Wuhan University Science Park, Peoples Republic of 
China).
Briefly, samples with known acid labile IFN were examined using this assay.
A standard curve was set up using a twofold dilution series of bovine IFN-rol 
(provided in the ELISA kit).
All reagents and samples were allowed to reach room temperature prior to use. 
lOOpl of standards or samples were added to the relevant wells of a pre-coated 
ELISA plate, in duplicate, and incubated at 37°C for 2 hours.
The samples and standards were removed and lOOpl of a biotinylated anti-IFN-col 
antibody was added to each well. Samples were then incubated for 1 hour at 37°C, 
prior to the samples being removed and the ELISA plate washed three times using 
the wash buffer supplied in the kit. One hundred microlitres of a kit supplied avidin- 
HRP was then added to each well and the samples incubated for 1 hour at 37°C. The 
samples were removed and the plate washed 5 times using the kit supplied wash 
buffer. To develop the ELISA, 90pl of kit supplied 3,3 ',5,5 '-Tetramethylbenzidine 
(TMB) substrate was added and the plate incubated at 37°C for 15 minutes. The 
reactions were stopped using 50pl of stop solution.
ELISA plates were read at 450nm using a Dynex MRXII ELISA plate reader 
(Magellan Biosciences, Chelmsford Massachucetts, US))
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4.6 Results
It is known that Pestiviruses can infect MDBK cells and in the case of Npro deletion 
mutant viruses, can induce IFN. In the experiments reported here, we have used both 
wild type and Npro deletion mutant viruses XIKE A and XIKE A ANdN (Meyers et 
al., 2007). In order to compare the levels of IFN generated during pDC interaction 
with BVDV, we had to destroy the virus in the supernatants recovered from pDCs 
using acid (see material and methods 4.2). Previous studies have used UV 
inactivation of the virus to inhibit the effect of virus on the reporter cells. In this 
study we did not have access to this facilty so another method of virus inactivation 
was used. Preliminary experiments were carried out to determine if acid inactivation 
of BVDV was sufficient to inhibit IFN induction in MDBK Mx-CAT assays. This 
method of virus inactivation will not destroy type-I IFN as this is known to be acid 
stable, however it will destroy any acid labile IFN (type-III). This method is only 
useful to detect the presence of acid labile IFN in a given sample, however it is not 
quantitative and molecular methods (qRT-PCR) have to be used to quantify type-III 
IFN as no ELISA is available.
pDC enriched cell 
population________________
Infected w ith BVDV for 48  hours
V
Supernatants harvested
N X x \ à  Supernatants split in tw o
Untreated
Equivalent volum e of 
acid /alkalai added
Acid trea ted  24hrs 
(pH 2.0)- Neutralised
MDBK t /2  reporter cells 24 hrs 
Cells w ashed and  lysed in 1ml 
CAT ELISA lysis buffer
Figure 4.4 Determining the presence of acid labile IFN by reporter cell assay.
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4.6.1 BVDV Infection of MDBK Mx-CAT cells and acid inactivation.
MDBK Mx-CAT cells were incubated with wild type BVDV (XIKE A), and Npro 
deleted virus (XIKE A NdN), (m.o.i. of 0.1), and equivalent virus samples that had 
been acid inactivated for 24 hours. Cells were incubated for 24 hours prior to cell 
lysis and CAT ELISA determination of the presence of IFN.
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untreatreated Acid treated
n
NdN XIKE A NdN  
cell source /  antigen
Figure 4.4.1 IFN induction in MDBK Mx-CAT cells by BVDV
Wild type virus (XIKE A) does not induce IFN in the reporter cells. XIKE A A NdN 
however, does lead to the production o f IFN by reporter cells. Acid treatment o f both 
viruses prior to incubation on reporter cells abrogates this effect.
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4.6.2 The interaction of bovine pDCs with BVDV (XIKE A and ANdN viruses). 
After determining that acid inactivation of BVDV, specifically, the Npro deletion 
mutant, was sufficient to eliminate the ability of the virus to induce interferon in the 
MDBK Mx-CAT reporter cells, we examined the effect of BVDV on bovine pDCs 
and the ability of these cells to produce interferon in response to these viruses.
Type-I IFN in general has been reported to be acid stable and therefore any type-I 
IFN produced in response to viral infection should be unaffected by acid treatment of 
the supernatants. There have been a few reports of an acid labile type-I IFN. 
DeStefano et al., (1982) reported the presence of an acid labile IFN-a in the serum of 
HIV infected patients. There have also been reports of acid labile IFN-a in the serum 
of patients with systemic lupus erythematosus (SLE; Preble et al. 1982; Yee et al., 
1990). Kontsek et al., (1991), reported that IFN-co and the acid labile IFN-a reported 
in human serum were recognised and neutralised by specific monoclonal antibodies 
to IFN-a and suggest that they are one in the same. However other studies dispute 
this and report that IFN-omega is unrelated to IFN-a, -J3 and -y in its antigenic 
properties, as it does not cross-react with antisera or monoclonal antibodies in 
immunoassays or antiviral neutralization bioassays. Further evaluation and 
discussion of the presence of IFN-ro following BVDV infection will be carried out 
later in this chapter.
In most of the cases described above, the presence of an acid labile type-I IFN was 
evaluated using a viral growth inhibition bioassay, where samples were either treated 
with acid or left untreated. Type-III IFN will have an inhibitory effect on viral 
growth in a manner similar to type-I IFN and the acid labile interferon present could 
be construed or misinterpreted to be a type-I IFN.
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In this series of experiments, cells were isolated as previously described (see 
material and methods, chapter 2) and plated at 1 xlO6 cells per well. BVDV (XIKE 
A and ANdN) were added to duplicate wells at an m.o.i. of 0.1. CpG 
oligodeoxynucleotides were added as a positive control. Plates were incubated for 
48 hours, 37°C, 5% CO2 prior to collection of supernatants. One set of samples was 
acid treated for 24 hours, the other left untreated prior to assay on the MDBK Mx- 
CAT assay. Samples were collected from three different animals.
206
7000
6000
5000 -
4000 -
3000
untreated
■ 1  series 1 
ESH series 2 
I I series 3
Acid treated
o
cells XIKE A NdN CpG cells Al XIKE Al NdN Al CpG Al
cell source / antigen
Figure 4.5 Acid labile interferon produced by pDC in response to XIKE A and 
ANdN infection.
Cell populations enriched for pDCs, isolated from three different animals were 
incubated with BVDV (XIKE A and ANpro) in duplicate. One set o f samples was 
acid treated and the other untreated prior to assay for IFN. Referring back to figure 
4.4. XIKE A does not induce IFN in the reporter cells. However IFN is produced by 
pDC in response to XIKE A and is destroyed by acid treatment (highlighted in blue 
box). Npro deletion mutant (ANdN) appears to induce higher levels o f IFN in pDCs, 
however, a proportion o f that IFN will be due to infection o f reporter cells. Again the 
level o f IFN is reduced by acid treatment o f samples prior to assay.
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4.6.3 Acid treatment of serum samples from a XIKE A infected animal
Previously, significant levels of serum type-I IFN have been reported in ncpBVDV 
infected animals (Charleston et a l, 2002; Smirnova et a l, 2008). This serum IFN is 
detected early during acute and transient infections of cows and calves. Upregulation 
of interferon-stimulated-gene 15 (ISG15), a downstream member of the interferon 
response and a marker for upregulation of IFN has been demonstrated in a genome- 
wide microarray analysis experiment. This gene upregulation was demonstrated 
following transient BVDV infection of pregnant dams carrying either transiently 
infected foetuses ( infected day 175) or persistently infected foetuses (infected day 
75) (Smirnova et al., 2009). These data clearly demonstrate that IFN is induced in 
vivo in response to ncpBVDV challenge, even though viral proteins Npro and Ems 
have been shown to disrupt the interferon pathway in cell culture systems.
Following the observation that the majority of the IFN produced in vitro by bovine 
pDCs in response to BVDV was in fact acid labile, we decided to examine the serum 
IFN from a BVDV (XIKE A) infected animal (Meyers et al., 2007). Serum samples 
from day 0 to day 7 post infection were acid treated for 24 hours (pH 2.0), 
neutralised and examined by Mx-CAT reporter assay (see material and methods, 
chapter 4.2).
Examination of the serum samples from the XIKE A infected animal clearly show a 
large reduction in the level of biologically IFN measured by the Mx-CAT reporter 
assay (fig 4.6). These results suggest that a large proportion of the IFN produced in 
response to BVDV infection is in fact acid labile and therefore unlikely to be a type-I 
IFN. A more recently described bovine IFN, type-III IFN (IL-28B or IFN13; Diaz- 
San Segundo et al., 2011) is known to be acid labile and to behave in a similar 
manner to type-I IFN by activating the antiviral genes such as Mx.
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Figure 4.6 Serum Interferon from a XIKE A challenged animal
Serum samples from a single animal, intranasally challenged with 105 TCID50 wild 
type BVDV (XIKE A), (Meyers et al., 2007) were used to determine the presence or 
absence o f acid labile IFN produced in vivo, using the M x-CAT reporter assay.
Due to the lack o f sample availability, samples were assayed in duplicate, plus and 
minus acid treatment. A large reduction in the IFN titre (IU/ml) can be seen for all 
serum samples treated with acid compared to untreated, suggesting a high proportion 
o f the serum IFN produced during BVDV infection is in fact acid labile.
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4.6.4 Comparison of Mx promoter activation by type-I IFN and type-III IFN
Several studies in both primary cells and cell lines have shown that type-III IFN, like 
type-I IFN is expressed in response to TLR ligands and viruses (Coccia et al., 2004; 
Ank et al., 2006; Ank et al., 2008). These studies show that most cells are capable of 
producing type-III IFN if they receive the appropriate stimuli, however, dendritic 
cells, both cDC and pDC produce greater quantities of type-III IFN (Coccia et al., 
2004; Thompson et al., 2009). These data were further strengthened by a report 
showing that both type-I and type-III IFN gene promoter regions shared many 
similarities, with binding sites for members of the IRF family and NFKB and that 
these IFNs were induced through common signalling pathways (Onoguchi et al., 
2007).
Type-III IFN has been shown to be acid labile under the conditions that we employ 
to destroy BVDV. A study by Kugel et al., (2011) clearly demonstrates that reducing 
the pH of the sample to pH 2.0 for 24 hours destroys type-III IFN. However, a 
further study by Rentsch et al., (2011) determined that type-III IFN was acid stable 
over a shorter period of treatment (30 minutes) and that type -III IFN was sensitive 
to alkaline treatment over this time period whereas type-I IFN (IFN-(3) was stable.
To confirm that type-III IFN induced the Mx promoter in our MDBK Mx-CAT 
promoter-reporter cell line we used two sets of standards, recombinant bovine 
interferon alpha (RboIFNa) and a human IFN lambda3 (IL-28B) as no bovine 
standards were available, to compare the level of induction of Mx protein (fig 4.7).
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Figure 4.7 Comparison of Mx-CAT promoter-reporter induction by 
recombinant bovine IFN-a and human IFNX3
Standard curves comprising o f threefold dilutions o f each o f the IFN preparations 
were made and added to the MDBK M x-CAT reporter cells to compare Mx 
promoter induction between the IFN preparations and to confirm that type-III IFN 
did induce Mx protein expression in our system. Human type-III IFN does induce 
Mx proteins expression but to a lower level than type-I IFN.
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4.6.5 The production of acid labile IFN by pDCs and mDCs
Although most cells are capable of producing type-III IFN in response to viral 
infections, just as they are type-I IFN, it has been shown that dendritic cells and 
especially pDCs may be more potent producers of this cytokine, in much the same 
way they as they do type-I IFN. Coccia et al., (2004) demonstrate that type-III IFN 
(IFN-Xs) are produced by pDCs to a greater extent than by monocyte-derived DCs 
after influenza A virus (IAV) infection, suggesting that pDCs are the primary IFNI 
producing cells. In a study by Ank et al., (2008), a comparison of the mRNA levels 
for type-III IFN from herpes simplex virus-2 (HSV-2) infected murine pDCs and 
mDCs (4 hours post infection) demonstrate that both cell types are capable of 
producing type-III IFN, with the message levels being very similar. However, type- 
III IFN is not only induced by viral infection and stimulation of TLR ligands but is 
also an interferon stimulated gene (ISC), (Ank et al., 2006) and the levels of 
expression may be very different over longer time periods.
As type-III IFN is acid labile and both mDCs and pDCs are capable of producing 
these IFNs in response to viral infection, it was decided to examine the different 
bovine cell populations for their ability to produce acid labile IFN in response to 
BVDV infection over a 48 hour incubation period. Cells were separated as 
previously described (material and methods chapter 2), plated at 106 cells per well 
and infected at an m.o.i. of 0.1 for 48 hours. Supernatants were collected, acid 
treated as appropriate and assayed on the MDBK Mx-CAT assay for IFN production 
(fig 4.8).
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Figure 4.8 Comparison of Acid labile IFN produced by bovine pDCs and mDCs 
in response to BVDV (XIKE A and XIKE A ANdN) infection.
Three cell populations from three animals were examined for acid labile IFN 
production in response to BVDV infection following 48 hour incubation. Samples 
were assayed using the MDBK Mx-CAT assay, i) CD1 lc+/- mixed population, 
lineage depleted but still containing both cDCs and pDCs. (ii) CD11c- (pDCs). (iii) 
CD1 lc+  (mDCs). CpG and Sendai virus stimulation were used as positive controls. 
The higher quantity o f acid labile IFN was produced by pDCs (CD11c-; Blue box) in 
response to both XIKE A and XIKE A ANdN infection compared to cDCs.
Note: XIKE A ANdN will induce IFN in the reporter cells prior to acid treatment, 
however XIKE A will not.
213
(A)
(B)
Figure 4.9 Boxplots of log. IFN produced in response to BVDV infection
Boxplots o f the log.IFN o f each sample generated using ANOVA general linear 
models, clearly demonstrate the difference in the levels o f IFN produced in response 
to each treatment. Where no overlap is seen there is a significant difference in the 
levels o f IFN. There is a significant difference in the level o f acid labile interferon 
and total interferon produced by pDCs in response to both wild type virus (XIKE A; 
p = 0.0008 (A)) and the Npro deletion mutant (ANdN2, p = 0.0407 (B)). However, in 
cDCs (CD1 lc+  cells) the levels produced in response to wild type virus showed no 
statistically significant difference, the Npro deletion mutant did induce a 
significantly different level o f acid labile interfon in these cells (p < 0.05). There was 
also a significant difference in the level o f interferon produced by pDCs in 
comparison to cDCs in response to wild type virus (p = 0.002) and ANdN2 (p= 
0.0225).
Boxplot of log.IFN for XIKE A infection of different cell populations
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Statistical analysis of the differences in the levels of acid labile interferon produced 
by the different cells types (CD1 lc+ = cDCs, CD11c- = pDCs and the mixed 
populations = CD1 lc+/-) was carried out using the Minitab programme and ANOVA 
general linear models. The IFN produced in response to BVDV (XIKE A) infection 
of pDCs has an acid labile component as evidenced by the dramatic and statistically 
significant reduction in the levels of Mx-CAT expression following acid treatment of 
the samples (p=0.0008). The data collected for the ANdN2 samples also showed a 
significant reduction in the levels of Mx-CAT production (p=0.0407) following acid 
treatment, however, this virus also induced low level expression of Mx-CAT in the 
reporter cells alone which makes this result difficult to interpret. The levels of IFN 
produced from wild type BVDV (XIKE A) infection of cDCs was close to 
background, suggesting that at pDCs are responsible for at least the initial production 
of IFN in response to BVDV infection, This IFN may then act in an autocrine 
fashion to further amplify IFN production in infected pDCs or in a paracrine fashion 
to induce type-III IFN production in uninfected cells. The levels of IFN produced by 
bovine pDCs in response to BVDV are much lower than those seen in CSFV 
infection of porcine pDCs, where depending on the virulence of the strain used to 
infect the cells, values of around 3000IU/ml have been reported (Summerfield et al., 
2006; Renson et al., 2010). These differences in the levels of IFN produced may 
have a role to play in the very different pathologies associated with these virus 
infections in their respective natural hosts.
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4.6.6 PCR amplification of bovine IFNX3 (IL-28B) from BVDV infected cells
In the previous experiments we show that there is an acid labile IFN produced during 
BVDV infection of bovine pDCs. However, as there are no reagents available to 
determine if this IFN is in fact type-III IFN (IFN-X3), it was decided to use 
molecular techniques to ascertain if type-III IFN was induced, at the molecular level, 
in BVDV infected cells. Several sets of primers were designed (see material and 
methods 4.3.1) to try to amplify type-III IFN mRNA from infected cells using 
reverse transcription polymerase chain reaction (RT-PCR). Bovine pDCs were 
isolated as previously described (see material and methods chapter 2), plated at 1 x 
106 cells per well and infected for 24 hours with either wild type BVDV (XIKE A) 
or the Npro deletion mutant (XIKE A ANdN) at an m.o.i. of 0.1. The cells were 
harvested into 1ml of trizol for RNA extraction and purification (see material and 
methods 4.3 -  4.3.2). First strand synthesis and RT-PCR reactions were set up (see 
material and methods 4.3.3 -  4.3.3.2) and the resulting reactions run on agarose gels 
(see material and methods 4.3.4) to determine the production of bands of the 
appropriate molecular weight.
In the preliminary experiments, many of the RT-PCR primer combinations gave 
multiple bands and were determined not to be specific enough for our purposes. This 
problem was overcome by setting up a nested PCR. A preliminary RT-PCR reaction 
using primers designated F4 (forward) and R1 (reverse) was carried out and a second 
PCR using a gel purified product of the expected size (406bp; figure 4.10 (a)), of the 
RT-PCR reaction was set up using a second set of primer 3F (forward) and R1 
(reverse). This reaction was expected to generate a product of 254bp (figure 4.10 
(b)). This product was again gel purified and sequenced (see material and methods 
4.3.6) to confirm type-III IFN (fig.4.11).
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(a)
F4/R1(406bp) 
1 2  3 4
Lane 1 Uninfected pDCs 
Lane 2 XIKE A infected pDCs
6 0 0 bp
4 0 0 bp -  ]
Lane 3 XIKE A ANdN infected pDCs 
Lane 4 CpG treated pDCs
2 0 0 bp
(b)
3F/R1 (254bp) 
1 2  3 4
4 0 0 bp
2 0 0 bp
1 m»**» ;
Figure 4.10 RT-PCR amplification of type-III IFN message.
200ng o f total RNA from BVDV infected pDCs (24 hours) was isolated and used to 
generate type-III IFN RT-PCR products, (a) Primers F4/R1 generated a band o f 
approximately the correct molecular weight (406bp). This band was especially 
visible in the CpG treated pDCS. The band was excised and gel purified, (b) Gel 
purified band from the RT-PCR reaction was used as template for internal priming 
(nested PCR) using primers 3F/R1, This PCR reaction generated a band o f the 
expected molecular weight (254bp) which was subsequently excised, gel purified 
and sequenced to confirm type-III IFN.
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Gene ID: 100298542 IL28B - interleukin 28B (interferon, lambda 3) [Bos taurus]
(10 or fewer PubMed links)
Score = 257 bits (139),Expect = le-66 
Identities = 139/139 (100%), Gaps = 0/139 (0%)
Strand=Plus/Plus
Q u e r y  11 TTCTCACGCTGCAGAACATCCACTCCAAGCTCCAGGCCTGTGTCCCAGCTCAGCCCACAG 70
I I I I I I I M I I I I I I I I I I I I M I I! I II I II I I I I I I I I M I I I I I I I I I I I I I I I I I I 
S b j c t  36 8  TTCTCACGCTGCAGAACATCCACTCCAAGCTCCAGGCCTGTGTCCCAGCTCAGCCCACAG 427
Q u e r y  71 CA A G CTCCA G GCCC CGG G GCCG CCTCCA CCA CTG GC TGC ACCG CCTCCA G GA G GCCCG G A  1 3 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I | | I | | | | |
S b j c t  428 CA A G CTCCA G GCCC CGG G GCCG CCTCCA CCA CTG GC TGC ACCG CCTCCA G GA G GCCCG G A  487
Q u e r y  131  AGGAGTCCCAGGACTGCCT 1 49  
I I I I I II II II I II II II I 
S b j c t  4 88 AGGAGTCCCAGGACTGCCT 5 0 6
Figure 4.11 Sequencing results for type-III IFN PCR product.
Blast alignment o f sequence obtained from nested PCR reaction. This degree o f 
alignment confirms that type-III IFN (IFN-X3) is generated by bovine pDCs in 
response to BVDV virus infection. (Sequencing reactions carried out by Dr. Julian 
Seago; IAH).
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4.6.7 RT-PCR reaction on bovine pDCs infected with BVDV for 16 hours
As the bands generated with the previous RT-PCR reactions were very faint, it was 
decided to repeat the infection for a shorter time period (16 hours) and to increase 
the concentration o f the RNA template used to 500ng to confirm type-III IFN using 
another set o f primers F3 (forward) / R1 (reverse). This RT-PCR reaction was 
expected to generate a product o f 554bp.
Lane 1 Uninfected pDCs 
Lane 2 XIKE A infected pDCS 
Lane 3 XIKE A ANdN infected pDCs 
Lane 4 CpG treated pDCs 
Lane 5 no template control
Figure 4.12 RT-PCR reaction on bovine pDCs infected with BVDV for 16 
hours.
500ng o f total RNA from BVDV infected pDCs (24 hours) was isolated and used to 
generate type-III IFN RT-PCR products using primers F3 and R l.PC R  products o f 
approximately 554bp are generated from all RNA samples with the exception o f the 
no template control. Uninfected pDCs may be activated to a degree following 
handling or may constitutively produce low level type-III IFN.
F3/R1 (554bp)
1 2 3 4 5
l O O O b p
SOObp
» 0 0 b p
4 0 0 b p
2 0 0 b p
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4.6.8 Cloning and sequencing of the type-III IFN product
The gel purified PCR product (254bp; fig: 4.10) was cloned into pcDNA3.1/V5-His- 
TOPO (see materials and methods 4.3.5). Seven bacterial colonies were selected, 
grown and DNA extracted for sequencing (see material and methods 4.3.5.1- 4.3.6).
(265) 265_____270___________ 280___________ 290____________________ 308
Type-3 IFN seq-5 2 113) ■ B t g B | g c c | g c g g a g a c c a g t g t g t c t g a a a g g g c a a t t c t g
Type-3 IFN sec-6 2 >57) | g1 t g H - - c t g c g g a g a c c a g t g t g t c t g a a a g g g c a a t t c t g
Type-3 IFN seq-7 2 172) c | c t g c c c t c | g c g g a g a c c a g t g t g t c t g a a a g g g c a a t t c t g
Consensu S (265) A T GTGTT C A G C G G A G A C C A GI G X G T C T G A A A G G G C'A A1 1 C IG
 Section 8
(309) 309_____________ 320___________ 330___________ g40____________ 352
Type-3 IFN sec-5 2 157) CAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCG
Type-3IFNseq-6 2 >99) CAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCG
Type-3 IFN seq-7 2 _>16) c a g a t a t c c a g c a c a g t g g c g g c c g c t c g a g t c t a g a g g g c c c g
Consensus (309) CAGATATCCAGCACAGTGGCSGCCGCTCGASTCTAGASGSCCCG
 Section 9
f353) 353_______360___________ 370___________ 380__________________ 396
Type-3 IFN sec-5 2 !01) CGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGA
Type-3 IFN seq-6 2 143) CGGTTCGAà GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGA
Type-3 IFN seq-7 2 _ :60) CGGT TCGAAGGTAAGCCTATCCCTAAC C C I  CTC CTCGGTCTGGA
Consensus (353) CGGTTCGAAGGT AAGCCT ATCCCTAACCCT CTCCTCGSTCTC3A
 Section 10
(397) 397________________410___________ 4% ___________ 430_________ 440
Type-3 IFN seq-5 2 H5) TTCTACGCGTACCGGTCATCATCACCATCACCATTGAGTTTAAA
Type-3 IFN sec-6 2 187) TTCTACGCGT ACCGGTCATCATCAC C ATCACC ATT G AGIT T A.AA
Type-3 IFN sec-7 2 104) TTCT AC GCGTACCGGTCATC ATCACC ATCACC ATT GAGTTTAAA
Consensus(397) TTCTACGCGTACCGGTCATCAXCACCATCACCATTGASXTTAAA
 Section 11
(441) 441__________ 450___________ 460___________ 470_______________ 484
Type-3 IFN seq-5 2 589) CCCGCTGATCAGCCTGGACTGTGCCTTCTAGTTGCCAGCCATCT
Type-3 IFN Seq-6 2 131) CCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCT
Type-3 IFN seq-7 2 548) CCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCT
Consensus (441) CCCGCTGATCAGCCICGACTGTGCCTTCTAGTTGCCAGCCATCT
 Section 1.2
(485) 485 490 500 510 528
Type-3 IFN seq-5 2 133) g t t g t t t g c c c c t c c c c c g t g c c t t c I B H B H H H I ^ I
Type-3 IFN seq-6 2 175) GTTGTTTGCCCCTCCCCCGTGCCTTC---------------------------------------
Type-3 IFN seq-7 2 $92) G T T G T T T G C C C C T C C C C C G T G C C T T C H H ^ ^ H i H H i H I
Consensus (4851 GTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGC
Figure 4.13 Sequence of type III IFN clones
Sequence o f pcDNA3.1/V5-His-TOPO-type-III IFN clones. Plasmid DNA purified 
from Clones 5, 6 and 7 generated sequences which matched the type-III IFN PCR 
product. (Cloning and sequencing carried out by Dr. Julian Seago; IAH).
Note : Clone 5 was selected to take forward to make RNA standards.
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4.6.9 Amplification of DNA from Clone 5 to prepare RNA standards
Bacterial suspension o f clone 5 was used to seed a fresh agar plate. Three colonies 
from this plate were picked, gown and DNA purified as described before. These 
clones were checked by enzyme restriction digest (see material and methods 4.3.5 -  
4.3.5.3). Samples were linearized using EcoRV, left uncut, or double digested with 
EcoRV and Bam Hl enzymes (figure 4.14). The insets from 5B and 5C were then 
sequenced to confirm type-ITI (figure 4.15). This work was carried out by Dr N 
Juleff, (IAH).
(A)
(B)
Linearised L ncut
m&JeW
Bands excised and purified for 
Megascript RNA transcription
5A 5B 5C
| x |  - Plasmid not used any further
Vector -  Insert
Figure 4.14 Restriction enzyme digests to check pcDNA3.1/V5-His-TOP-Type- 
IIIIF N  clones.
DNA from clones 5A, 5B, and 5C were analysed by restriction enzyme digest and 
gel electrophoresis to confirm the presence o f an insert o f the correct size. (A) DNA 
was either linearised using EcoRV or left uncut. Clones 5B and 5C appear correct, 
clone 5A appears too large. (B) Double digest using EcoRV and BamHl enzymes. 
All clones appear to give an insert o f the correct size (344bp). Clone 5A was not 
taken any further as the uncut band was not as expected.
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type III IFN insert • - * • i • • * - I . . . .  I . . . .  i . . . .  i . . . .  i . . . .  i . . . .  i . . . .  i . . . .  i
10  2 0  30 4 0  so
g g a g a c c c a a  g c t q g c t a g t  n a a g c t e g g t  a c c g a g c t c q  g a r .e c u e L u g
type ill IFN insert . . . .  I . . .  ^
L c c a g t g t q g  t g g a a t t g e e  c t t A C T C A T C  CCTGGGCCAC AGCCTGGAGC
type III IFN insert . . . .  I . . . .  I . . . .  I . . . .  I . . . .  i . . . .  i . . . .  i . . . .  i . . . .  i . . . .  i
210 120 130 140 150
A G C C C C T T C T  C A C G C T G C A G  A A C A T C C A C T  C C A A G C T C T A  G G C C T G T G T C
typelll ,FNinsert a . . o . . . o . o
C C A G C T C A G C  C C A C A G C A A G  C T C C A G G C C C  C G G G G C C G C C  T C C A C C A C T G
t y p e M M F N m s e r t - o . . . . o . . . .
G C T G C A C C G C  C T C C A G G A G G  C C C G G A A G G A  G T C C 7 A G G A C  T G C C T C A A A G
typelll , FN insert o . . . . i . . . . , o . . . . q . . . .
C C 7 C T G T G A T  G T 7 C A A C C 7 C  C T C C G C C 7 C C  T C A C C G G G G A  C C T G A A A T G 7
t y p e l l l  IFN insert . . . .  I . . . .  i . . . .  i . . . .  i . . . .  i . . . .  i . . . .
310 3 2 0  3 3 0  340
G T T G C C A G C G  G A G A C C A G T G  T G T C T G A a g g  g c u u L L c L g e  o y a t .
L en g th  -  344 b ase p a i r s
M o l e c u l a r  W e ig h t  1 0 5 5 2 5 .0 0  D a l t o n a ,  s i n g l e  s t r a n d e d
M o l e c u l a r  W e ig h t  -  2 0 9 0 0 0 . 0 0  D a l t o n s ,  d o u b le  s t r a n d e d  
G+C c o n t e n t  -  61.05%
A + T  c o n t e n t  = 30.95V.
N u c l e o t i d e
A
C
G
T
Number
68
120
9 0
66
M o l  »  
1 9 . 7 7  
3 4  . 8 8  
2 6 .  1 6  
1 9 . 1 9
Figure 4.15 sequence of type-III IFN insert in pcDNA3.1/V5-His-TOPO
Sequence in capital letters represents type-III IFN insert. Remaining sequence is 
vector sequence. These insets were used to generate RNA to make bovine type-III 
IFN standards.
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4.6.10. The generation of RNA transcripts for type-III IFN standards.
In order to quantify the copy number per micro I iter o f type-III IFN generated during 
BVDV infection o f pDCs, it was necessary to prepare a set o f RNA standards with 
known copy number that could be used to generate a standard curve.
RNA transcripts were generated using the Megascript kit (see material and methods 
4.3.8). The transcript size (344bp) consisting o f the type-III IFN insert and vector 
sequence was sequenced and the molecular weight assessed by multiplying the 
numbers o f each nucleotide present by the molecular weight for each o f the four 
nucleotides and adding together to give the molecular weight in daltons (figure 
4.17). The RNA integrity was checked by agarose gel electrophoresis (figure 4.16) 
and the concentration was determined using a nanodrop spectrophotometer. Copies 
per microliter were calculated and qPCR efficiency assessed (figure 4.17). This work 
was carried out by Dr. Nicholas Juleff (IAH).
Markers 5B 5C
Figure 4.16 RNA integrity assessed by agarose gel electrophoresis.
RNA was generated from clones 5B and 5C using the M egacript T7 kit. Intact RNA 
with minimal degradation was generated for each sample.
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For the type III IFN standard sequence:
Nucleotide
number of 
nucleotides in 
transcript
mol. weight of 
nucleotide
mol. weight in 
transcript
A 68 347.2 23609.60
C 120 323.2 38784.00
G 90 363.2 32688.00
U 66 324.2 21397.20
Total 344 116478.80
RNA concentration was 1344ng/pl
The copies per pi were calculated as follows:
Avagadros constant (6.023 x 1023) X concentration in s/ml 
Molecular weight in daltons
= 16.023 x 1023) X 0.001344 s/ml
116478.8
= 6.95 x 1015 copies / ml; = 6.95 x 1012 copies / pi 
A log dilution series of RNA transcripts was set up and checked by qPCR. This 
dilution series was used to generate a standard curve during each qPCR run to allow 
quantification of transcript copy number for each sample following normalisation to 
a house keeping gene and to determine qPCR efficiency for each run.
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Each coloured line represents the amplification plot o f bovine IFN-III standards from 
109 -  101 copies per pi.
Standard Curve: FAM Standards RSq: 0.997. FAM, Y=-3.374 x LOG (X) + 41.83 
Efficiency = 97.9%. (Work carried out by Dr. Nicholas Juleff; IAH).
Figure 4.17 RNA quantification and standard curve generation.
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4.6.10.1 Selection and validation of qPCR housekeeping gene
It is unlikely that an ideal universal housekeeping gene exists. However, the genes 
chosen to act as housekeeping genes are typically constitutively expressed genes 
that are transcribed at a relatively constant level when subjected to varying 
conditions and their expression is assumed to be unaffected by experimental 
parameters. The expression of reference genes can vary greatly among cell types and 
experimental systems and many of the “classical” reference genes such as GAPDH 
and a-actin, are unsuitable for general use (Radonic et al., 2004). Therefore, any 
potential reference gene should be validated to assure stability of expression under 
your specific experimental conditions. A great number of housekeeping genes have 
been proposed as references for gene expression analysis (Warrington et al., 2000; 
Dheda et al., 2004; Cronin et al., 2004). The choice of suitable reference genes for 
normalization of qPCR data must be relatively unaffected by marked changes in 
transcriptional activity. Assessing and comparing the performance of your chosen 
housekeeping genes can be achieved by widely available computational methods 
developed to assess the expression stability of candidate reference genes, namely 
geNorm (Vandesompele et al., 2002), NormFinder (Andersen et al., 2004 and 
BestKeeper (Pfaffl et al., 2004). The geNorm software uses a pairwise analysis of 
gene expression to identify stable reference genes. BestKeeper performs a pairwise 
comparison, whereas NormFinder uses a mathematical model to estimate overall 
expression variation of candidate reference genes and variation between sample 
groups. No single accepted method to examine gene expression stability exists and 
different statistical methods can yield variable results, validation of reference genes 
using different computer applications and identifying differences and similarities
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between the outputs of alternative software, makes the consensus conclusions more 
reliable.
4.6.10.2 Validation of housekeeping gene stability
The housekeeping genes chosen for assessment and validation under our 
experimental conditions were 28S, p-actin and YHWAZ.
28S ribosomal RNA is the eukaryotic nuclear homologue of the prokaryotic 23 S 
ribosomal RNA and is the structural RNA for the large component of eukaryotic 
cytoplasmic ribosomes, and therefore one of the basic components of all eukaryotic 
cells, p-actin is one of two highly conserved non-muscle cytoskeletal proteins. 
YHWAZ is a member of the 14-3-3 family of proteins which mediate signal 
transduction by binding to phosphoserine-containing proteins and are highly 
conserved.
In order to compare and validate the housekeeping genes chosen, a log dilution of 
the cDNA generated from the first strand synthesis reaction was prepared for each of 
the experimental conditions in our RT-qPCR. The RT-qPCR was carried out under 
the experimental conditions to be used (see material and methods 4.3.9) to assess any 
change in type-III gene expression and the results were assessed using RefFinder 
software (Figure: 4.4.10.2-2). The programme authors define it as “a web-based 
comprehensive tool developedfor evaluating and screening reference genes from  
extensive experimental datasets. It integrates the currently available major 
computational programs (geNorm, Normfinder, BestKeeper, and the comparative 
ACt method) to compare and rank the tested candidate reference genes. Based on the 
rankings from each program, it assigns an appropriate weight to an individual gene 
and calculated the geometric mean o f their weights fo r  the overall final ranking”, 
and can be found on the Cotton EST Database website (http://www.leonxie.corn).
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The slope o f each dilution curve and PCR efficiency was also calculated to ensure it
was between the accepted values o f 90% - 110% (figure 4.18).
Average Ct 28S dilution curves
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Figure 4.18 PCR efficiency and dilution curves.
Serial log dilutions o f each cDNA for each experimental condition were used to 
determine the Q-PCR efficiency. The slope o f the line was calculated by plotting log 
dilution against Cq values. The PCR amplification efficiency was calculated using 
the equation E = 1+ io ("1/slope). The efficiency o f the PCR should be between 9 0 - 
110% (-3 .6  > slope > -3 .1 ). If the efficiency is 100%, the CT values o f the 10 fold 
dilution will be 3.3 cycles apart (there is a 2-fold change for each change in CT). If 
the slope is below -3 .6 , then the PCR has poor efficiency. All the housekeeping 
genes examined proved to be efficient.
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Figure 4.19 RefFinder comparison and ranking of housekeeping genes.
RefFinder software was used to compare and rank the housekeeping genes. The 
programme compares results generated by normFinder, Genorm, Bestkeeper and the 
ACT methods to rank the housekeeping genes in order. Analysis suggests that 
YHWAZ or 28S should be used as the reference gene in future experiments. Due to 
the discrepancies between the results for YHWAZ and p-actin in the different 
analysis programmes and the previous result showing inefficient amplification of P- 
actin, 28S was chosen as the housekeeper to be used in the following RT-qPCR 
reactions.
(Software used from http://www.leonxie.com).
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4.6.11. RT-qPCR for type-III IFN from BVDV infected plasmacytoid dendritic 
cells.
Following the validation of the housekeeping genes, 28S was chosen as the gene best 
suited for normalisation of the RT-qPCR reactions for type-III IFN.
A population of cells enriched for pDCs were isolated as previously described (see 
material and methods 2.5 - 2.10) and a time course of infection (0, 4,8, 16 and 24 
hours) with either XIKE A, XIKE A ANdN, or treated with CpG was set up. A 
further set of samples was set up to assay for acid labile interferon using the 
previously described acid treatment and Mx-CAT induction assay (figure 4.22). 
Samples from the time course were collected into 1ml of trizol for RNA extraction 
(see material and methods 4.3). RNA was quantified and 500ng used for each RT- 
qPCR reaction. Reactions were set up for all samples (see material and methods
4.3.9) using type-III IFN primers and probe and 28S primers and probe, results were 
normalised and the copies /pi calculated (figure 4.4.11 -2). Log dilutions of RNA 
generated for the type-III IFN standard curve were also set up with type-III IFN 
primers and probe to allow quantitation of message generated in experimental 
samples (figure 4.4.11-1). All experimental samples were set up in triplicate and 
RNA standards were set up in duplicate.
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Figure 4.20 Standard curve and PCR efficiency for type-III IFN
A type-IIl IFN standard curve (duplicates) was set up to validate the qPCR 
efficiency. The data falls within the accepted efficiency limits o f between 90% and 
110%. The standard curve will allow quantitation o f the message generated from 
experimental samples following normalisation to 28S levels.
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Figure 4.21 Quantitation of type-III IFN message in BVDV infected 
experimental samples.
RNA was extracted for each time point o f infection from cells isolated from three 
separate animals (green, brown and blue). Triplicate Ct values generated during RT- 
qPCR reactions were averaged and normalised to 28S for each sample. (A) Averaged 
normalised Cq values for each sample time point from three separate animals (red, 
black and green). (B) Copies per microliter for each time point o f infection from 
three separate animals (green, brown and blue) were calculated using the standard 
curve generated with the type-III IFN standards (figure 4.20).
The data presented represents the results o f samples generated from cells from three 
animals. S tatistical analysis using ANOVA general linear models shows a 
significant difference in XIKE A 24 hour p = 0.0443 and all the Cpg treated samples 
p< 0.05. It should be noted that type-III IFN message is generated late in XIKE A 
infection (between 16 and 24 hours). Type -III message is expressed at low levels 
following XIKE A ANdN infection and is not statistically  significiant p> 0.05.
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Figure 4.22. Induction of acid labile interferon in the cell populations used to 
generate the RNA time course.
A pDC enriched population o f cells, (from three animals; blue, brown and green), 
were plated at 1 x 106 cells per well in duplicate, infected with either XIKE A or 
XIKE A ANdN at an m.o.i o f  0.1 for 48 hours. Controls were either left untreated or 
stimulated with CpG (2pM).
One set o f samples were acid treated for 24 hours before neutralisation and assay 
using the MDBK Mx-CAT reporter assay. The level o f interferon produced in 
response to XIKE A infection are clearly reduced following acid treatment 
confirming the presence o f  an acid labile interferon. Lower levels o f acid labile IFN 
are generated in response to XIKE A ANdN.
2 3 3
The results of the IFN assay confirm the production of acid labile interferon 
following infection of the pDC enriched cell population with XIKE A (wild type 
BVDV) in both animals and a smaller quantity following infection with XIKE A 
ANdN.
This data is mirrored by the RT-qPCR data which shows type-III IFN message 
production increase between 16 and 24 hours post infection with XIKE A and a 
markedly smaller quantity of type-III IFN message following infection with XIKE A 
ANdN.
The induction of both type-I and type-III IFN during viral infection has been well 
documented (Spann et a l, 2004; Kotenko et a l, 2003). However, several studies 
have reported elevated levels of type-III IFN compared to type-I IFN. The ability of 
many viruses to selectively target the pathway leading to interferon regulatory factor 
(IRF) activation may go some way to explaining the increased levels of type-III IFN 
but not type-I. Jewell et.al, (2010) reported elevated levels of type-III IFN but not 
type-I IFN in the lungs of mice infected with influenza A virus (IAV). Elevated 
levels of type-III IFN were also found in liver biopsies from patients with chronic 
hepatitis C virus (HepC) infection (Mihm et. a l, 2004). Both of these viruses inhibit 
IRF-3 activation and as a result inhibit type-I IFN induction in mucosal epithelial 
cells, fibroblasts and conventional dendritic cells or hepatocytes respectively.
BVDV and another pestivirus CSFV have also been shown to target IRF-3 for 
proteasomal degradation to inhibit type-I IFN induction (Hilton et a l, 2006; Seago et 
a l, 2007).
The results of both the interferon assay and the RT-qPCR would therefore suggest 
that the acid labile interferon found in the supernatants from BVDV infected pDCs 
and the serum of infected animals is type-III IFN. Type-III IFN is able to drive the
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Mx gene expression we see in the promoter reporter assay and we have shown that 
mRNA for the bovine type-III IFN gene IFNX3 (IL-28B) is induced following 
BVDV (XIKE A) infection of a pDC enriched cell population. Interestingly, the 
Npro deleted virus (XIKE A ANdN) did not induce type-III IFN message to the same 
degree. There has been a suggestion that IFNs may compete for downstream 
signalling components (Sheppard et al., 2003) and it may be that the higher level of 
type-I IFN generated by the Npro deleted virus competes for these signalling 
molecules thereby reducing their availability for the type-III pathway.
4.4.12. Interferon Omega and acid lability.
There have been several early reports in the literature of an acid labile type-I IFN 
(Copobianchi et al., 1988; DeStefano et al., 1982) and a suggestion that this may in 
fact be interferon Omega (IFN©; Kontsek et al., 1991). In these early reports, human 
leukocyte IFNa preparation, autoimmune sera and AIDS sera were found to contain 
an acid labile, thermolabile component that showed relatedness to both IFNa and 
recombinant IFN©1. Kontsek et #/.,(! 991), demonstrated with the use of monoclonal 
antibodies generated against virus induced leukocyte IFNa and IFN©, that both the 
antiviral and antiproliferative activities of IFN© could be neutralised and this IFN 
corresponded to the acid labile component of leukocyte IFNa.
For this reason it was decided to investigate the possibility that the acid labile IFN 
generated during BVDV infection could in fact be IFN©.
4.4.12.1. Generation of supernatants containing acid labile IFN.
In order to examine the possibility that the acid labile IFN generated during BVDV 
infection could be IFN©, a population of cells enriched for pDCs was isolated from 
bovine PBMCs and from mesenteric lymph nodes. These cells were infected with
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either XIKE A, XIKE A ANdN for 48 hours, the supernatants collected and either 
left untreated or acid treated (pH 2.0) for 24 hours. These samples were then assayed 
using the MDBK M x-CAT reporter assay to confirm the presence o f acid labile IFN 
(figure 4.23).
Once the presence o f an acid labile IFN had been confirmed the samples were then 
assayed (both untreated and acid treated) by ELISA (see material and methods
4.3.10) for the presence o f  bovine IFN col (figure 4.24).
PBMC
Acid inactivated Acid inactivated
E  1 0 0
i
• Al = acid inactivated
Figure 4.23 Acid labile IFN generated in response to BVDV.
Acid labile IFN is generated in response to BVDV (XIKE A) in cell populations 
enriched for pDCs, isolated from peripheral blood mononuclear cells (PBMC) and 
mesenteric lymph nodes (MEN). Lower levels o f acid labile IFN are also seen 
following infection with Npro deleted virus (XIKE A ANdN). Values represent 
average o f duplicates.
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Figure 4.24 IFN Omega (IFNco) production following BVDV infection.
IFN© was not present in the supernatants from BVDV infected pDCs (enriched
populations from PMBC and MLN) that had been confirmed to contain acid labile 
IFN (fig. 4.23). A standard curve was set up using a twofold dilution series o f bovine 
IFN© from 4000pg/ml to 0 (provided in the ELISA kit). Samples generated and 
tested in (fig 4.23) for the presence o f acid labile IFN were further analysed for the 
presence o f IFN-©. A standard curve was set up using a twofold dilution series o f 
bovine IFN-tol (provided in the ELISA kit). No detectable IFN-© was found to be 
present in the samples analysed.
Note: There was no positive control available other than the recombinant bovine 
IFN© standards.
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4.4.13. Acid inactivation of IFN generated in response to FMDV immune 
complexes.
Following on from the results generated by acid inactivation of the samples 
recovered from BVDV infected pDCs, it was decided to revisit the FMDV immune 
complex generation of IFN from these cells to compare the IFN profiles and 
determine if acid labile IFN was generated.
4.4.13.1 Acid stability of IFN generated by bovine pDCs in response toFMDV 
immune complexes.
Bovine pDCs were isolated as previously described, incubated with FMDV immune 
serum, virus or immune complexes for 24 hours in duplicate. The supernatants were 
harvested and either acid treated as described for BVDV inactivation, or left 
untreated. The resulting samples were assayed using the Mx-CAT reporter assay to 
ascertain if there was indeed acid labile IFN produced during FMDV-IC activation 
of pDCs (fig. 4.25).
238
4000
3500
3000
z 2500
F 2000
3 1500
1000
500 -
0 -
untreated Acid treated
e>
o .u
<
o
Q .u
cell treatment/sample treatment
Figure 4.25. Acid stability of IFN generated in response to FMDV immine 
complexes.
Bovine pDCs were harvested from the mesenteric lymph nodes o f three animals 
(data represented as blue, brown and green). These cells were incubated with serum, 
virus or immune complexes (IC). The resulting supernatants were then either acid 
treated (Al) or left untreated.
Acid treatment o f the samples resulted in a very small drop in the levels o f M x-CAT 
activation suggesting that a very limited amount o f acid labile IFN is generated in 
response to FMDV IC.
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4.4.14 Discussion
Pestiviruses have evolved mechanisms to inhibit type-1 IFN induction in the 
majority of cells. However, elevated levels of serum interferon following infection, 
originally believed to be type-I, suggested the existence of a population of cells still 
capable of producing IFN following viral infection. In this chapter we have 
demonstrated that IFN is produced in response to ncpBVDV and the cells 
responsible for the majority of this IFN are bovine pDCs. The interesting observation 
that the majority of the interferon produced in response to BVDV infection was acid 
labile, initiated a series of experiments to examine the possibility that this IFN was in 
fact type-III IFN as had been reported for other viral infections that target the 
respiratory and gastrointestinal tracts. Type-III IFN has been shown to be the 
predominant interferon induced in vivo during Influenza A virus infection (Jewell et 
al., 2010). Indeed, in a comprehensive study by Mordstein et al., (2010) in mice, 
type-III IFN was shown to play a crucial role in protecting respiratory tract epithelial 
cells from infection with pneumotropic virus such as Influenza A virus, Influenza B 
virus, respiratory syncytial virus (RSV), human metapneumovirus and severe acute 
respiratory syndrome (SARS) coronavirus. The authors also suggest a role for type- 
III IFN in protecting gastrointestinal epithelial cells from infection. They 
demonstrate that the type-III IFN receptor is present on epithelial cells of the 
esophagus, stomach, small intestine and colon. Pott et al., (2011) demonstrate that 
intestinal epithelial cells, which are the prime target of rotavirus, respond strongly to 
type-III IFN but only marginally to type-I IFN. These results suggest that type-III 
IFN may have a crucial role to play in protecting mucosal epithelial cells from viral 
infection.
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In the majority of cells induction of the interferon pathways are reliant on IRF-3. 
RIG-1, MDA5 or TLR3, 7 or 8 activate the kinases IKKs or TBK-1 via the adaptor 
proteins MAYS, Trif or MyD88 respectively leading to the phosphorylation of IRF-3 
and then 7 and ultimately to the activation of the IFN-p promoter. IFN-a is then 
produced as a result of positive feedback on the cells. However, in pDCs constitutive 
expression of IRF-7 allows IFN-a to be produced much more rapidly and it may be 
the case that a level of IFN-a is produced by pDCs in response to BVDV infection 
prior to the action of Npro. In CSFV infection, Fiebach et al., (2011) demonstrate 
that the zinc binding domain of Npro is necessary for binding IRF-7 in infected 
pDCs and this targeting of IRF-7 leads to a reduction in type-I IFN expression. 
Type-III IFN has been shown to be an interferon stimulated gene (ISG) as well as 
being induced directly by viral infection (Ank et al., 2008). It is therefore possible 
that the type-III IFN seen in response to BVDV infection is produced by uninfected 
cells in response to type-I IFN. Yet another possibility is that uninfected pDCs 
produce interferon in a TLR dependent manner provided they are in contact with 
infected cells. This was shown to be the case for hepatitis C virus, where pDCs in 
direct contact with infected hepatocytes produce interferon in a TLR7 dependent 
manner, suggesting a mechanism for cell to cell transfer of RNA that has yet to be 
described (Takahashi et al., 2010; Sagan and Samow, 2010).
In vivo only 10 -  30% of DCs have been shown to be infected by BVDV, the 
remaining cells potentially could response to type-I IFN by producing type-III IFN. 
The production of IFN during infection lasts over a significant period of time (5-7 
days). This suggests a period in which sequential infection of cells leads to the 
induction of IFN, which could possibly be amplified by uninfected cells producing 
type-III IFN. In our experiments, a multiplicity of infection (m.o.i.) of 0.1 was used.
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This again opens up the possibility that uninfected cells may be responsible for the 
production of type-III IFN, however, when comparing the results of the acid labile 
interferon generated in response to XIKE A and XIKE A ANdN, the small quantity 
of type-III produced in response to the Npro deleted virus would suggest that 
uninfected cells are not the source of this IFN as these cells had produced larger 
quantities of type-I IFN. The RT-qPCR results also seem to confirm this as only low 
levels of type-III IFN mRNA were found in the XIKE A ANdN infected cells 
compared to XIKE A infected cells.
Interestingly the RT-qPCR results suggest that IFNX3 (IL-28B) is produced fairly 
late in infection. It is known that IFNX1 is an early response gene dependent 
primarily on IRF-3, whereas IFNX2 or 3 require IRF-7 for activation (Kotenko et al., 
2011). It may be hypothesised that in infected pDCs, type-I IFN initially 
outcompetes type-III IFN for this interferon regulatory factor until the action of Npro 
inhibits type-I IFN production. Type-III IFN is not as tightly regulated as type-I IFN 
and it has been shown that over expression of NFkB can activate these gene 
promoters albeit to a lower level (Osterlünd et al., 2007). Npro has also been shown 
to bind to IicBa (Doceul et al., 2008) and it is hypothesised that it competes with the 
heterodimeric p65/p50 NFkB for this repressor. This could represent a mechanism 
whereby the NFkB transcription factor would be available to bind the type-III IFN 
promoter and activate low level gene transcription, but further work is needed to 
ascertain if this is indeed the case.
In our evaluation of the IFN response to BVDV, we have not assayed for IFN-a 
directly, either by ELISA or RT-qPCR. At present there is no ELISA available for 
bovine IFN-a. To include IFN-a in the qPCR we would have to select a few genes 
from the 13 bovine IFN-a genes that have been annotated to date (Walker and
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Roberts, 2009) and as this represents a significant body or work, will form part of 
future work.
To summarize, in this chapter we have confirmed the presence of an acid labile 
interferon that we propose to be IFNÀ3 (IL-28B), the only type-III IFN gene so far 
annotated in the bovine genome. We show that a cell population enriched for bovine 
pDCs produce the majority of this acid labile interferon in response to BVDV 
infection, though mDCs do produce low level type-III IFN in response to XIKE A 
ANdN and that this IFN is induced fairly late in infection (16-24 hours). We also 
revisit FMDV immune complex induction of IFN in these cells and show that the 
IFN profile is very different, with very little acid labile IFN produced.
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Chapter 5: Final Discussion and future work
Plasmacytoid dendritic cells (pDCs) play a crucial role in the control of viral 
infections, especially in response to viruses that have evolved mechanisms to block 
the type-I IFN signal transduction pathway. Many types of cells are capable of 
producing type-I IFN, but pDCs produce very high levels of type-I IFN in response 
to infection with enveloped viruses (Fitzgerald-Bocarsly and Feng. 2007.). Non­
enveloped viruses induce very little, if any, type-I IFN in pDCs (Feldman et 
or/., 1994.; Palmer et al., 2005). However, it has been shown that antibodies 
complexed to non-enveloped viruses such as FMDV lead to viral uptake, abortive 
replication, and the production of high levels of type-I IFN in porcine pDCs 
(Guzylack-Piriou, et al., 2006). pDCs have been isolated and characterized from a 
number of species, including humans, mice, and pigs (Asselin-Paturel et al. 2001; 
Facchetti et al. 1989.; Grouard et al. 1997; Nfon et al., 2010; Summerfield et al., 
2003), but we believe this to be the first isolation and characterisation of these cells 
in cattle.
In the present study we have isolated and characterised bovine pDCs and examined 
their interaction with FMDV (Reid et al., 2011) and BVDV. These cells represented 
less than 0.1% of the total lymphocyte population in blood, pseudo-afferent lymph, 
and lymph nodes. pDCs are described as large low density cells and our initial 
experiments comparing tissue distribution indicated that higher numbers are present 
in bovine secondary lymphoid tissue as compared to blood or pseudo-afferent 
lymph. This is not necessarily the case for other species as these cells appeared to be 
in sufficient numbers in blood or lymph to allow isolation and characterisation. We 
also know that these cells can be isolated from porcine blood in high enough number 
to permit in vitro experimentation (Guzylack-Piriou, et al., 2006). Obtaining
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sufficient numbers of these cells from bovine blood for our purposes proved 
challenging and therefore secondary lymphoid tissue was deemed a better source. 
We defined the phenotype of bovine pDCs to be CD3“ CD 14", CD21", NKp46", 
TCRô-chain" (expressed on yS -  Tcells), CD11c", CD45RB+, CD172+, MHC H+, and 
expressing CD4. This is in agreement with the data published by Pascale et al. 
(2008), describing the phenotype of ovine pDCs isolated from lymph. We have 
characterised a bovine cell population that is lineage negative, CD4+, and generally 
corresponds to the pDC populations described for other species (table 1.3.1)
The fact that these cells can be found in bovine pseudo-afferent lymph opens up the 
possibility of further examination of the biology of these cells. Cannulation of large 
animals such as cattle, would allow us to study trafficking and maturation of these 
cells following challenge with, for example, TLR agonists or more importantly as a 
direct effect of viral infection. We would also be able to examine the role of these 
cells in antigen presentation and T-cell stimulation following viral infection.
The viruses used in this study (BVDV and FMDV) have positive sense single 
stranded RNA genomes. BVDV, in general has quite a broad tropism, being able to 
infect epithelial cells and leukocytes including monocytes, macrophage, T and B 
cells and importantly dendritic cells. FMDV on the other hand has a more restricted 
tropism early in infection, with cells expressing the appropriate integrins, such as 
epithelial cells being targeted. This tropism however is likely to change with 
production of FMDV specific antibody and immune complex formation. Robinson et 
a l, (2011), demonstrate that FMDV in complex with antibody loses the ability to 
infect target cells expressing the appropriate integrins but gains entry to monocyte 
derived dendritic cells (MoDC) expressing CD32 (FeyII). The infection of these cells 
was shown to be productive, ultimately leading to cell death. Monocytes were also
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found to express the same Fc receptor but the authors found no evidence of 
replication in these cells, suggesting the requirement for an as yet unidentified 
factor(s) in cellular susceptibility to infection.
We found that in freshly isolated bovine pDCs, following Fc mediated immune 
complex uptake, FMDV does replicate, but whether this replication is productive 
remains to be examined as the high level of interferon produced by these cells made 
the classic cellular virus isolation procedures redundant. We found no evidence of 
accelerated cell death these cells compared to uninfected controls. We have also 
shown the necessity for live FMDV-immune complexes to initiate IFN production in 
these cells and confirm that pDCs are responsible for the IFN produced early in 
infection in vivo. The IFN produced in response to FMDV immune -complexes has 
been also been shown to be predominantly acid stable and therefore presumably 
type-I IFN.
The interferon profile is very different when examining the interaction of bovine 
pDCs with ncpBVDV. Our results show that pDCs are responsible for the majority 
of the IFN produced in response to ncpBVDV (XIKE A) and the majority of this 
interferon has been shown to be acid labile, both in vitro and in vivo. However, 
interestingly, the interferon produced in response to an Npro deletion mutant (XIKE 
A ANdN) has been shown to be predominantly acid stable and therefore is likely to 
be type-I IFN. Following an observation that pDCs appeared to be primed for 
interferon production in CSFV pre-immunised pigs, Balmelli et a l, (2005) examined 
the possibility that virus- immune complexes were responsible for this effect. They 
found that preformed CSFV immune complexes inhibited the production of IFN in 
pDCs and hypothesise that cytophilic antibodies bound to FcyR on the “immune” 
pDC surface may be responsible for this enhanced IFN production.
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The interferon response in cattle infected with ncpBVDV lasts for much longer (up 
to 8 days) during acute, transient infection, compared with infection with FMDV (2- 
3 days). Further work needs to be done to elucidate if this is a direct effect of viral 
infection ofpDCs with the different viruses, is due to the different methods of viral 
entry, their methods of interferon antagonism, or possibly related to the differences 
in viral growth kinetics and titre.
The effect that the different classes of interferons (type-I/type-III) have on disease 
progression is also markedly different. The predominantly type-I interferon produced 
during FMDV infection has little or no impact on disease progression. There may 
however be locally protective effects and type-I IFN has been shown to play a role in 
enhancing the follicular B cell contribution to the T cell independent antibody 
response in humans (Swanson et a l, 2010). The higher level of type-III IFN 
produced over the much longer time period could have a role to play in the transient 
immunosuppression seen during acute ncpBVDV infection.
Type-I and type-III IFN have been shown to induce the expression of several 
antiviral proteins, such as Mx proteins, dsRNA-activated protein kinase R (PKR) and 
oligoadenylate synthetases (OAS), which ultimately mediate the antiviral actions of 
IFNs (Kotenko ef aL, 2003; Sheppard et a l, 2003; Dumontier et a l, 2004). Although 
these two different classes of IFN use distinct receptors, both activate the Jak/STAT 
pathway. Zhou et aL, (2007), using gene expression studies, clearly demonstrate that 
stimulation with either class of IFN leads to the stimulation of a similar pattern of 
antiviral genes. Indeed two recent studies demonstrate the antiviral activity of type- 
III IFN against FMDV. In a study by Diaz-San Segundo et a l, (2011), the bovine 
IFNA3 gene was first described and characterized. Antiviral activity against FMDV 
was assessed by interferon stimulated gene (ISG) upregulation in vitro and in vivo.
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Tissues from the upper respiratory tract and skin, known to be susceptible to FMDV 
infection displayed upregulation of ISGs following inoculation with a replication- 
defective human adenovirus type 5 vector expressing bovine IFNX3 (Ad5-boIFN- 
13). A further study by Perez-Martin et aL, (2012), demonstrated that inoculation of 
cattle with the same adenoviral construct, followed by either intradermolingual or 
aerosol challenge with FMDV, led to a significant delay in disease progression of 6 
and 9 days respectively. Disease was assessed as clinical signs, viraemia and viral 
shedding.
Both of these studies present data that confirm the effectiveness of type-III IFN in 
inducing an antiviral state in cells permissive to FMDV infection and could 
potentially represent an effective mechanism of preventing viral spread during an 
outbreak situation. However, type-III IFN did not fully protect from FMDV 
infection, suggesting that viral replication occurs in a permissive cell population not 
expressing the type-III IFN receptor. One further caveat is that the effect of 
inoculation with this adenoviral vector expressing type-III IFN and the interaction 
with, or effect on FMDV vaccination, classically used in outbreak situations, has not 
been examined.
Although type-III IFN induces an antiviral state in a restricted number of cells, 
dependent on receptor expression, it is not induced to any great degree during 
FMDV infection. Our results confirm that the majority of IFN induced is in fact acid 
stable type-I IFN.
In addition to their direct antiviral action, IFNs have many immunomodulatory and 
immunoregulatory functions. They induce the expression of interferon stimulated 
genes (ISGs) including several cytokine and chemokine genes. They also prime cells 
for enhanced virus-induced production of IFNs and other cytokines. Type-I IFN has
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been shown activate NK cells (Biron et aL, 1999), upregulate MHC class I and co­
stimulatory molecules, enhance exogenous antigen cross presentation and promote 
T- cell expansion (Honda et aL, 2003; Stager and Kaye 2004; Curtsinger et aL, 2005; 
Kolumam et aL, 2005; Havenar-Daughton et aL, 2006). Type-I IFN has also been 
demonstrated to enhance the humoral response and promote isotype switching by 
stimulating dendritic cells (Fink et aL, 2006; Le Bon et aL, 2003).
The effect type-I IFN has directly on T cells can vary from stimulatory to inhibitory 
and has been reported to be dependent on the activation of various signal transducer 
and activation of transcription (STATs) and also on the milieu of pro-inflammatory 
cytokines induced by specific pathogens (Tanabe et aL, 2005; Thompson et aL,
2006; Keppler et aL, 2012). Type-I IFN effects on T- cell stimulation are dependent 
on the timing of the exposure. T- cells exposed to IFN and antigen simultaneously, 
show enhanced T- cell proliferation, whereas those exposed prior to stimulation have 
inhibited T- cell proliferation. A study by Marshall et aL, (2010) clearly 
demonstrates the inhibition of bystander CDS T- cell proliferation, in vivo, to third 
party cognate antigen during acute viral infections. Using a type-I IFN receptor 
knockout mouse model, they clearly demonstrate that this effect is due to type-I IFN 
signaling directly on T-cells. Huber et aL, (2010) demonstrated that IFN-a/p potently 
inhibited the ability of IL-4 to drive human Th2 cell differentiation. Furthermore, 
they also show that type-I IFN destabilized pre-commitment to a Th2 phenotype and 
blocked Th2 cytokine expression. These effects were mediated by inhibiting the 
transcription factor GAT A3, which is the master transcription factor for the 
differentiation of Th2 cells (reviewed in Ho et aL, 2009). This mirrors the data 
presented by Contoli et aL, (2006), who clearly demonstrate that IFN11 also inhibits 
GAT A3 expression and suppresses Th2 responses in naïve and memory T cells. The
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up-regulation of expression of IL-4Ra, associated with activation of Th2 cells, is 
suppressed and the authors demonstrate that IL-4 and IL-13 expression is inhibited 
in these cells without affecting their ability to proliferate. Lymphocyte trafficking 
has also been reported to be affected by type-I IFN, leading to a transient 
lymphopenia (Kamphuis et aL, 2006). This was also reported for IFNX1 (Dai et aL, 
2009), where expression of CD62L and CCR7 on T cells leads to retention in 
lymphoid tissue. Normally during differentiation, these markers are down-regulated 
allowing T cells to exit into the periphery and non-lymphoid sites. However, both 
naïve and memory T cells that had been exposed to IFNX1, retained CD62L and 
CCR7 cell surface markers following stimulation, suggesting that these cells would 
preferentially be retained in lymphoid tissue. These data could also be explained by 
the suppression of GATÂ3 up-regulation and the concomitant effect on IL-4Ra 
expression and IL-4 secretion following IFN exposure.
The emerging story, however, is that the effects of type-I IFN on CD4 T cells are 
dependent on the context in which they are exposed. For example, Dondi et ah, 
(2004) showed that TcR stimulation with exogenous IFN-a is antiapoptotic early and 
proapoptotic later. Interestingly, they report that entry into the cell cycle was delayed 
when TcR stimulation followed IFN-a exposure, apparently due to sequestration by 
the type-I IFN receptor complex of CD45, lymphocyte-specific protein tyrosine 
kinase (Lck), and Zeta-chain-associated protein kinase 70 (ZAP-70; Petricoin et aL, 
1997), all of which are necessary to initiate, but not to sustain, cellular responses to 
stimulation through the TcR (Chan et aL, 1994).
The addition of type-III IFN to the mix potentially complicates the picture further. 
Type-III IFNs have been shown to up-regulate cytotoxic responses to virally infected 
cells (Ank et aL, 2008) and to induce proliferation of FoxP3-expressing regulatory T
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cells, in a dendritic cell dependent manner, in vitro (Mennechet and Uze, 2006). 
Addition of IL-29 (IFNX.1) to human PBMC or T cell cultures in vitro has been 
shown to inhibit the production of IL-5 and IL-13, cytokines produced 
predominantly by Th2 cells (Dai et al, 2009; Jordan et al, 2007; Sri ni vas et al, 2008). 
A further study by Siebler et al., (2007) shows that transgenic expression of 1L-28A 
(IFN12) in vivo promotes the induction of a Tel rather than Th2 responses.
Allergic asthma patients have been shown to exhibit deficient induction of IL-28 
and IL-29 in response to rhino virus infection, and this deficiency in expression 
correlates with the severity of rhinovirus-induced asthma exacerbations and virus 
load in experimentally infected human volunteers (Contoli et al, 2006). Further to 
this, a study by Bullens et aL, (2008) shows an inverse correlation between IL-28 
and IL-29 mRNA levels and the severity of allergic response in the airways of 
asthma patients with active disease but with no detectable viral infection. They 
further demonstrate that IL-28 A promotes ThI cell differentiation in vivo and 
suppresses T^2-mediated responses in the airways.
Data reported by Chi et aL, (2006) demonstrate the co-operative effect of respiratory 
syncytial virus (RSV) induced type-I IFN and type-III IFN in supressing CD4+ T cell 
proliferation to itself, cytomegalovirus (CMV) or Staphylococcus enterotoxin B. Pre­
treatment of T cells with antibodies to either receptor, selectively blocking the type-I 
or type-III pathways, only marginally affected suppression of T cell proliferation, 
however, when used together, resulted in either a complete block or significant 
reduction in the inhibition of CD4 T cell proliferation.
The marked immunosuppression noted early during BVDV infection and the 
prolonged production of IFN, predominantly type-III IFN, begs the question, is this 
an immunosuppressive mechanism that acts on CD4+ T cells and / or antigen
251
presenting cells during infection? Could type-I / type-III IFN be inhibiting T cell 
proliferation or perhaps activation or differentiation early in BVDV infection? All 
these questions will generate future work in the study of BVDV infection and 
immunomodulation due to viral infection.
5.1 Further work
Further studies will be carried out to determine the effect type-I /type-III interferon is 
having on the ability of cattle to mount an effective immune response to BVDV. 
Initially this will include examining the effect of both purified type-I and type-III 
IFN on bovine T cell proliferation and differentiation. Further experiments to 
examine the effect of supernatants recovered from the isolated pDCs that have been 
infected with both wild type BVDV and the Npro deleted mutant virus will be 
carried out. Examination of the effect type-I and type-III IFNs are having on APCs, 
in terms of their ability to present effectively and further studies to examine the 
direct effect of type-I and type-III IFN on T cell proliferation and differentiation will 
also be carried out in an effort to determine the mechanism of action of type-III IFN. 
Cannulation studies could be carried out to examine not only the trafficking and 
maturation of pDCs but also to examine the trafficking of T cells early during 
ncpBVDV infection to determine if indeed there is lymph node retention of these 
cells in relation to the observed lymphopenia. It is hoped these studies will give an 
insight into the transient immunosuppression seen during acute ncpBVDV infection 
and go some way to explaining the relatively late production of antibodies in 
response to this virus.
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